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Abstract
Evolution does not happen at random and one strain of a bacterium cannot evolve directly to
another arbitrary strain. Nature allows only certain paths in going from one strain to another.
Based on this idea, this research aims to identify what the fHbp (factor H binding protein) antigen
of the Neisseria meningitidis bacterium is likely to mutate into so that vaccines and therapies can
be developed in advance for the most likely mutants. Neisseria meningitidis is the bacterium that
causes the potentially devastating disease meningococcal meningitis in humans.
The target of this research was to generate valid new variants of fHbp based on the characteristics
of the existing fHbp sequences. The characteristics were that the sequences had specific invariant
regions which flanked restricted variable regions, the mutations in each position of the variable
regions were highly constrained, there were peptides in the homologous sequences which were
correlated or were co-occurring with each other, and there were regions which were more or less
likely to mutate than by chance. As part of determining the characteristics, tertiary structures of
the existing sequences were also predicted and energy values of those structures were determined.
A pipeline of programs was written to generate variants of the fHbp sequence which satisfied these
characteristics. The new variants were studied, their tertiary structures were predicted, and energy
values of those structures were determined, similar to what was done for the existing variants.
New variants whose associated energy values fell into the range defined by existing sequences were
deemed to be “allowable” by nature.
Unfortunately, all of the variants of fHbp generated were valid according to our energy criterion.
All generated variant being “allowed” is an unlikely result. Therefore, we conclude that a more
stringent methodology for evaluating the viability of fHbp variants is necessary.
Another contribution of our work is the program for generating variants. Like the methodology,
it is highly modular, and can be easily used as starting platform for research into additional filtering
criteria.
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Chapter 1
Introduction
Neisseria meningitidis is a major human pathogen that causes the disease meningococcal menin-
gitis. It is a gram-negative, aerobic bacterium which infects only humans. Transmission of this
bacterium occurs directly by droplets spread from person to person. The most common symptoms
of meningitis include fever, headache, nausea, vomiting, skin rashes, and neck stiffness. The disease
can also lead to stupor and coma, or leave the infected individuals with irreparable permanent
damage like paralysis or amputated limbs.
Factor H binding protein (known as fHbp, GNA1870, or LP2086) is an antigen which is present
on the surface of all strains of the Neisseria meningitidis bacterium. fHbp binds with factor H
(fH), a key regulatory component of the human complement immunological pathway. It enables
the meningococcus to avoid innate immune responses by inhibiting complement-mediated lysis in
human plasma (Section 2.6). Thus fHbp is important for survival of the N. meningitidis in human
blood and human sera, and in the presence of antimicrobial peptides. This makes fHbp a potential
vaccine antigen [68, 70]. Hence, it was chosen for this research.
The goal of this research is to aid in the development of vaccines and therapies for the meningitis
disease based on the concept of predicting the evolution of the fHbp antigen. Evolution does not
happen randomly and the transformation of this bacterial antigen is allowed to follow only in
certain evolutionary paths which in turn are influenced by genetic diversity of the sequences. In
this research we tried to determine what the fHbp antigen will mutate into, with the ultimate goal of
generating valid new, likely variants of fHbp. The new variants will then facilitate the development
of vaccines and therapies in advance of the appearance of mutant strains containing them.
In order to generate the new variants of fHbp that have not yet appeared but which nature
might “allow”, it is essential to study the characteristics of the existing fHbp sequences so as to
be able to generate new sequences (variants) which have those same characteristics. The relevant
characteristics include specific properties of the fHbp sequences, like having restricted variable
regions flanked by particular invariant segments, amino acid substitution domains in each position
along the sequence alignment, peptides in the sequences which are either correlated (indicating to
what extent a mutation in one position of an alignment affects the presence or absence of other amino
acids in another position) or are co-occurring (peptides in different positions along an alignment
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existing together in a pattern) with each other, sites where the amino acids tend to mutate (positive
selection sites) and sites where the amino acids tend to remain conserved (negative selection sites),
and the tertiary structures of the sequences and their energy values. A computer program, written
as part of this research work, then uses these characteristics to guide the generation of new variants
of fHbp. The characteristics of the new variants are then verified with those of the already existing
fHbp sequences in order to determine whether they have the same properties. The variants that
have the necessary properties are the new fHbp sequences which have not as yet seen but which
nature will “allow”.
For this research all available fHbp sequences are collected from the UniProtKB database (Sec-
tion 4.1). After collecting the set and removing duplicate sequences, a multiple sequence alignment
is performed on the set, and later investigated. This is done in order to see whether the sequences
all satisfy the criteria of starting with a specific amino-terminal repetitive element followed by seg-
ments of restricted variable regions flanked by the invariant segments (as is classified by Beernink et
al. [34] in their work). The restricted variable regions are then studied to determine the correlation
and co-occurrence in the mutation of the amino acids in the different positions of fHbp. After this
the constraints of the restricted variable positions are characterized, such as whether one amino
acid has higher possibility of substituting another amino acid or if mutation between two amino
acids involves presence of an intermediate amino acid, etc. The tertiary structures of the original
fHbp sequences are then predicted and their energy values are recorded. This is done in order
to determine the valid boundary set by the highest energy value that an existing fHbp sequence
can have. Based on all the constraints determined for the fHbp sequences, a computer program is
developed which generates new variants of fHbp sequences. The new variants are then examined to
determine which of the amino acid substitutions satisfy the constraints determined in the previous
steps. Any variants that do not satisfy all of the constraints are discarded. In addition, any dupli-
cates (of variants or of the original set of sequences) are discarded. In the next step, the tertiary
structures of the new variants are predicted, after which their energy values are determined. The
energy value for each variant is then compared to those for the original fHbp sequences to determine
whether it is below the valid energy boundary. It is assumed that molecular variants that pass this
test will be “allowed” by nature but have not as yet appeared.
Unfortunately, the 300 new variants generated in this research were all found to be valid, which
was an unlikely result. At least some variants whose energy values were not within the valid range
were expected due to the stochastic nature of the generation process. Some of the possible reasons
behind such results are the absence of bio-chemical verification of these new variants in wet labs
and the limited number of structural templates used for predicting the tertiary structures of the
fHbp sequences and variants. It could also be that generation of 300 new variants was too few to
result in creating diverse variants and more number of variants should be generated.
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An important note about this research is that the methodology and the computer program
written for generating the new variants are both modular in nature and quite extensible, thereby
laying the groundwork for further work on this topic.
1.1 Thesis Organization
The thesis is organized as follows:
• Chapter 2 describes the background knowledge for better comprehension of this research.
• Chapter 3 outlines the goal of this research.
• Chapter 4 discusses the data collected for this research and the methodology followed. Parts
of the results are also included in this chapter since some steps of the methodology were
dependent on the results generated in the previous steps. This is done for better understanding
of the methodology of the work.
• Chapter 5 presents and evaluates the results.
• Chapter 6 discusses the conclusion of this research and possible future work.
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Chapter 2
Background Information
To better understand this research some background knowledge is required. This background
knowledge relates to protein sequence databases, genome annotations, multiple sequence align-
ments, antigens, vaccines, the human complement system, Neisseria meningitidis and its antigen
fHbp, the concept of evolution, and protein structures and their energies. Sections 2.1 to 2.12 give
brief descriptions of these topics, aiming to give the reader an introduction to predicting antigen
evolution and its associated advantage in vaccine development.
2.1 Protein Sequence Databases and Genome Annotation
A variety of protein sequence databases exist, ranging from simple sequence databases to ex-
pertly curated universal databases covering all species. DDBJ, GenPept, NCBI, UniProtKB, and
PIR are some examples. Such databases play a significant role as central comprehensive resources
of protein information [32].
Genome annotation is the process of attaching biological information to sequences and is done
in two steps [7]:
1. identifying elements of the genome, a process called gene prediction, and
2. attaching biological information to these elements.
There are structural annotations consisting of information on gene structure, coding regions, etc.
and there are functional annotations consisting of biological information like biochemical function,
biological function, etc. [7].
2.2 Multiple Sequence Alignments
Multiple sequence alignments are common operations in bioinformatics and are widely used
in all areas of nucleotide and protein sequence analysis. They are needed whenever sets of ho-
mologous sequences are compared and are an essential precursor to numerous further analyses.
ClustalW, ClustalX, T-Coffee, MUSCLE, MAFT, PROBCONS, Kalign are some of the commonly
used multiple sequence alignment tools [79].
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2.3 Innate and Adaptive Immunity
Innate immunity forms the first line of defence of the human body to infection and brings about
an initial response to infectious agents. The term innate immunity (also called natural or native
immunity) refers to the fact that this type of host defense is always present in healthy individuals,
prepared to block the entry of microbes and to rapidly eliminate microbes that do succeed in
entering host tissues [31].
Adaptive immunity (also called specific or acquired immunity) forms the second line of defence
and develops more slowly. It is stimulated by microbes that invade tissues; that is, it adapts to the
presence of microbial invaders [31].
2.4 The Human Complement System
The human complement system is a crucial component of the innate immune system that is
present over the course of an individual’s lifetime. However, it can be recruited and brought into
action by the adaptive immune system. It is a system of serum and cell surface proteins that
interact with one another and with other molecules of the immune system to generate important
effectors of innate and adaptive immune responses. The complement system helps the antibodies
(Section 2.5) to clear pathogens from an organism [31, 39].
2.5 What is an Antibody?
An antibody is a large molecule used by the immune system to identify and neutralize foreign
objects like bacteria and viruses. The antibody recognizes a unique part of the foreign object,
known as the antigen (Section 2.6) [6]. An antibody matches an antigen much as a key matches a
lock. Whenever antigen and antibody interlock, the antibody marks the antigen for destruction.
2.6 What is an Antigen?
An antigen is a molecule, usually foreign, that prompts generation of antibodies [31, 48]. An
antigen binds to an antibody or a T cell antigen receptor (TCR). Antigens that bind to antibodies
include all classes of bio-molecules; for instance, carbohydrates, lipids, and nucleic acids. Most
TCRs bind only peptide fragments of proteins complexed with major histocompatibility molecules;
both the peptide ligand and the native protein from which it is derived are called T cell antigens.
Although a substance that induces a specific immune response is usually called an antigen, it
is more appropriately called an immunogen. Immunogenicity is the ability to induce a humoral
and/or cell-mediated immune response. A humoral immune response is one in which host defenses
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are brought in by antibodies present in the plasma, lymph, and tissue fluids and it gives protection
against extracellular bacteria and foreign macromolecules. A cell-mediated immune response, on
the other hand, is one in which the host defenses are brought in by antigen-specific T cells and
various other cells which are not specific to a particular target of the immune system and it gives
protection against intracellular bacteria, viruses, and cancer [48].
Antigenicity is the ability to combine specifically with secreted antibodies and/or surface re-
ceptors on T cells. Although all molecules that have the property of immunogenicity also have the
property of antigenicity, the reverse is not true. For instance, some small molecules, called haptens,
are antigenic but incapable by themselves of inducing a specific immune response. In other words,
they lack immunogenicity [48].
The portion of an antigen that is recognized and bound by an antibody or TCR is known as an
epitope [48]. The antigen-antibody (Ag-Ab) interaction is a biomolecular association similar to an
enzyme-substrate interaction, except that it does not lead to an irreversible chemical alteration in
either the antibody or the antigen. The association between an antibody and an antigen involves
various non-covalent interactions such as hydrogen bonds, ionic bonds, hydrophobic interactions,
and van der Waals interactions. These interactions are individually weak in comparison to covalent
bonds; hence a large number of such interactions are required to form a strong antigen-antibody
(Ag-Ab) interaction. In addition, each of these non-covalent interactions operates over a very short
distance, usually about 1 angstrom, A˚ (1 x 10−7 mm) [48]. As result a strong Ag-Ab interaction
depends on a very close fit between the antigen and antibody. Such fits require a high degree of com-
plementarity between antigen and antibody, a requirement that underlies the exquisite specificity
that characterizes antigen-antibody interactions [48].
2.7 What is a Vaccine?
A vaccine is a preparation of microbial antigens that is administered to individuals to induce pro-
tective immunity against microbial infections. The antigens may be in the form of live but avirulent
microorganisms, killed microorganisms, or purified macromolecular components of microorganisms.
All these types of vaccines have respective advantages and disadvantages. For instance, live atten-
uated vaccines induce strong immune response, which often sustain lifelong immunity with just few
doses. The disadvantage is that this type of vaccine may mutate to a virulent form. Inactivated
or killed vaccines on the other hand are stable and safer than live vaccines; however they result in
weaker immune response and they usually require booster shots to provide on-going immunity [31].
Vaccine development has been one of the greatest successes of immunology. Progress in im-
munology and molecular biology has not only led to the development of effective new vaccines,
but it has also led to promising new strategies for finding new vaccine candidates. Knowledge of
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the differences in epitopes recognized by T cells and B cells has enabled immunologists to design
vaccine candidates to maximize activation of both cellular and humoral immune responses.
2.8 Neisseria meningitidis
Neisseria meningitidis causes the meningococcal disease known as cerebrospinal meningitis in
developed and developing countries around the world. It is transmitted by person-to-person contact
through respiratory droplets of infected people.
According to the World Heath Statistics 2008 [66], the rate of meningococcal meningitis is
the highest in the sub-Saharan Africa, which has been named as the “meningitis belt”. This
belt covers 21 countries with about 350 million population, and the highest disease occurrence is
recorded during the dry season. Meningococcal meningitis has hit this area in periodic waves. The
last major hit was in 1996/1997 in which more than 220,000 people were affected in 17 countries.
After this there was a low disease incidence in the belt until the year 2006, when there was again
another rise in the meningitis rates. This increased further in 2007, when there were 54,676 cases
of meningitis and 4062 deaths reported in the belt countries [66].
Decrease in immunity among a population against the meningococcus bacterium leads to an
increase in the incidence of the disease. In addition, HIV infection, smoking, over-crowding, other
respiratory infections, and climatic conditions such as prolonged drought and dust storms contribute
to the development of the disease. Meningitis is devastating despite the availability of effective
antibiotics. Up to 25% of those who survive are left with permanent damage, such as amputated
limbs, mental retardation, hearing loss, speech disorders and paralysis [55].
N. meningitidis is an encapsulated gram-negative bacterium, which infects the upper respiratory
tract of ∼10% of the human population and from these infected individuals it occasionally spreads,
causing the disease [55]. The onset of symptoms is sudden and death can follow within hours. The
flu-like symptoms can rapidly progress into a life-threatening condition, even in healthy individu-
als [29]. There are two age groups which show higher susceptibility to the disease: children under
the age of 2 years and older teenagers. However, during epidemic periods attack rates increase, age
distribution broadens (generally 4-19 years of age), and death rates can rise to 10 to 15% [42]. In
nonepidemic periods, approximately one of every 100,000 people per year, the bacterium enters the
blood stream where it multiplies, causing infections and eventually the disease [55].
Humans are the only hosts which the Neisseria meningitidis infects. The bacterium is classified
into 13 serogroups: A, B, C, D, 29E, H, I, K, L, X, Y, Z, and W-135 [40]. Among them, five
serogroups, A, B, C, Y, and W-135, cause disease [38] and to very minor extent X and Z have been
associated with disease [55]. Serogroup A strains cause most of the major epidemics around the
world, particularly in less developed countries. Serogroups B and C generally cause endemic disease
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and occasionally epidemics. In North America, the most common serogroups causing diseases are
C, B, and Y. Serogroup B strains tend to infect children greater than 2 years old, and serogroup C
strains are more common in older children, adolescents, and adults. In addition, serogroup C strains
are more commonly associated with local outbreaks of the disease. Disease caused by serogroup B
and Y strains are usually more sporadic [40].
According to the recent information published by WHO, there are three types of vaccines avail-
able for meningococcal meningitis [30]:
• Meningococcal polysaccharide vaccines which are either bivalent (groups A and C), trivalent
(groups A, C and W), or tetravalent (groups A, C, Y and W135) have been available to
prevent the disease for over 30 years.
• Polysaccharide vaccines for serogroup B cannot be developed due to antigenic mimicry with
polysaccharides in human neurologic tissues. As a result, vaccines against B developed in
Norway, in Cuba and Netherlands are outer membrane proteins (OMP).
• Since 1999, meningococcal conjugate vaccines (a type of vaccine that is created by joining
an antigen to a protein molecule) against group C have been available and widely used.
A tetravalent A, C, Y and W135 conjugate vaccine has recently been licensed for use in
children and adults in the United States and Canada. In 2001, a partnership was created
between WHO and PATH [23] to eradict meningitis in Africa through the development of
an affordable meningococcal A conjugate vaccine. From December 2010, the Men A vaccine
was introduced nationwide in Burkina Faso, Mali, and Niger. Unlike polysaccharide vaccines,
conjugate vaccines are more immunogenic and provide longer immunity.
2.9 fH and fHbp
Activation of the human complement immune response is controlled through membrane-bound
and soluble plasma-regulatory proteins, including complement factor H (fH), which is a 155 kDa
protein composed of 20 domains (termed complement control protein repeats) [70]. Factor H is
the central complement regulator that is found in the plasma and that binds to the surface of host
cells and biological surfaces. It acts in combination with additional complement regulators and
thus the surface attached factor H assists the membrane anchored regulators. This surface activity
is particularly relevant during local inflammation and complement stress, and for damaged host
cells [39, 84].
Several pathogens have copied this protective process and adapted the mechanism of sequester-
ing fH to their surface in order to avoid complement-mediated killing. Factor H binding protein
(fHbp) is one such antigen which targets factor H, thus enabling the meningococcus to avoid the
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innate immune response by inhibiting complement-mediated lysis in human plasma. fHbp is a
27kDa lipoprotein which is present on the surfaces of all strains of N. meningitidis and it is the sole
receptor for fH on the meningococcus. fHbp is essential for survival of N. meningitidis in human
blood, in human sera, and in the presence of antimicrobial peptides, hence making it a unique
vaccine antigen [68, 70, 84]. Individuals carrying a genetic polymorphism in a presumed regulatory
region for factor H have been reported to have increased level of factor H and an increased risk for
meningococcal disease [59]. However, one limitation of fHbp as a vaccine antigen is its low density
on the surface of some strains of the meningococcus [80] and its sequence variability [42, 55].
Giuliani and et al. [43] have divided the fHbp molecule into a series of regions, termed ‘A’,
‘B’, and ‘C’, in order to study its function. Schneider and coworkers [70] studied these 3 regions
and determined that high affinity interactions between fH and fHbp involved all three of these
regions; that is, fHbp has an extended recognition site for fH across its entire surface. Schneider
and coworkers then identified which of the 20 complement control protein (CCP) domains of fH
were involved in the interaction with fHbp. They found that the regions of fH recognized by fHbp
were the sixth and seventh domains, CCPs 6 and 7, which they also termed as fH67. They then
identified the residues in both fHbp and fH involved (Figure 2.1). Figure 2.1 a) illustrates the
structure of fHbp that folds to form two β-barrels. The amino-terminal repetitive segment termed
as the N-term is part of region A coloured in yellow, region B is coloured in green, and region C
in cyan. Figure 2.1 b) shows the fHbp-fH67 complex where fH67 is coloured in dark blue. The
interaction surfaces between the two molecules forming salt bridges are shown by the red ball-and-
stick representations with the inset box as the zoomed illustration of the interactions between fHbp
and fH67. Figure 2.1 c) shows the topological structural complex of fHbp-fH67. It illustrates the
number of the amino acids in fHbp and fH67 that take part in the interactions between the two
molecules to form the fHbp-fH67 complex. The fH67 molecule is composed of two parts, CCP 6
and CCP 7 as seen in this part of the figure. The hydrogen bond (H-bond) and the salt-bridge
interactions between the residues of the two molecules are shown in red.
Masignani and coworkers [55] classified fHbp into three variants, namely variants 1, 2, and 3
based on sequence diversity. After the classification, it was observed that the amino acid identity
between variants 1 and 2 was 74.1%, between variants 1 and 3 was 62.8%, and that between variants
2 and 3 was 84.7% [55].
Using similar analyses as mentioned above, Fletcher and coworkers [42] classified fHbp into
two subfamilies, A and B, where subfamily A corresponded to variants 2 and 3 and subfamily B
corresponded to variant 1 [42].
When analyzing the fHbp sequence, Beernink et al. [34] divided the sequence into an amino-
terminal repetitive element region followed by five variable modular segments. The amino-terminal
repetitive region begins with a cysteine (C) residue that was lipidated by signal peptidase II, which
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Figure 2.1: Structure of fHbp and its complex with fH67 as shown by Schneider & et
al. [70]. a) Two views of fHbp (residues 80-320). Region A, yellow; region B, green; region C,
cyan. b) fHbp-fH67 complex with fHbp coloured as in a) and fH67 in dark blue. Side chains
from both proteins involved in forming salt bridges across the interaction surface shown in
red as ball-and-stick representations. c) Topology of fHbp and fH67 coloured as in b) with
the number of the residues involved in the interactions between the proteins highlighted in
red. The numbering scheme used is from UniProtKB sequence Q9JXV4.
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Variant	  1
CSSG
5
GG
73 93 159 180 253
SRFDF GEFQ DD IEHLK KQ
Variant	  2 5 73 93 158 179 252
Variant	  3 10 81 101 166 187 260
N-­term VA VB VC VD VE
Figure 2.2: Schematic representation of fHbp showing positions of blocks of invariant
residues (shown as black vertical rectangles), the amino-terminal repetitive region designated
as the N-term, and the variable regions as VA, VB , VC , VD, and VE [34]. Masignani and
coworkers classified fHbp into three variant groups: Variant 1, Variant 2, and Variant 3 [55].
in turn is followed by three invariant amino acid residues, ‘SSG’. This invariant region is followed by
a repetitive element consisting of 1 to 6 glycines (G) and / or serines (S) followed by two invariant
glycine residues (Figure 2.2).
The five modular variable regions have been termed Regions VA, VB , VC , VD, and VE as
shown in Figure 2.2. These five regions are separated by blocks of invariant residues. For instance,
Region VA starts right after the invariant region ‘GG’ of the amino-terminal region and extends
until the invariant segment, ‘SRFDF’ after which is the region VB . Hence the variable segments
are each separated by the blocks of invariant segments (Figure 2.2). These five modular variable
segments have specific numbers of amino acids as mentioned by Beernink et al. [34] (Figure 2.2).
• VA contains 66 to 69 amino acids.
• VB contains 15 amino acids.
• VC contains 61 to 62 amino acids.
• VD contains 19 amino acids.
• VE contains 68 to 71 amino acids.
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2.10 Evolution & Mutation
Evolution is the process by which living things change through a process of incremental trans-
formation over extended periods of time. It is a modification which occurs due to genetic variability,
which in turn is produced by the process of mutation. In the early days of genetic studies, any
genetic change in phenotypic characteristics was referred to as mutation, with no knowledge of the
reason behind the change. However, with time and with further studies and research it was revealed
that various factors are involved in causing genetic changes of phenotypes. These factors can be
studied at three different levels, namely, molecular, chromosomal, and genomic [60].
For this research, it is only required to know what evolution is at the molecular level. A simple
definition of molecular evolution is that it is the process of evolution at the scale of DNA, RNA, and
proteins, and that mutation plays an important role in it [8]. Mutation is a permanent, transmissible
change to the genetic material (usually DNA or RNA) of a cell and it is considered a driving force
of evolution.
DNA and RNA with viruses are the carriers of all genetic information that controls the mor-
phological and physiological characteristics of organisms. Any mutational changes in these char-
acteristics are hence the result of some changes in DNA molecules and RNA with viruses. There
are four basic types of changes in DNA and RNA with viruses: (i) substitution of a nucleotide
for another nucleotide (Figure 2.3 b), (ii) deletion of nucleotides (Figure 2.3 c), (iii) insertion of
nucleotides (Figure 2.3 d), and (iv) inversion of nucleotides, where nucleotides are reversed in a
sequence (Figure 2.3 e). Insertion, deletion, and inversion may occur with one or more nucleotides
as a unit. Nucleotide substitutions are of two types: (i) transition, which is the substitution of
a purine (adenine or guanine) for another purine or the substitution of a pyrimidine (thymine or
cytosine) for another pyrimidine, and (ii) transversion, which is the substitution of a purine for
pyrimidine or vice versa [60].
The amino acid sequence of a protein is determined by the nucleotide sequence of its gene.
Hence any change in amino acid sequence is caused by a mutation occurring in DNA. However, a
mutational change in DNA does not always result in a change in amino acid sequence because of
the degeneracy of the genetic code (synonyms of codons). Mutations that result in synonymous
codons are called synonymous or silent mutations, while others are called nonsynonymous or amino
acid altering mutations [60].
The other important aspect of molecular evolution is determining regions which are under
positive selection pressure and those that are under negative selection pressure. A positive selection
site is a site which is under active natural selection; that is, nature preferably changes or mutates
that position in order to bring new evolutionary results [56]. For instance, over time this process
can result in the emergence of new mutants which have higher fitnesses than the average in the
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population (provided the environment is also optimal for the change), and the frequencies of the
mutants increase in the following generations [75]. In other words, positive selection is an important
process by which evolution takes place within a population of organisms. A negative selection site,
on the other hand, is the opposite of positive selection, where nature conserves the type of amino
acid present at that site and does not want changes to occur. In fact it will prevent any changes
from occurring to that site [56]. As a result of this process, newly produced mutants have lower
fitnesses than the average in the population, provided the environment is also changing. In that
case, conservation will likely be deleterious. However, if the environment has not changed, and
if the sequence is already somehow “optimal”, then conserving the sequence is beneficial to the
survival of the organism. In addition to all these, negative selection pressure leads to a decrease in
the frequencies of the mutants in the following generations [75].
In a protein sequence set, positive and negative selection sites can be determined by finding
ratio of the number of nonsynonymous substitutions per nonsynonymous site (designated as KA or
dn) to the number of synonymous substitutions per synonymous site (designated as KS or ds) [56].
The rate of synonymous substitution is much higher than that of nonsynonymous substitution
and is similar for many different genes of closely related species [61]. Methods for estimating the
KA/KS ratio can be classified into two groups: approximate method for closely related sequences
and maximum-likelihood method for distantly related sequences [82].
The approximate method involves three steps [82]:
1. counting the number of synonymous and nonsynonymous sites in the two sequences—usually
by multiplying the sequence length by the proportion of each class of substitution
2. counting the number of synonymous and nonsynonymous substitutions
3. correcting for multiple substitutions
The maximum-likelihood approach uses probability theory to complete the above three steps si-
multaneously [82].
Although the basic genetic change occurs in DNA, evolutionary change of proteins is also im-
portant, since proteins are essential building blocks for morphological characteristics and carrying
out physiological functions. Also they are more conserved than DNA sequences and thus provide
useful information on long-term evolution of genes or species [62].
13
a. Wild type         ACC         Thr         TAT    TTG CTG       Tyr        Leu       Leub. Substitution        ACC       Thr         TCT       Ser         TTG         CTG       Leu        Leu
c. Deletion        ACC       Thr        Phe        TTT         TGC       Cys         TG ‐       ‐ ‐ ‐ 
d. Insertion        ACC       Thr         TAT       Tyr         TTG       Leu         CTG       Leu      
e. Inversion        TAT       Tyr         GTT       Val         GTC       Val       Pro        CCA
Figure 2.3: Four basic types of mutations at the nucleotide level. The nucleotide sequence
is represented in units of codons or nucleotide triplets in order to show how the encoded
amino acids are changed by the nucleotide changes [60].
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2.11 Mature Protein Part and Signal Protein Part
The “mature protein” part, also termed as the “final peptide”, is the protein product following
post-translational modification of a protein [18]. Post-translational modification is the chemical
modification of a protein after its translation step, which is one of the later steps in protein biosyn-
thesis [9].
A signal peptide is a short (3-60 amino acids long) peptide chain that directs the transport of
a protein. “Targeting signal”, “signal sequence”, “transit peptide”, or “localization signal” [11] are
some of the synonyms for the term “signal peptide”.
2.12 Protein Structure Prediction
One of the major goals of Bioinformatics is to understand the relationship between amino acid
sequence and three-dimensional structure in proteins. If this relationship were known, then the
structure of a protein could be reliably predicted from the amino acid sequence. Knowing the
structure of a protein is important, since it provides much more biological information than the
protein amino acid sequence. The structural analysis of proteins plays a significant role in detecting
many physical-chemical properties of proteins and prediction of protein-protein interactions [57].
The structure of a protein is conventionally described in four ways. The primary structure of a
protein is the sequence of amino acids produced at ribosomes. The secondary structure of a protein
describes those parts of the primary structure that fold into regular and repeated patterns, such
as α-helices, β-sheets, or turns. The tertiary structure results from interactions between secondary
structure elements, forming more complex units and providing the three-dimensional shape of the
protein. The quaternary structure of a protein is a description of how several separate polypeptide
sequences have come together to form a complex protein [46].
2.13 Energy of Protein Structures
Energy characteristics are distributions of potential energy over amino acid chains of proteins.
Conformational changes, mutations, structural deformations and other disorders are reflected in
energy distributions. Hence energy characteristics can be used in detection and verification of such
states [58].
Minimization of energy is an important concept used in repairing distorted geometrics of a
structure of protein, especially if the protein has some kind of mutation, when it is distorted
manually, or when there is a manual reconstruction of loops in the structure. Energy minimization
can repair distorted geometrics by moving atoms to release internal constraints [20].
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Energy plays a significant role in evaluating a structure of a peptide molecule. For instance,
when predicting a tertiary structure of a protein using a template structure that is already avail-
able, the energy that is determined during this prediction plays an important role in determining
how accurately the structure has been predicted. It is usually seen that predicted structures with
higher percentage of structural identity with the template structure will exhibit lower energy values,
whereas the opposite is true when structures have greater structural variations from the template
structure. Energy of peptide molecules are completely based on their structural properties and
not on their sequential properties. Two peptide molecules sequentially similar can have vast struc-
tural differences due to conformational changes in their loops or side chains, etc. thus exhibiting
pronounced changes in energy values.
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Chapter 3
Research Goal
Evolution does not happen at random and one strain of a bacteria cannot evolve directly to
another arbitrary strain. Nature allows only certain paths in going from one strain to another and
such transformation is influenced by both past mutation and current genetic diversity. Based on
this idea, this research aims to identify what the fHbp antigen of Neisseria meningitidis bacterium
is likely to mutate into so that vaccines and therapies can be developed in advance.
The factor H binding protein (fHbp) was chosen for this research because it is present on the
surface of all strains of N. meningitidis and plays a significant role in the survival of the bacterium in
human blood in the presence of antimicrobial peptides, hence making it a potential vaccine antigen.
The goal of this research is to predict valid new variants of fHbp so that vaccines and therapies can
be developed in advance before the mutants appear and cause the disease. The variants generated
are to have the same sequential and structural properties as those of the original fHbp sequences
but not be duplicates of the existing ones.
Creating new variants of fHbp and validating whether they have the same properties as those
of the existing ones is not a single-step process. The followings are the specific objectives of this
research in order to meet the overall goal.
• Construction of a methodology which is extensible in nature, such that it will form the
foundation for additional work.
• Determination of the characteristics of the existing fHbp sequences.
• Characterization of the constraints between the amino acid positions with variations in the
fHbp sequence alignment.
• Selection of a suitable protein modelling software for predicting the tertiary structures of the
sequences.
• Selection of a suitable software for determining the energy of the tertiary structures.
• Development of a pipeline of programs for generating the new variants of fHbp. The program
should be both extensible and flexible in nature and should be based on the properties of the
existing fHbp sequences. It can be used as a prototype for additional future work.
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• Determination of the validity of new variants based on the properties of the existing fHbp
sequences.
When the overall goal of the research is met, the viability of the variants can be determined in
a wet lab; that is, whether the N. meningitidis bacterium with the proposed altered fHbp antigen
can exist in nature or not. This can be carried out as a future work for this research.
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Chapter 4
Data & Methodology
This section discusses the data collected and the methodology followed for this research. How-
ever, parts of the results of Chapter 5 are also discussed in this section since some of the steps
in the methodology were dependent on the results generated in the previous steps. This has been
done to enhance reader comprehension of each step of the methodology.
4.1 Data
The data—that is, the factor H binding protein sequences for this research—were downloaded
from the UniProtKB database [27]. The sequences were retrieved using ‘fHbp’, ‘gna1870’, or
‘nmb1870’ as the query keyword since all of these are synonyms for factor H binding protein. The
query was further constrained by specifying that the source organism has taxonomy identifier 487,
that for Neisseria meningitidis. In total 270 matching sequences were downloaded on June 09,
2009. There were 197 sequences of fHbp, 72 of gna1870, and 1 sequence of nmb1870.
4.2 Methodology
The methodology followed for this research is illustrated in Figure 4.1 with explanations for
each step in the sections that follow.
Step 1
For this research, all known fHbp sequences independent of serotype and serogroup were down-
loaded from UniProtKB. Other aspects of this step have already been described in Section 4.1.
Step 2
There are duplicates and fragments present in protein sequence databases [32]. One of the prime
reasons for this may be that removing redundancy based on genome annotation (Section 2.1) is a
difficult task. However, removing duplication based on sequence identity is a tractable problem.
Publicly accessible software exists for doing it with high degree of correctness. There is far less
software for removing redundant sequences based on annotation and it gives only mixed results.
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1. Download all known fHbp sequences for N. meningitidis.
2. Filter duplicates and fragments.
3. Perform a multiple sequence alignment of the sequences.
4. Eliminate sequences that do not conform to the established sequence pattern for fHbp. Perform multiple 
sequence alignment on the final set of sequences.
5. Identify and discard the signal protein part.
6. Identify conserved, restricted variable, and unrestricted variable positions in the multiple sequence 
alignment. Identify substitution domains for each restricted variable position.
7. Identify correlation and co-occurrence between positions with restricted variation.
8. Characterize constraints of the restricted variable positions. 
9. Determine the energies and the valid boundary set by the highest energy of fHbp structures.
10. Develop a pipeline of programs using the substitution domains, the correlation and co-occurring 
relationships, and the constraints determined for generating new variants. 
11. Study the new variants generated and filter off the duplicates. 
12. For each new variant which satisfies 
the constraints
13. Predict structure.
14. Determine and record the energy of the structure.
Is the energy below the valid energy 
boundary value determined in Step 9?
15 i. Record as a valid new variant.
Are there any more 
variants left to check?
Set of valid new variants of fHbp that nature might "allow" 
but which have not as yet appeared.
15 ii. Discard as invalid variant.
YESNO
YES
NO
Figure 4.1: Methodology Flow Chart
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At the databases which filter for redundancy, only one type of redundancy filtering is performed.
For instance, UniProtKB filters only by annotation; UniRef filters only by sequence identity. No
database combines these two approaches, for example filtering by both annotation and sequence
identity. Hence, for this research the strategy was to download from UniProtKB to take advantage
of the filtering based on annotation which they provide and then filtering by sequence identity
in-house.
For this research, duplicates and fragments were filtered using an extremely fast protein sequence
clustering program called CD-HIT (Cluster Database at High Identity with Tolerance) [14, 52, 53,
54]. CD-HIT uses a greedy incremental clustering algorithm that is capable of handling large
databases like NCBI’s non-redundant protein database containing more than 560 000 sequences.
The algorithm was developed by Weizhong Li in 2001 and is still under active development, with
promises of new features in future. CD-HIT is used at many research and educational institutions.
For instance, it is used at UniProt (Universal Protein Resource) to generate the UniRef (UniProt
Reference Clusters) clusters at 100%, 90%, and 50% sequence identity thresholds and also at PDB
to remove redundant sequences [52, 53, 54]. CD-HIT has been hosted at bioinformatics.org as an
open source project since 2004 [14].
Using CD-HIT to remove duplicates and fragments.
The three sets of sequences downloaded from UniProtKB were merged into one set, totaling 270
sequences. CD-HIT was then used at 100% sequence identity on this merged set and any duplicates
or fragments identified were removed. This resulted in a set of 200 unique fHbp sequences.
Step 3
This step involved the multiple sequence alignment (Section 2.2) of the 200 sequences obtained
from the previous step using ClustalW. ClustalW was chosen because it is an easy-to-use general
purpose multiple sequence alignment program for DNA or proteins which implements a straightfor-
ward progressive alignment algorithm. A progressive alignment algorithm is one in which sequences
are added one by one in order, starting with the most similar sequences. It takes a modest amount
of time and memory to align a set of 200 sequences of typical length. ClustalW produces biologically
meaningful multiple sequence alignments of non-divergent sequences, as in this case [19, 65].
After the multiple sequence alignment was generated by ClustalW, the EMBOSS prettyplot
program was used to represent it [5]. This was because prettyplot displays aligned sequences with
colouring and boxing, making it easier to locate conserved and variable regions. It reads in a set of
aligned DNA or protein sequences (e.g. the output from ClustalW) and displays them graphically,
with conserved regions highlighted in various ways.
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Step 4
Close study of a sequence alignment facilitates detection of any sequence that may seem erro-
neous or inappropriate. For example, sometimes sequences belonging to a different species may be
inadvertently retrieved from a sequence database. Erroneous or inappropriate sequences should be
discarded at an early stage of the methodology so that they do not adversely affect the results.
Table 4.1: Result generated after investigation of the 200 sequences.
Length of the sequences Number of sequences
84 amino acids 1 sequence
133 amino acids 1 sequence
250-260 amino acids 125 sequences
261-270 amino acids 19 sequences
271-280 amino acids 38 sequences
281-290 amino acids 12 sequences
320 amino acids 1 sequence
427 amino acids 1 sequence
492 amino acids 1 sequence
497 amino acids 1 sequence
In this step of the research, the multiple sequence alignment of the 200 sequences was stud-
ied to identify any sequences that did not conform to the signature criteria of fHbp: having the
amino-terminal repetitive element region and five modular variable segments flanked by invariant
regions [34] as discussed in Section 2.9. The first task was to find the lengths of the 200 sequences in
the merged set. Table 4.1 lists the results. All the sequences were then closely studied to determine
if any were problematic and should be discarded.
Investigating the sequence of length 84 amino acids.
Referring to Table 4.1, there was one sequence with a length of 84 amino acids. Investigation
of the sequence determined that it violated the sequential structure of fHbp sequences as specified
in Section 2.9. Mention of the term ‘fHbp’ in the reference portion of its annotation had resulted
in it being retrieved. Hence it was discarded from the set of fHbp sequences.
Investigating the sequence of length 133 amino acids.
The sequence with 133 amino acids in Table 4.1 was too short according to the allowed sizes
of variable segments mentioned in Section 2.9. Further study showed that this sequence had the
amino-terminal repetitive region, regions VA and VB , but had an incomplete region VC and none
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of the regions VD or VE , confirming that it was an incomplete sequence. Hence this sequence was
eliminated from the final set of fHbp sequences.
Investigating the sequence of length 320 amino acids.
In order to investigate whether the sequence with 320 amino acids could be kept in the final
list of sequences, the results generated by CD-HIT at different sequence identities were examined.
It was found that at 95% sequence identity, 24 sequences clustered with this particular sequence.
Thus the sequence had very high similarity with other sequences in the set. However, there was no
clustering at 100% sequence identity, since all the duplicates were removed in Step 2. In addition,
this sequence had the amino-terminal repetitive region plus all five of the variable segments including
the invariant regions separating the variable segments. Also the size of the variable segments were
as specified in Section 2.9. Hence it was kept in the final list of fHbp sequences.
Investigating the three sequences of length 427, 492, and 497 amino acids.
Of the three longest sequences in Table 4.1, none formed clusters with any other sequences at
100, 95, 90, 85, or 60% sequence identity when CD-HIT was used. However, the sequences clustered
with each other. When these sequences were investigated individually, it was found that they had a
missing invariant ‘SSG’ region after cysteine (C) in the amino-terminal repetitive segment. Instead
they had ‘GGG’. Further studies showed that they had none of the invariant segments that delimit
the five variable regions (Figure 2.2). Upon checking these sequences at the UniProtKB website
it was found that the proteins had ‘fHbp’ in their annotation: “fHbp, nadA and gna2132 in group
B meningococci”. This explained their presence in the retrieved set of sequences. Based on these
findings the three sequences were eliminated from the set of sequences.
Removal of more sequences.
The sequences were further probed to determine if there were any which did not fit the criteria
of having the amino-terminal repetitive region, the invariant regions flanking the variable segments
with the specified number of amino acids in the variable regions as mentioned in Section 2.9. Four
sequences were found to be variant in the amino-terminal repetitive region (Figure 2.2). Normally,
these sequences should have an invariant ‘CSSG’ followed by one to six glycines or serines, followed
by the invariant ‘GG’. Instead, one sequence had ‘GGGSGGGG’ (i.e. 8 glycines or serines) between
the two invariant regions. Another had a sequence with 4 extra glycines or serines (10 in all) between
the invariant regions. The third sequence had an ‘R’ instead of a ‘G’ in the first invariant; that
is, it had ‘CSSR’ instead of ‘CSSG’. The fourth sequence had ‘CSG’ instead of ‘CSSG’ as the first
invariant region. Based on these observations the four sequences were discarded from the set of
sequences.
23
One of the sequences had a missing ‘Q’ in the invariant segment ‘KQ’ at the end of the region
VE ; it only had ‘K’ instead of ‘KQ’. Hence, this sequence was eliminated.
In total this step discarded ten sequences from the set of sequences. As a result the final set
had 190 fHbp sequences. Multiple sequence alignment using ClustalW was performed again on this
final set and the EMBOSS prettyplot program was used to represent it (as was done in Step 3).
Step 5
In this step, the consensus sequence for the multiple sequence alignment was determined. Then,
for each sequence, the mature and signal portions (Section 2.11) were identified, and the signal
portion discarded.
A consensus sequence is a single sequence that represents the most common nucleotide or amino
acid found within corresponding columns of a multiple sequence alignment [57]. The consensus
sequence for this research was created from the multiple sequence alignment using the cons program
from EMBOSS [4].
For this research, SignalP 3.0 Server [17, 35, 63] was used for determining the mature part of the
sequences. SignalP 3.0 server predicts the presence and location of signal peptide cleavage sites in
amino acid sequences from different organisms, including gram-negative prokaryotes. The method
uses a prediction model based on a combination of several artificial neural networks and hidden
Markov models [17, 41]. SignalP 3.0 Server suggests the usage of the consensus sequence as input
for predicting the signal protein part and the mature protein part.
From the published work of Masignani et al. [55], it was already known that the mature part
of the fHbp protein sequence starts from the invariant ‘CSSG’ region. For further confirmation,
SignalP 3.0 Server [17] was used in this research to determine the mature protein part. From
Section 2.6, it was already known that Beernink et al. [34] had divided the fHbp sequence into
various segments where the first part is the amino terminal repetitive segment, termed as the
“N-term” in Figure 2.2. Hence, the consensus sequence up to and including the amino terminal
repetitive region, that is, up to the “N-term” was input to the SignalP 3.0 Server [17]. In response,
the server reported that the mature part of the consensus sequence of the 190 fHbp sequences started
at the cysteine of the amino-terminal repetitive region; that is, it started from the invariant region
‘CSSG’. This was consistent with the finding of Masignani et al. [55]. For further confirmation,
a couple of the 190 fHbp sequences themselves were input to the SignalP 3.0 Server. The results
generated showed the same output like that of the consensus sequence of the 190 fHbp sequences
mentioned above. Hence, the portion upstream of the invariant ‘CSSG’ region was then discarded
from each sequence in the collection. This resulted in a set of 190 sequences with their mature
protein part only.
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Step 6
In a set of homologous protein sequences, there are regions which are conserved and those
which are not conserved (variable). The latter regions can be further divided into two groups:
segments that are restricted, meaning that there is little variation or the variation is very lim-
ited, and segments that are unrestricted, meaning there is a high degree of variation in these
regions. Identification of conserved and variable regions is needed to determine the correlation or
co-occurrence relationships between positions of a homologous set of sequences. Thus, at this step
the conserved, restricted variable, and unrestricted variable regions were identified in the multiple
sequence alignment.
Five scripts (given in Appendix A) were developed to automate this step. These scripts (Ap-
pendix A.4 and A.5) determined which columns were conserved and which were not, and also
whether variation was restricted or unrestricted. They also determined which columns had ‘gap’
symbols (Appendix A.3) and the domain of possible amnio acid substitutions for each restricted
variable position (Appendix A.1 and A.2).
Step 7
For the purpose of this thesis, “correlation” is taken to have a particular meaning. Here,
correlation between different positions in a sequence alignment indicates to what extent a mutation
in one position of an alignment affects the presence or absence of other amino acids in another
position; that is, correlation for this thesis is directional. A co-occurring relationship, on the
other hand, means that the peptides in different positions occur together in a pattern. Two types
of co-occurring relationships were observed in this research: “fully” co-occurring and “partially”
co-occurring. Figure 4.2 illustrates the concepts of correlation and both types of co-occurring
relationships. In the figure, amino acid ‘D’ in position 3 is correlated to the amino acid ‘N’ in
position 1, both of which are highlighted in red for convenience. Whenever ‘D’ occurs in position
3 there has to be an ‘N’ in position 1. However, the reverse is not true. When there is an ‘N’
(highlighted in light green) in position 1 there may be other amino acids in position 3, for instance,
‘E’ and ‘Q’. Hence, amino acid ‘D’ in position 3 is correlated to amino acid ‘N’ in position 1.
Positions 2, 4, 5, and 6 depict a co-occurring relationship among their amino acids, with position 5
illustrating a “partially” co-occurring relationship and positions 2, 4, and 6 a “fully” co-occurring
relationship. It is seen that amino acids ‘A’, ‘V’, ‘L’ (all highlighted in yellow) and amino acids
‘S’, ‘R’, ‘F’ (all highlighted in green) in positions 2, 4, and 6, respectively, occur in coordinated,
fixed manner. Thus positions 2, 4, and 6 are “fully” co-occurring. Amino acids ‘C/I’ (highlighted
in yellow) and ‘M’ (highlighted in green) in position 5 occur in coordination with amino acids of
positions 2, 4, and 6, with amino acids ‘C/I’ constituting the same proportion as the amino acids
‘A’, ‘V’, and ‘L’ in positions 2, 4, and 6. Since there are more than one type of amino acids (‘C/I’)
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Position	  1 Position	  2 Position	  3 Position	  4 Position	  5
G A E V C
G A E V I
N A E V I
N A D V C
N A Q V C
G S Q R M
G S Q R M
N S D R M
G S E R M
G S E R M
N A D V C
N A Q V I
Position	  6
L
L
L
L
L
F
F
F
F
F
L
L
Figure 4.2: Correlation and Co-occurring relationships
constituting the same proportion as the amino acids ‘A’, ‘V’, and ‘L’, the position with more than
one type of amino acids is “partially” co-occurring with the positions with single type of amino
acid. Thus position 5 is “partially” co-occurring with positions 2, 4, and 6. In general, it can be
said that “co-occurrence” is a more restrictive relationship than “correlation”.
For this research, different positions of the aligned sequences were visually examined to deter-
mine if variations in one position of one of the five restricted variable regions were correlated or
co-occurring with changes in another position (which may be part of the same region or a different
one).
Step 8
This step characterizes constraints of the restricted variable positions of the existing fHbp
sequence alignment. The constraints can be molecular evolutionary constraints, structural con-
straints, etc. Constraints help to determine conditions, such as whether one amino acid will have
higher possibility of substituting another amino acid or if mutation between two amino acids in-
volves presence of an intermediate amino acid, etc. For this research, determining the constraints
are important, since they act as templates for generating valid new variants in the later steps.
The following are some constraints, some of which were utilized in this research. The remaining
constraints couldn’t be utilized since they fell outside of the scope of this thesis. However, they can
be carried on as part of future work (Section 6.2).
i. Molecular Evolution. This constraint is based on the evolution or change from one amino
acid to another. The mutation may involve one codon position or more than one. Some
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Asparagine	  (N)
Aspartic	  acid	  (D)
Asparagine	  (N)
Lysine	  (K)
AAT AAC
GAT GAC
AAT AAC
AAA AAG
Figure 4.3: Mutating from asparagine (N) to aspartic acid (D) and from asparagine (N) to
lysine (K) requires nucleotide changes in only one codon position.
mutations require a third–temporary and intermediate–amino acid to which mutation may
occur before going to the final changed amino acid. Amino acid mutations which require
changes in only one codon position are more likely to occur than those which require more
than one or involve an intermediate residue. Another relevant characteristic of molecular
evolution is the distinction between transition and transversion (Section 2.7). Transition
is more likely to occur than transversion because the former involves mutational changes
between the same types of bases; for instance, between the two purine bases or between the
two pyrimidine bases. The later involves mutational changes between the two different types
of bases, purines and pyrimidines.
The following examples illustrate the ideas above.
Example 1. Mutating from asparagine (N) to aspartic acid (D) and from asparagine (N) to
lysine (K) requires nucleotide changes in only one codon position as illustrated by Figure 4.3.
For both the evolutions, change is required in only one codon position. Despite this, according
to the properties of the amino acids illustrated in “Amino Acid Properties and Consequences
of Substitutions” in the book “Bioinformatics for Geneticists” [36], the likelihood of mutating
from asparagine (N) to aspartic acid (D) is greater than that from asparagine (N) to lysine
(K); that is, substitution of N by D is more favored than substitution of N by K. In addition,
the evolution from N to D is a transition since the nucleotide change has been between two
purines (adenine and guanine) whereas the one between N to K is transversion involving
change from pyrimidine to purine (thymine to adenine and cytosine to guanine). Hence, this
example illustrates the constraint where one amino acid has higher possibility of substituting
for another amino acid.
Example 2. Suppose asparagine (N) is substituted for glutamine (Q). There are two codons
for N and two for Q. It is possible for both the codons for N to mutate to a codon for Q by
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Asparagine	  (N)
Histidine	  (H)
Glutamine	  (Q)
AAT AAC
CAT CAC
CAA CAG
Figure 4.4: Mutating from asparagine (N) to glutamine (Q) involves mutating to an inter-
mediate codon for histidine (H).
involving an intermediate codon for histidine (H), with one nucleotide substitution resulting
in the codon for H and a second yielding the codon for Q. This is illustrated in Figure 4.4.
Since the mutation from N to H involves change in only one nucleotide and that to Q involves
two nucleotides, there is a high possibility of N mutating to H before it mutates to Q; that
is, mutating to an intermediate amino acid before mutating to the final amino acid. In
addition, according to the substitution properties illustrated in “Amino Acid Properties and
Consequences of Substitutions” [36], substitution of N by H is more favoured than substitution
of N by Q. Hence, this example illustrates the constraint where the mutation from one amino
acid to another may involve an intermediate amino acid.
The positive and negative selection sites in a sequence alignment is another aspect leading
to significant constraints on molecular evolution (Section 2.7 discusses positive and negative
selection pressure); for instance, positive selection sites would be more likely to change, and
amino acids in these positions would be more prone to mutation, thus changing to different
amino acids. The negative selection sites, on the other hand, would tend to be more conserved.
Also, these sites would more likely be binding sites of a protein molecule, since the binding
sites tend to remain unchanged, so that they would be recognized by the molecule with which
they bind.
Codon-based detection of positive and negative selection involves a method known as the
sliding window approach. It requires two parameters: a window width and a step length.
The window width is the size of the range of positions in a sequence alignment that is taken
into account for determining the KA/KS ratio for those positions. Step length is the number
of positions that the window is moved along the alignment in order to determine the next
KA/KS ratio [81]. If the ratio of KA/KS is greater than 1, then the positions within that
window width are under positive selection pressure and if it is less than 1, then they are under
negative selection pressure [56]. There are many tools which determine the ratio of KA/KS ;
for instance, MEGA4 [22, 76], WSPMaker [51], and KaKs Calculator 2.0 [2, 83].
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ii. Spatial and physicochemical constraints. This constraint is based on the tertiary structures of
the sequences and the physicochemical properties of the amino acids. The tertiary structural
constraints would involve two things:
(a) amino acids that must be within certain distances of each other to form, for example,
an active site;
(b) amino acids with conflicting physicochemical properties that cannot be within certain
proximities of each other.
The tertiary structures can be predicted using various protein modelling software which can
predict the structures and can also provide information about protein folding, interactions,
etc. Some widely used protein modelling servers involved in tertiary structure prediction
are SWISS-MODEL [13, 33, 47, 67], CPHmodels [15, 64], and EsyPred3D [21, 50], all of
which are good at predicting structures. Also, the protein structures can be superimposed
on each other in order to determine the differences in their structures and to calculate their
respective root mean square deviation (termed RMSD). RMSD is the measure of the average
distance between the backbones of superimposed protein structures and is usually measured
in Angstroms, A˚ [10]. The higher the RMSD value, the more deviated the structures are.
There are various molecular modelling and visualization tools which can be used to view the
tertiary structures; for instance, Swiss-PdbViewer [20, 45], Rasmol [26, 69], Jmol [12], and
PyMol [25, 71].
iii. Sampling frequency. This constraint is based on the amino acid combinations that are not
observed in a sequence alignment. This is an important but the most difficult category to
deal with because it means that a combination of amino acids is not taken into consideration
since it is not seen in the collection of the sequences that has been gathered. Not seeing a
specific correlation or co-occurrence of certain amino acids does not mean it does not occur at
all in nature. There can be instances where certain positions must have specific amino acids
together but the combination was not considered because it was not seen in the sequences
collected for a research. Hence, the constraint here involves taking into consideration all the
allowed combinations of amino acids either correlated or co-occurring with each other.
For this research, the purpose of this step was to determine the constraints on the restricted
variable positions. Hence, the three constraints characterized above can be used while generating
the new variants of fHbp. Below described are the characterized constraints and how some of them
have been implemented in this research.
i. Molecular Evolution. Finding amino acids where one has higher possibility of substituting
another amino acid and finding intermediate residues in possible mutations was deemed out
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of the scope of the thesis, hence this aspect of molecular evolution was not included in this
research work. However, it can be considered as a prospective future work for this research
as discussed in Section 6.2 (Future Work).
Determining the ratio of KA/KS for detecting positive and negative selection sites was in-
cluded in this research. This was done in order to establish the templates for generating valid
new variants. The determination of KA/KS ratio required nucleotide sequences of the protein
sequences. Hence, each corresponding nucleotide sequence of the 190 fHbp sequences were
downloaded from UniProtKB. Since our 190 fHbp sequences were closely related, the approx-
imate method was used for determining the KA/KS ratio. The tool used for this purpose
was MEGA4 [22, 76]. MEGA4 has in total five methods by which the KA/KS ratio can be
calculated. The most recent method is the Kumar Method, which is a modification of previ-
ous methods [62]. In addition, this method takes into account transitions and transversions
between codons while calculating KA/KS . For these reasons, the Kumar Method was chosen.
The sliding window approach was used, where the window width was 18 base pairs and the
step length was 3 base pairs. KS was estimated from the whole sequence alignment of the 190
sequences. This was because KS tends to 0 for closely related sequences (like the 190 fHbp
sequences of this research) and/or when the window size is small [81].
ii. Spatial and physicochemical constraints. SWISS-MODEL [13, 33, 47, 67] was used for pre-
dicting the tertiary structures of the 190 fHbp sequences. SWISS-MODEL, a fully automated
protein structure homology-modeling server, is a web-based integrated service that assists
and guides in building protein homology models at different levels of complexity. For vi-
sualization, analysis, superimposition between two structures and for RMSD calculations
Swiss-PdbViewer (also known as DeepView) [20, 45] was used.
The mutationally correlated or co-occurring positions in region VA were studied in the ter-
tiary structures generated by SWISS-MODEL and Swiss-PdbViewer. Positions that were
spatially close to this region were taken into consideration. This resulted in examining not
only positions within region VA, but also segments from the other regions (VB - VE). It was
observed that even though residues were far apart in the sequential alignment, they could be
in close spatial proximity in the tertiary structures and have a correlational or co-occurring
relationships between them. It was out of the scope of this thesis to consider the second ter-
tiary structural constraint mentioned above: “amino acids with conflicting physicochemical
properties that cannot be within certain proximities of each other”. However, in future, this
constraint can be considered.
iii. Sampling frequency. This research was strictly based on the sequences that were collected
from UniProtKB (Section 4.1) and the combinations of amino acids considered were from the
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alignment of those sequences. Hence, the constraint involving taking into consideration all
the possible combinations of amino acids either correlated or co-occurring with each other was
not utilized for this thesis. Correlations, co-occurrences and the domain of possible amino
acid substitutions for each position were taken into considerations only if they were seen to
occur in the sequences downloaded for this research.
Step 9
Energy of protein structures reflects conformational changes, mutations, and structural defor-
mations and other disorders [58]. Section 2.9 briefly outlines the importance of the energy of protein
structures. There are various tools to determine the energy of protein structures and FoldX is a
widely-used one. It is a computer algorithm developed at the European Molecular Biology Labora-
tory in Heidelberg. FoldX uses a full atomic description of the structures of proteins [44, 72, 73, 74].
The FoldX energy function is as follows [44, 72, 73, 74]:
∆G = Wvdw • ∆Gvdw + WsolvH • ∆GsolvH + WsolvP • ∆GsolvP + ∆Gwb + ∆Ghbond+
∆Gel + ∆GKon + Wmc • T • ∆Smc + Wsc • T • ∆Ssc
• ∆G : free energy of unfolding of a target protein
• ∆Gvdw : sum of the van der Waals contributions of all atoms with respect to the same
interactions with the solvent
• ∆GsolvH : difference in solvation energy for apolar group when they change from the unfolded
to the folded state
• ∆GsolvP : difference in solvation energy for polar group when they change from the unfolded
to the folded state
• ∆Gwb : extra stabilising free energy provided by a water molecule making more than one
hydrogen bond to the protein (water bridges) that cannot be taken into account with non-
explicit solvent approximations
• ∆Ghbond : free energy difference between the formation of an intra-molecular hydrogen bond
compared to inter-molecular hydrogen-bond formation (with solvent)
• ∆Gel : the electrostatic contribution of charged groups, including the helix dipole
• ∆Smc : entropy cost of fixing the backbone in the folded state and this is dependent on the
intrinsic tendency of a particular amino acid to adopt certain dihedral angles
• ∆Ssc : entropic cost of fixing a side chain in a particular conformation
• ∆GKon : reflects the effect of electrostatic interactions on the association constant Kon (this
applies only to the subunit binding energies)
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Figure 4.5: Modular structure of the pipeline of programs
• Wvdw, WsolvH , WsolvP , Wmc, and Wsc (van der Waals contribution), which is 0.33 (the van
der Waals contributions are derived from vapor to water energy transfer, while in the protein
it derived when going from solvent to protein).
From the previous step we had the tertiary structures of all the 190 fHbp sequences. Now as
the first stage of this step, energy minimization was performed on these 190 tertiary structures.
The energy minimization was performed using Swiss-PdbViewer [20, 45], which repairs distorted
geometrics by moving atoms [20, 45]. Next, FoldX was used on the structures with minimized
energy and energy values were calculated. From these energy values the highest energy value was
identified in order to set the boundary for the valid energy values that fHbp sequences can have.
Step 10
In this step a pipeline of programs was developed using the domains of possible amino acid
substitutions for each position (Step 6), the correlation and co-occurrence relationships (Step 7)
and all the constraints determined (Step 8) for generating new variants. The programs were written
in the Perl programming language and were coordinated using a UNIX shell script written in bash.
Each program had different functionality in setting the amino acids for the different positions in
the alignment. There were programs which only generated amino acids for the positive selection
sites, programs which generated amino acids for the amino-terminal repetitive regions, programs
for the conserved regions and for the restricted variable regions, etc. Algorithm 4.1 to Algorithm 4.6
illustrate some of the programs implementing these various functions. A design goal of the pipeline
was flexibility in the order of execution of individual programs; that is, the order of the Perl scripts
within the pipeline could be varied. The exception was the first program in the pipeline. To achieve
this design goal each program was made independent and able to use outputs generated from any
program preceding it in the pipeline. Another characteristic was that additional Perl scripts (e.g.
implementing additional constraints) can be added to the pipeline—there is no fundamental limit
on the number of components that can be added. One unfortunate consequence of this design was
that the pipeline was quite long. This cost was considered minor compared to the benefits of the
design. Figure 4.5 illustrates the modular structure of the pipeline.
In addition to the substitution domains, correlation and co-occurring relationships and all the
constraints, the following characteristics were taken into consideration for the pipeline:
32
i. The number of new variants to be generated is specified as a command line argument to the
first program in the pipeline.
ii. The first program in the pipeline generates the initial variants and does not have any input,
whereas all the other programs read as input the output generated from the program preceding
it in the pipeline.
iii. Since the maximum length of the mature part of the 190 fHbp sequences was 263, a maximum
of 263 was used for the length of new variants.
iv. The final output is the set of variants of fHbp generated by the last program in the pipeline.
v. The amino acid substitution domains for the variable positions, the correlation and co-
occurring characteristics, and the constraints were incorporated in the pipeline of programs.
vi. The constraints associated with separate positions can and did interact in complex ways; for
instance, programs in the beginning of the pipeline generated the amino acids for a particular
position following the constraint associated with the positive selection sites, and some of these
positive selection sites may have correlated or co-occurring relationships with other positions
which were not positive selection sites. When the amino acids for a particular position
following the constraints associated with the correlated or co-occurring characteristics were
generated by programs later in the pipeline, the amino acids associated with the positive
selection sites already generated would again be included in this later program due to its
correlated or co-occurring characteristics. This meant that the same position could have an
interference problem due to repeated generation of amino acids for these positions. For such
positions there were two alternatives.
• First, if the amino acid was already set for a particular position, then we keep that
setting.
• The alternative is to allow subsequent steps to modify an already placed amino acid
according to the constraints at that stage.
For our program we decided to implement the first option. The alternative option can be
implemented as future work (Section 6.2).
vii. A random number generator, the Perl function rand, was used to generate the amino acids in
positions which were not conserved. Random floating-point numbers uniformly distributed
between 0 and 100 were generated [78]. The occurrence frequencies of the amino acids in each
position of the original 190 sequences determined in step 6 were translated to a scale of 100%
(Figure 4.6 where the scale of 100 is given to one decimal place). The scale is divided into n
intervals, where n is the number of different amino acids which occur at that position. The size
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Figure 4.6: Frequency of amino acids for a particular position of the 190 fHbp sequence
alignment represented on a scale of 100%
of each interval is proportional to the occurrence frequency of the corresponding amino acid
at that position. By mapping the generated random number (between 0 and 100) onto this
scale, an amino acid can be generated with the appropriate frequency. Figure 4.6 illustrates
this concept with an example involving position 19 of the alignment. At this position, only
three amino acids appeared: A, T, and V. Amino acid A appeared 72.6% of the time, T
25.3%, and V 2.1%. To produce an amino acid for this position, a random number uniformly
distributed between 0 and 100 is generated as described above. If the random number was
between 0 to 72.6 (not inclusive) then an ‘A’ was produced for that position. If the random
number was between 72.6 to 97.9 (not inclusive) then a ‘T’ was produced. Finally, if the
random number was between 97.9 to 100 (not inclusive) then a ‘V’ was produced.
The rand function was also used in setting the correlation or co-occurring relationships be-
tween the different positions in the alignment. The same random number was used to generate
the amino acids for the correlated and the “fully” and “partially” co-occurring positions, so
that the frequency at which the amino acids occurred remained the same for all these posi-
tions. For example, position 19 illustrated in Figure 4.6 is “fully” co-occurring with position
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20, where the amino acids, C, I, and L appear. Since the positions are “fully” co-occurring
the amino acids will occur in the same percentages; that is, C appearing 72.6%, I 25.3%,
and L 2.1% in relation with amino acids A, T, and V respectively of position 19. The amino
acids for both the positions will be generated by the same random number and in one single
program of the pipeline.
As mentioned above, the Perl programs were coordinated in the pipeline using a UNIX shell
script. The input for each program was read from standard input from the program preceding
it in the pipeline except for the first program in the pipeline. The output of each program was
generated on the standard output. This was done to facilitate inter-operability and for monitoring
the operation of the pipeline.
Algorithm 4.1 Algorithm for the first program in the pipeline.
1 Read the number of variants to be generated as input from the command line argument
2 Set the maximum length of the variants to 263 amino acids long
3 For each new variant to be generated
4 Mark the first invariable part of the amino-terminal repetitive region, ‘CSSG’
5 For the next six variable positions of the amino-terminal repetitive region which
is comprised of glycines (G), serines (S), or ‘gap’ ‘–’
6 Use the rand function to generate a random floating point number on a scale of 0 to 100
7 Mark ‘G’, ‘S’, or ‘–’ based on the random value
8 Mark the last invariable part of the amino-terminal repetitive region, ‘GG’
9 Mark the five invariant segments which flank the variable regions VA - VE
10 Mark the five modular variable regions VA - VE as ‘X’
11 Output the initial variants to standard output
Algorithm 4.2 Algorithm for the program which denotes the negative selection sites as ‘n’ and
the positive selection sites as ‘p’.
1 Read a line from standard input and store it in a two-dimensional array where index i
represents each variant (row) and index j columns (positions in the variant)
2 For each variant (row)
3 Locate the negative selection sites
4 Mark ‘n’ as a symbol for the negative selection sites which are currently using ‘X’
5 Locate the positive selection sites
6 Mark ‘p’ as a symbol for the positive selection sites which are currently using ‘X’
7 Mark the remaining positions unchanged
8 Output the result to standard output
Algorithm 4.1, the first program in the pipeline, outputs the amino-terminal repetitive region
and the invariant segments that flank the modular variable regions VA through VE . For the variable
region in the amino-terminal repetitive segment, the program generates ‘G’, ‘S’ or ‘gap’ (‘–’) using
the random number based generator explained above. For the remaining modular variable regions
(VA, VB , VC , VD, and VE), it outputs ‘X’. Figure 4.7 shows portions of the output generated from
this algorithm: the amino-terminal repetitive region, invariant segments ‘SRFDF’ and ‘GEFQ’,
and the two modular variable regions VA and VB (flanked by ‘SRFDF’) marked by ‘X’. The 8 lines
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Algorithm 4.3 Algorithm for a program which determines the amino acids for positions with
correlations.
1 Read a line from standard input and store it in a two-dimensional array where index i
represents each variant and index j columns within the variants
2 For each variant
3 Use the rand function to generate a random floating point number on a scale of 0 to 100
4 For each position which is correlated to other position(s)
5 If the position which is correlated to other position(s) is ‘X’, ‘n’, or ‘p’ and if the
random value generated corresponds to outputting the amino acid with
correlational characteristics
6 Check the other positions with which this position is correlated
7 If they are ‘X’, ‘n’, or ‘p’
8 Mark the amino acids that should be in all the positions
for the correlation to exist
9 If the required amino acids for correlational characteristic already exists
10 Mark the amino acid in the position which is correlated to others
11 If some other amino acids or gap ‘–’ exists
12 Go back to step 3 and generate a new random number in order to
mark a different amino acid
13 Mark the remaining positions unchanged
14 Output the result to standard output
Algorithm 4.4 Algorithm for a program which determines the amino acids for positions with
“fully” and “partially” co-occurring relationships.
1 Read a line from standard input and store it in a two-dimensional array where index i
represents each variant and index j columns within the variants
2 For each variant
3 Use the rand function to generate a random floating point number on a scale of 0 to 100
4 For each position with “fully” or “partially” co-occurring relationship
5 Check if it is ‘X’, ‘n’, or ‘p’
6 Mark the amino acids or gaps ‘–’ allowed for this position based on the
random value generated by the rand function
7 Mark the remaining positions unchanged
8 Output the result to standard output
Algorithm 4.5 Algorithm for a program which determines the amino acids for conserved positions.
1 Read a line from standard input and store it in a two-dimensional array where index i
represents each variant and index j columns within the variants
2 For each variant
3 Locate the position that is supposed to be conserved
4 Check if it is ‘X’, ‘n’, or ‘p’
5 Mark the amino acid intended for the conserved position
6 Mark the remaining positions unchanged
7 Output the result to standard output
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Algorithm 4.6 Algorithm for a program which determines the amino acids for restricted variable
positions with no correlation or co-occurring relationships.
1 Read a line from standard input and store it in a two-dimensional array where index i
represents each variant and index j columns within the variants
2 For each variant
3 Use the rand function to generate a random floating point value on a scale of 0 to 100
4 Locate the restricted variable position
5 Check if it is ‘X’, ‘n’, or ‘p’
6 Mark the amino acids according to the random value generated in step 3
7 Mark the remaining positions unchanged
8 Output the result to standard output
in Figure 4.7 are randomly selected from the output file of Algorithm 4.1 and shows positions 1
through 105.
Algorithm 4.2 symbolizes the negative selection sites as ‘n’ and the positive selections sites as
‘p’ only if they are already designated as ‘X’. The negative and positive selection sites are derived
from Step 8. It is observed that none of the negative or positive selection sites overlapped with
the invariant segments and all are in the variant regions. Portions of the output generated by this
algorithm are shown in Figure 4.8, where the negative selection sites are marked by ‘n’ and the
positive selection sites by ‘p’. The 8 lines and the positions 1 through 105 in this figure correspond
to those in Figure 4.7.
Algorithm 4.3 outputs the amino acids for the correlated positions. It generates a random
value using the rand function based on the concept depicted in Figure 4.6 in order to determine
whether the amino acid required to establish the correlational characteristic will be output. In
addition, it checks if the position correlated to other positions is designated as ‘X’, ‘n’, or ‘p’. If
all these conditions are satisfied, the program checks the positions to which this particular position
is correlated. If these positions are either ‘X’, ‘n’, or ‘p’ then the amino acids for all the positions
involved in the correlation are marked with the appropriate amino acids. If not, the program checks
if these positions already had the required amino acids for correlational characteristic, and then
the program marks the position which is correlated to these positions with the appropriate amino
acid. If this condition also turns out to be false and the positions had either different amino acids
or ‘gap’ (‘–’), then the program loops back to step 3 and generates a new random value to mark
the position with different amino acids. Figure 4.9 shows 8 lines (positions 34 through 130) which
are randomly selected from the output of Algorithm 4.3 and illustrates correlation between the two
positions, 122 and 125. This is a case where the position of interest (position 125) is correlated to
a position preceding it in the alignment (position 122). In this example, whenever there is an ‘L’ in
position 125 marked by the red arrow, there is always an ‘E’ in position 122 marked by the black
arrow. However, the reverse is not true. Hence, position 125 is correlated to position 122 but not
vice-versa.
Algorithm 4.4 illustrates a program which outputs amino acids for the positions with “fully” and
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CSSGGG-S-SGGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
CSSGG-GS-GGGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
CSSGG-----GGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
CSSGG-G---GGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
CSSGG--S-SGGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
CSSGGG-SG-GGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
CSSG-----GGGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
CSSGGGG--GGGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
Figure 4.7: Portions of the output generated by Algorithm 4.1. This is the output generated
by the first program in the pipeline.
“partially” co-occurring relationships. It uses the rand function based on the concept depicted in
Figure 4.6. It also uses the rand function for generating the amino acids in the same frequency for
all the positions with both types of co-occurring relationships (mentioned above). Figure 4.10 shows
15 lines (positions 1 through 86) which are randomly selected from the output of Algorithm 4.4
and illustrates both types of co-occurring relationship between the positions. Columns marked by
the blue arrows (that is, positions 43, 45, 49, 50, and 52) exhibit “fully” co-occurring relationship.
Columns marked by the red arrows (that is, positions 37, 42, 46, and 47) exhibit “partially” co-
occurring relationships. Both sets of marked positions are co-occurring with each other. Hence,
positions 37, 42, 43, 45, 46, 47, 49, 50, 52 are either always ‘Q/R’, ‘D/N’, ‘Q’, ‘V’, ‘R’, ‘K/R’, ‘E’,
‘K’, ‘K’, respectively, or else they are ‘K’, ‘E’, ‘D’, ‘I’, ‘S/P’, ‘Q’, ‘G’, ‘T’, ‘T’, respectively.
Algorithm 4.5 illustrates a program which outputs amino acids for conserved positions. It checks
if the position is designated as ‘X’, ‘n’, or ‘p’ and outputs the appropriate amino acid provided that
the condition is satisfied.
Algorithm 4.6 illustrates a program which outputs amino acids for the restricted variable position
where no correlation or co-occurrence is involved. The program uses the rand function in the same
way as explained in Figure 4.6. Next, it checks if the position is designated as ‘X’, ‘n’, or ‘p’ and
outputs the appropriate amino acids provided the condition is true.
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CSSGGG-S-SGGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXnXXnnnXXXXXXXXXXXXXpppppppXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
CSSGG-GS-GGGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXnXXnnnXXXXXXXXXXXXXpppppppXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
CSSGG-----GGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXnXXnnnXXXXXXXXXXXXXpppppppXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
CSSGG-G---GGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXnXXnnnXXXXXXXXXXXXXpppppppXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
CSSGG--S-SGGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXnXXnnnXXXXXXXXXXXXXpppppppXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
CSSGGG-SG-GGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXnXXnnnXXXXXXXXXXXXXpppppppXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
CSSG-----GGGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXnXXnnnXXXXXXXXXXXXXpppppppXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
CSSGGGG--GGGXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXnXXnnnXXXXXXXXXXXXXpppppppXXXXXXXXXXXXXSRFDFXXXXXXXXXXXXXXXGEFQ
Figure 4.8: Portions of the output generated by Algorithm 4.2, illustrating the negative
and the positive selection sites as ‘n’ and ‘p’ respectively.
KSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGD---SLNTGKLKNDKVSRFDFVQKIEVDRQTITLASGEFQVYKQSHSALTALQIEQEQDSEDSGS
KSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGD---SLNTGKLKNDKVSRFDFIRQIEVDGQLITLESGEFQVYKQDHSAVVALQIEKINNPDKIDK
KSLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGD---SLNTGKLKNDKVSRFDFIRQIEVDGQLITLESGEFQIYKQSHSALTALQIEQEQDLEHSGK
KGLQSLTLDQSVRKNEKLKLAAQGAEKTFKAGDKDNSLNTGKLKNDKVSRFDFIRQIEVDGQLITLENGEFQVYKQSHSALTALQTEQIQDSEHSGK
KGLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGD---SLNTGKLKNDKISRFDFIRQIEVDGQLITLESGEFQVYKQDHSAVVALQTEKINNPDKIDS
KGLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGD---SLNTGKLKNDKISRFDFIRQIEVDGQLITLESGEFQIYKQSHSALTAFQTEQEQDLEHSGS
KGLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGD---SLNTGKLKNDKVSRFDFIRQIEVDGQLITLESGEFQIYKQSHSALTALQIEQEQDPEHSGK
KGLQSLTLDQSVRKNEKLKLAAQGAEKTYGNGD---SLNTGKLKNDKVSRFDFIRQIEVDGQLITLESGEFQVYKQDHSAVVALQIEKEQDSDKIDK
Figure 4.9: Portions of the output generated by Algorithm 4.3, illustrating correlation.
Position marked by the red arrow is correlated to the position marked by the black arrow.
CSSGG----GGGVAADIGAGLADALTAPLDHKDKSLQXXXXDQXVRKnEKXKXAXXXXXXXYGNGD---XXXXXXXXXXXXSRFDF
CSSG-----SGGVAADIGAGLADALTAPLDHKDKGLQXXXXDQXVRKnEKXKXAXXXXXXXYGNGD---XXXXXXXXXXXXSRFDF
CSSGG--S-GGGVAADIGAGLADALTALLDHKDKGLQXXXXDQXVRKnEKXKXAXXXXXXXYGNGD---XXXXXXXXXXXXSRFDF
CSSGG-G--GGGVAADIGAGLADALTAPLDHKDKGLQXXXXDQXVRKnEKXKXAXXXXXXXFKAGDKDNXXXXXXXXXXXXSRFDF
CSSG-----GGGVAADIGAGLADALTAPLDHKDKGLKXXXXEDXIPQnGTXTXSXXXXXXXYGNGD---XXXXXXXXXXXXSRFDF
CSSGG-G--GGGVAADIGAGLADALTAPLDHKDKSLRXXXXDQXVRKnEKXKXSXXXXXXXFKAGDKDNXXXXXXXXXXXXSRFDF
CSSGG---G-GGVAADIGAGLADALTAPLDHKDKGLKXXXXEDXIPQnGTXTXSXXXXXXXYGNGD---XXXXXXXXXXXXSRFDF
CSSGGGG-GGGGVAADIGAGLADALTAPLDHKDKSLQXXXXDQXVRKnEKXKXAXXXXXXXFKAGDKDNXXXXXXXXXXXXSRFDF
CSSGG--S--GGVAADIGAGLADALTAPLDHKDKGLQXXXXDQXVRKnEKXKXAXXXXXXXYGNGD---XXXXXXXXXXXXSRFDF
CSSGG----GGGVAADIGAGLADALTTPLDHKDKGLKXXXXEDXIPQnGTXTXSXXXXXXXYGNGD---XXXXXXXXXXXXSRFDF
CSSGS-G-G-GGVAADIGAGLADALTAPLDHKDKGLKXXXXEDXIPQnGTXTXSXXXXXXXYGNGD---XXXXXXXXXXXXSRFDF
CSSGGG----GGVAADIGAGLADALTTPLDHKDKGLKXXXXEDXIPQnGTXTXSXXXXXXXYGNGD---XXXXXXXXXXXXSRFDF
CSSGG---GSGGVAADIGAGLADALTAPLDHKDKGLQXXXXDQXVRKnEKXKXAXXXXXXXFKVGDKDNXXXXXXXXXXXXSRFDF
CSSG---S-GGGVAADIGAGLADALTAPLDHKDKGLKXXXXEDXIPQnGTXTXSXXXXXXXFKAGDKDNXXXXXXXXXXXXSRFDF
CSSGGG---GGGVAADIGAGLADALTAPLDHKDKGLQXXXXDQXVRKnEKXKXAXXXXXXXFKAGDKDNXXXXXXXXXXXXSRFDF
Figure 4.10: Portions of the output generated by Algorithm 4.4 illustrating “fully” and
“partially” co-occurring relationships. The blue arrows mark the “fully” co-occurring posi-
tions and the red arrows mark the “partially” co-occurring ones.
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Step 11
In this step, the set of new variants generated in the previous step was examined for duplicates
and to determine if any of the new variants were duplicates of any of the original 190 fHbp sequences.
To accomplish this, CD-HIT was run at 100% sequence identity on a merged file containing the
190 fHbp sequences and the set of new variants. The second task was to determine the conserved,
restricted variable regions, and the amino acid substitution domains for the variable positions in
the variants; for this the scripts of Appendix A were used again. The next task was to determine
if the same correlations, co-occurrences and constraints determined for the existing sequences also
exhibited in the variants.
Step 12
This step begins a loop involving Steps 13, 14, and the two branches of Step 15. This loop was
executed for each new variant that was generated in Step 10 and studied for validity in Step 11.
The loop involves predicting the tertiary structure of each new variant and then determining and
recording the energy values of the structure. The last task involved validating the new variants
based on their energy values; that is, if the energy values fell within the boundary defined by the
existing fHbp sequences.
Step 13
This step determines the structures of each of the new variants. The same tools were used
as those for the original fHbp sequences: SWISS-MODEL [13, 33, 47, 67] to derive the tertiary
structures of the new variants and Swiss-PdbViewer [20, 45] for visualizing the structures. It was
also recorded whether SWISS-MODEL used the same model structures for the new variants as it
used for the existing fHbp sequences.
Step 14
This step involves the energy determination of the structures of the variants derived in the
previous step. The same procedure and tools were used as were used for the original fHbp sequences.
At first, energy minimization of all the variants was performed using Swiss-PDBViewer [20, 45], so
that the same procedure was followed for both the existing sequences and predicted variants.
The next phase of this step determines and records the energy values of the structures of all
the new variants using FoldX [44, 72, 73, 74], as was done for the original fHbp sequences. As each
energy value was calculated, it was checked against the valid boundary energy value determined in
Step 9 from the energy values of the 190 fHbp sequences.
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Step 15
In this step, the energy values determined in the previous step were examined and the disposition
of the new variant was determined as follows:
• Step 15 i
If the energy value of the variant was within the valid boundary for energy, then the variant
was recorded as a valid variant.
• Step 15 ii
If the energy value of the variant was above the valid boundary, then the variant was discarded
as an invalid variant.
After Steps 12 to 15 were executed for all the variants, the result was a set of valid new variants.
These valid new variants of fHbp were the ones that nature might “allow” but which have not as yet
appeared. The end result of this research is illustrated by the parallelogram highlighted in yellow
in the methodology flow chart (Figure 4.1).
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Chapter 5
Results
This chapter presents, discusses, and analyzes the results generated in this research.
5.1 Identifying the amino-terminal repetitive region and the
five modular variable regions
This section discusses the results generated from Steps 1 to 4 of the Methodology (Figure 4.1).
In total, 270 sequences of fHbp were downloaded from UniProtKB out of which the duplicates
and fragments were discarded using the CD-HIT algorithm. This reduced the number of sequences
to 200. The 200 sequences were then aligned using ClustalW. Further study of the multiple sequence
alignment revealed that there were ten sequences which did not conform to the pattern for fHbp
identified by Beernink et al. [34] (Section 2.6). The 10 sequences were discarded leaving a total of
190 fHbp sequences.
5.2 Identifying the mature protein part
This section discusses the results generated from Step 5 of the Methodology (Figure 4.1).
The first task was to determine the consensus sequence pattern for fHbp identified by Beernink
et al. [34]. EMBOSS cons algorithm was used to generate the consensus sequence illustrated in
Figure 5.1.
The portion up to and including the amino terminal repetitive segment (designated as the “N-
term” in Figure 2.2) of the consensus sequence (Figure 5.1) was then input into the SignalP 3.0
Server [17]—as discussed in Step 5 of Section 4.2—to determine the signal and mature protein
portion of the sequence. The black arrow in Figure 5.1 illustrates the end of the region up to and
including the amino terminal repetitive segment in the consensus sequence and comprises of 37
peptides.
Figure 5.2 illustrates the output generated by SignalP 3.0 server using a Neural Network
(SignalP-NN). The SignalP-NN output is comprised of scores, C, S, Y, S-mean, and D. The S
score reports the signal peptide prediction for each amino acid, with high scores indicating that the
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>EMBOSS_001
MTRSKPMNRTAFCCLSLTAALILTACSSGGGGSGGGGVAADIGAGLADALTAPLDHKDKG
LQSLTLDQSVRKNEKLKLAAQGAEKTYGNGDKDNSLNTGKLKNDKVSRFDFIRQIEVDGQ
LITLESGEFQVYKQSHSALTALQTEQIQDPDHSGKMVNKRQFRIGDIGGEHTSFDKLPKG
GKATYHGTAFGSDDAGGKLTYTIDFAAKQGHGKIEHLKTPELNVELAAAEIKPDEKHHAV
ISGDTLYNQEEKGTYHLGIFGGRAQEVAGSAEVKTANGIHHIGLAGKQEPL
Figure 5.1: The consensus sequence of the 190 fHbp sequences. The black arrow marks the
end of the portion up to and including the amino terminal repetitive segment.
amino acid is part of the signal peptide, and low scores indicating that the amino acid is part of
the mature protein part [16]. The tabular output in Figure 5.2 shows that the amino acids starting
from position 1 have a high S-score, with the values decreasing somewhat over positions 23 to 28.
There is a sharp decrease in score from positions 28 to 31, with the score continuing to be low for
the remaining amino acids. The graph in Figure 5.2 illustrates the same output with the S score
highlighted in light green colour. The C score is the “cleavage site” score, which marks the end
of the signal part and the beginning of the mature protein part [16, 35, 63]. The Y score is a
derivative of the C score combined with the S score, resulting in a better cleavage site prediction
than the raw C score alone. This is because multiple high-peaking C scores can be found in a
sequence, where only one is the actual true cleavage site [16, 35, 63]. From the graph of Figure 5.2,
it can be seen that there are multiple cleavage sites marked by both the red bars (C scores) and the
blue line (Y score) with the residue cysteine (C) of ‘CSSG’ region marked as one of the cleavage
sites. However, the highest C and Y scores are in position 20, indicating a possibility of the start
of the matured protein part. The S-mean score is the average of the S score, ranging from the N-
terminal amino acid to the amino acid assigned with the highest Y-max score; that is, the S-mean
score is calculated for the length of the predicted signal peptide. The D-mean score is the average
of the S-mean and Y-max score, which also determines the signal peptide region [16, 35, 63]. In
Figure 5.2, the values of the S-mean and D-mean score indicates that the signal peptide region
is from position 1 to 19 with the amino acid in position 20 serving as the first amino acid of the
mature protein part.
Figure 5.3 illustrates the output generated by the SignalP 3.0 Server using the Hidden Markov
Models (SignalP-HMM). The Hidden Markov Model calculates the probability of whether the sub-
mitted sequence contains a signal peptide or not; this is depicted by the S score [16]. Figure 5.3
shows the probability of being a signal peptide, illustrated by the S score being 1 for positions 1 to
25, and decreasing sharply at position 26 which marks the amino acid cysteine (C) of the ‘CSSG’
region. From there onwards, the probability decreases, leading to a score of 0 from position 33. The
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>Sequence              length = 37
# pos  aa    C       S       Y
    1   M   0.006   0.979   0.006
    2   T   0.006   0.988   0.005
    3   R   0.006   0.995   0.005
    4   S   0.006   0.995   0.005
    5   K   0.006   0.996   0.006
    6   P   0.006   0.998   0.007
    7   M   0.007   0.998   0.008
    8   N   0.007   0.986   0.011
    9   R   0.007   0.920   0.013
   10   T   0.008   0.939   0.014
   11   A   0.006   0.942   0.015
   12   F   0.014   0.952   0.023
   13   C   0.006   0.964   0.017
   14   C   0.015   0.961   0.033
   15   L   0.007   0.976   0.028
   16   S   0.007   0.994   0.034
   17   L   0.007   0.992   0.042
   18   T   0.006   0.999   0.042
   19   A   0.009   0.999   0.056
   20   A   0.094   0.987   0.199
   21   L   0.012   0.990   0.075
   22   I   0.021   0.982   0.106
   23   L   0.019   0.892   0.107
   24   T   0.007   0.878   0.066
   25   A   0.018   0.867   0.113
   26   C   0.046   0.746   0.186
   27   S   0.006   0.870   0.070
   28   S   0.039   0.780   0.180
   29   G   0.009   0.524   0.087
   30   G   0.016   0.255   0.119
   31   G   0.035   0.052   0.173
   32   G   0.017   0.027   0.116
   33   S   0.013   0.012   0.099
   34   G   0.018   0.009   0.109
   35   G   0.008   0.012   0.071
   36   G   0.012   0.007   0.080
   37   G   0.016   0.008   0.089
>Sequence              length = 37
# Measure  Position  Value  Cutoff  signal peptide?
  max. C    20       0.094   0.52   NO
  max. Y    20       0.199   0.33   NO
  max. S    18       0.999   0.92   YES
  mean S     1-19    0.978   0.49   YES
       D     1-19    0.588   0.44   YES
# Most likely cleavage site between pos. 19 and 20: LTA-AL
Figure 5.2: SignalP-NN output. This graphical output from SignalP 3.0 Server (Neural
Network) was based on a combination of several artificial neural networks.
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SignalP-HMM result:
>Sequence
# pos  aa    C       S      n-reg   h-reg   c-reg
    1   M   0.000   1.000   1.000   0.000   0.000
    2   T   0.000   1.000   1.000   0.000   0.000
    3   R   0.000   1.000   1.000   0.000   0.000
    4   S   0.000   1.000   1.000   0.000   0.000
    5   K   0.000   1.000   1.000   0.000   0.000
    6   P   0.000   1.000   1.000   0.000   0.000
    7   M   0.000   1.000   1.000   0.000   0.000
    8   N   0.000   1.000   1.000   0.000   0.000
    9   R   0.000   1.000   0.996   0.004   0.000
   10   T   0.000   1.000   0.685   0.315   0.000
   11   A   0.000   1.000   0.321   0.679   0.000
   12   F   0.000   1.000   0.152   0.847   0.000
   13   C   0.000   1.000   0.029   0.971   0.000
   14   C   0.000   1.000   0.006   0.994   0.000
   15   L   0.000   1.000   0.001   0.999   0.000
   16   S   0.000   1.000   0.000   0.999   0.000
   17   L   0.000   1.000   0.000   1.000   0.000
   18   T   0.000   1.000   0.000   0.998   0.002
   19   A   0.000   1.000   0.000   0.948   0.052
   20   A   0.000   1.000   0.000   0.806   0.194
   21   L   0.000   1.000   0.000   0.774   0.225
   22   I   0.000   1.000   0.000   0.559   0.441
   23   L   0.000   1.000   0.000   0.409   0.591
   24   T   0.000   1.000   0.000   0.174   0.826
   25   A   0.000   1.000   0.000   0.046   0.954
   26   C   0.195   0.805   0.000   0.002   0.802
   27   S   0.000   0.805   0.000   0.000   0.805
   28   S   0.192   0.612   0.000   0.000   0.612
   29   G   0.079   0.533   0.000   0.000   0.533
   30   G   0.205   0.328   0.000   0.000   0.328
   31   G   0.232   0.096   0.000   0.000   0.096
   32   G   0.096   0.000   0.000   0.000   0.000
   33   S   0.000   0.000   0.000   0.000   0.000
   34   G   0.000   0.000   0.000   0.000   0.000
   35   G   0.000   0.000   0.000   0.000   0.000
   36   G   0.000   0.000   0.000   0.000   0.000
   37   G   0.000   0.000   0.000   0.000   0.000
>Sequence
Prediction: Signal peptide
Signal peptide probability: 1.000
Max cleavage site probability: 0.232 between pos. 30 and 31
Figure 5.3: SignalP-HMM output. This output was based on the Hidden Markov Mod-
els which calculated the probability of whether the submitted sequence contained a signal
peptide or not.
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C score is the “cleavage site” score similar to the SignalP-NN output (Figure 5.2). The first cleav-
age site in Figure 5.3 is position 26 (C of ‘CSSG’). However the maximum cleavage site probability
is shown between the positions 30 and 31. The same results are illustrated in the graph of Fig-
ure 5.3, marked by the red bars. The n-reg, h-reg, and c-reg in Figure 5.3 represents the predicted
positively charged amino-terminal region, the hydrophobic region, and the polar carboxy-terminal
region, respectively, of the signal protein part [77]. From the data and the graph of Figure 5.3, it
can be seen that the n-region of the signal peptide is from position 1 to 8 with the scores gradually
decreasing from position 9. The h-region score increases from position 9 and starts decreasing after
position 17. The c-region score starts increasing from position 18 and starts dropping after position
25.
From the overall analysis of the outputs of both the SignalP-NN and SignalP-HMM and from
the findings of Masignani et al. [55] (mentioned in Step 5 of Section 4.2), it can be concluded that
the mature protein part of the fHbp sequence starts from the cysteine (C) of the ‘CSSG’ region.
Appendix C (Figures C.1 to C.6) show parts of the multiple sequence alignment of the 190 fHbp
sequences with the signal protein part, the amino-terminal repetitive region, the modular variable
regions, and the invariant regions highlighted with different colours.
After the detection of the signal protein part of the sequences, the task was to study them.
It was seen that among the 190 sequences, 50 of them had the signal protein part and 140 did
not. Most of the positions in the signal part were conserved. There was no correlation or co-
occurring relationships observed amongst the variable positions within the signal part or with the
positions of the mature part. The next task was to determine if the presence of the signal part
made any difference to the predicted tertiary structures of the sequences. For this purpose around
20 sequences which had the signal part were randomly selected. Two things were observed during
this investigation. First, it was seen that for some of the selected sequences with the signal part,
the presence of the signal peptides had impact on the PDB [24] template SWISS-MODEL was
using to derive the tertiary structures of the sequences. With the signal protein part, for some
of the selected sequences, SWISS-MODEL used 2W80H (one of the chains of the fHbp variant
2W80 in PDB) as its template. With the removal of the signal part and using only the mature
part of the sequence, SWISS-MODEL used 2W80C (which is referred to as the unique factor H
binding protein chain of 2W80 in PDB) as the template. The reverse was also true, when 2W80C
was used as the template in the presence of the signal part and 2W80H when the signal part was
removed. Among such cases, the second observation was related to the percentage identity with
the template used to derive the tertiary structure. It was seen that the presence of the signal parts
in the sequences affected the percentage identity with the templates used to predict the structures.
Both these observations were significant because these predicted tertiary structures would later
be used to determine the energy values of the sequences and to set the valid range of energy the
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Counts of the different amino acids across the columns of the alignment 
Figure 5.4: Graph showing the frequency of the different amino acids occurring in the
positions of the multiple sequence alignment of the 190 fHbp sequences. The blue curve was
based on data which included ‘gap’ in the count for each position. The red curve was based
on counts which ignored the presence of ‘gap’. Only positions of the mature part of the
protein sequence were considered.
new variants can have. In addition, as mentioned earlier, the presence of the signal part was not
consistent with all the sequences. Hence, it was decided to discard the signal protein part of the
fHbp sequences. This reduced the length of the longest fHbp sequence from 291 amino acids to
263.
5.3 Identifying the conserved, restricted variable, and unre-
stricted variable regions
The results described in this section were produced by the Scripts in Appendix A as part of
Step 6 of the Methodology (Figure 4.1) in order to identify the conserved, restricted variable, and
unrestricted variable regions, and the amino acid substitution domains for the variable regions in
the mature protein part of the sequences. The results generated are given in tabular formats in
Appendix B (Tables B.1 to B.5).
In Tables B.1 and B.2 the columns headed “190 fHbp sequences” depict the substitution domains
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for each of the restricted variable positions; that is, which amino acids were observed in each of
the positions of the restricted variable regions and in addition the frequencies of the occurrences
of each amino acid. Hence, the results in the tables presents occurrence profiles for each position
along the alignment of the 190 fHbp sequences. The first table generated using Script A.1 excludes
the count of the ‘gap’ symbols, and the second one generated using Script A.2 includes the count
of the ‘gap’ symbols.
The column labeled “190 fHbp sequences” in Table B.3 illustrates which positions in the align-
ment had at least one ‘gap’ symbol and is generated using Script A.3.
Scripts A.4 and A.5, determined the frequency distribution for the counts of the different amino
acids across the columns of the alignment, both excluding and including the ‘gap’. Tables B.4
and B.5 (Appendix B) give those results for the 190 fHbp sequences. They are illustrated graphically
in Figure 5.4. These results illustrate that the amino acid substitutions were limited; that is,
variation in the sequence alignment was restricted. Out of the 263 positions of the alignment,
almost half of them had only one type of amino acid (122 positions with the ‘gap’ symbol excluded
and 115 positions with the ‘gap’ symbol included), meaning that these positions were conserved.
Among these conserved positions, 24 positions belonged to the invariant positions in the amino-
terminal repetitive region and the five invariant segments that delimited the variable regions VA
through VE (illustrated as black bars in Figure 2.2). Also the maximum number of different amino
acids occurring at any one position was 6 (both including and excluding the ‘gap’ symbol) and that
was only for one position. Only 16 positions had 4 or 5 different amino acids, further supporting
the conjecture that variation in the alignment was highly restricted. Hence, it was deduced that the
mature part of the 190 fHbp sequence alignment had conserved and restricted variable segments
but no unrestricted variable regions.
5.4 Identifying correlation and co-occurrence between posi-
tions with restricted variations
The results discussed here were generated as part of Step 7 of our Methodology (Figure 4.1). It
was observed in the multiple sequence alignment of the 190 fHbp sequences that mutations in one
position were correlated or co-occurring (both “partially” and “fully”) with sometimes one position
and sometimes groups of positions in different variable regions. However, it was seen that there
were more “partially” and “fully” co-occurring regions than there were correlated ones. One reason
could be because correlations were examined visually and some could have been missed. It was out
of the scope of this thesis to use an automated tool for the examination. However, in future, this can
be done using a statistical or a computational tool for better accuracy, as mentioned in Section 6.2.
Figures 5.5 and 5.6 are portions of the multiple sequence alignment of the 190 fHbp sequences
48
Pretty plot of MSA_seq_Mature_part-Rearranged.msf
Tue  2 Nov 2010 11:16:49
UniRef100_B6EAW6_
UniRef100_C0JFM7_
UniRef100_B5U0Q5_
UniRef100_B2CQ01_
UniRef100_C0JFL9_
UniRef100_C0JF88_
UniRef100_B2CQ02_
UniRef100_Q6VRY3_
UniRef100_C0JFJ0_
UniRef100_B2CQ14_
UniRef100_C0JFI0_
UniRef100_C0JFJ1_
UniRef100_C0JF55_
UniRef100_C0JFF4_
UniRef100_C0JFJ5_
UniRef100_C0JFK9_
UniRef100_C0JF77_
UniRef100_C0JFJ8_
UniRef100_C0JFC9_
UniRef100_C0JF66_
UniRef100_C0JF56_
UniRef100_C0JFD7_
UniRef100_C0JF86_
UniRef100_C0JFN8_
UniRef100_C0JF51_
UniRef100_C0JFC8_
UniRef100_Q6QCB7_
UniRef100_B6EAW9_
UniRef100_C0JF69_
UniRef100_C0JFC7_
UniRef100_C0JFL7_
UniRef100_C0JFF1_
UniRef100_C0JFD0_
UniRef100_C0JFD1_
UniRef100_C0JFM1_
UniRef100_C0JF78_
UniRef100_C0JFA0_
UniRef100_C0JFN4_
147
142
142
142
142
142
142
142
142
142
142
142
142
147
147
142
142
142
142
147
147
142
147
147
142
142
142
142
142
147
142
142
142
142
147
142
142
142
F
F
E
E
E
E
E
E
E
E
E
E
E
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
L
S
S
S
S
S
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
E
E
E
R
R
R
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
I
I
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
P
P
P
P
P
P
P
P
P
P
H
H
H
H
H
H
H
H
H
H
H
H
H
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
N
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
R
R
R
R
R
R
R
R
R
R
R
R
K
K
K
K
K
K
K
K
K
K
K
Pretty plot of MSA_seq_Mature_part-Rearranged.msf
Tue  2 Nov 2010 11:16:49
UniRef100_B6EAW8_
UniRef100_Q6VRY2_
UniRef100_B5AAS3_
UniRef100_C0JFD9_
UniRef100_C0JF76_
UniRef100_B2CQ04_
UniRef100_C0JFD6_
UniRef100_Q6VRZ1_
UniRef100_C0JFF9_
UniRef100_C0JFH9_
UniRef100_C0JFN3_
UniRef100_C0JFG5_
UniRef100_C0JFJ6_
UniRef100_C0JF60_
UniRef100_Q6VRY1_
UniRef100_C0JFK6_
UniRef100_C0JF52_
UniRef100_C0JFH8_
UniRef100_C0JFC1_
UniRef100_C0JF53_
UniRef100_C0JFI8_
UniRef100_Q6VS09_
UniRef100_A1IQ30_
UniRef100_Q6QCB6_
UniRef100_C0JFJ3_
UniRef100_C0JF57_
UniRef100_C0JFN1_
UniRef100_C0JFH0_
UniRef100_C0JF82_
UniRef100_C0JFE6_
UniRef100_C0JFA4_
UniRef100_C0JF68_
UniRef100_C0JFL8_
UniRef100_Q6VRX9_
UniRef100_C0JF49_
UniRef100_Q6QCC2_
UniRef100_Q9JXV4_
UniRef100_C0JF85_
142
142
142
142
142
142
142
142
142
142
142
142
142
142
142
142
142
147
142
142
142
142
142
142
142
142
142
142
142
147
142
147
142
142
142
142
142
142
R
F
F
F
F
F
F
F
F
F
F
F
F
E
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
L
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
D
R
A
S
S
A
A
A
A
A
A
A
A
A
A
A
V
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
I
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
L
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
I
I
I
I
I
I
I
I
I
I
I
I
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
G
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
H
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
T
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
S
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
D
N
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
V
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
R
R
R
R
R
R
Figure 5.5: An example of correlation between amino acids in different positions.
This portion of the multiple sequence alignment was taken from the alignment of the 190
fHbp sequences. The two positions marked by the blue arrows had a correlated relationship.
The correlated amino acids are marked by the blue circles. Whenever there was a leucine
(L) n the position marked by the second arrow, there was always a glutamic acid (E) in the
other position. However, the reverse was not true. For glutamic acid (E) in the first marked
position, there were other amino acids apart from leucine (L) in the second marked position
(for instance, P). Hence, if the second marked position was ‘L’, then the first marked position
would have to be an ‘E’, thus establishing a correlated relationship.
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Figure 5.6: An example of co-occurring relationships between amino acids in different
positions. This portion of the multiple sequence alignment was taken from the alignment of
the 190 fHbp sequences. Positions marked by the blue arrows are “fully” co-occurring and
those marked with red arrows are “partially” co-occurring. It can be seen that the marked
positions are either always ‘S’, ‘L’, ‘T’, ‘T’, ‘Q’, ‘D’, ‘S’, ‘E’, ‘H/D’ respectively, or else they
are ‘D/N’, ‘V’, ‘V’, ‘I’, ‘K’, ‘N’, ‘P’, ‘D’, ‘K’ respectively, hence establishing a co-occurring
relationship amongst them.
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illustrating correlated and both kinds of co-occurrence relationships among different positions in
the alignment.
In Figure 5.5 the blue arrows mark two positions, 122 and 125, involved in a correlated relation-
ship, the only correlation found in the 190 fHbp sequences. Whenever there was a leucine (L) in
position 125 (marked by the second blue arrow), there was always a glutamic acid (E) in position
122 (marked by the first blue arrow). However, the reverse was not true; that is, whenever there
was a glutamic acid (E) in position 122, there were other amino acids in addition to leucine (L) in
position 125. This correlation can be denoted as L→E.
In Figure 5.6 the blue arrows mark “fully” co-occurring positions, and the red arrows “partially”
co-occurring ones. Both the blue and red arrow marked positions have co-occurring relationships
amongst themselves. Starting from the left hand side, the columns marked are either always ‘S’,
‘L’, ‘T’, ‘T’, ‘Q’, ‘D’, ‘S’, ‘E’, ‘H/D’ respectively, or else they are ‘D/N’, ‘V’, ‘V’, ‘I’, ‘K’, ‘N’, ‘P’,
‘D’, ‘K’ respectively, hence establishing a co-occurring relationship amongst them.
Table 5.1 lists the instances of co-occurrences in the 190 fHbp sequences. As shown in the
table, there were 7 instances of co-occurring relationships comprising both “fully” co-occurring and
“partially” co-occurring positions, involving a total of 85 positions. The instances are highlighted
in alternating red and white colour for clarity. Each block (either red or white) composed of several
“fully” and “partially” co-occurring positions (rows) represents each instance of co-occurrence. The
percentages in brackets are the percentage occurrence of the amino acids in each position. The first
instance (highlighted with red) of co-occurrence was between positions 37, 42, 43, 45, 46, 47, 49, 50,
52, and 54 where 43, 45, 49, 50, and 52 belonged to the “fully” co-occurring group and 37, 42, 46, 47,
and 54 to the “partially” co-occurring group. In this instance, the percentage distribution between
the amino acids “fully” co-occurring with each other is 72.1% and 27.9%; that is, in these positions,
two different amino acids occur and in fixed proportion. In the “partially” co-occurring positions
even though two or more different amino acids occur, the percentage distribution is maintained. For
instance, in position 37, amino acids Q (which occurs 70%) and R (which occurs 2.1%) constitute
a 72.1% portion of the percentage distribution. In other words, whenever there is Q in position 43,
there is always either Q or R in position 37, and whenever there is D in position 43 there is amino
acid K in position 37, thus establishing a co-occurring relationship among them.
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Table 5.1: “Fully” and “partially” co-occurring positions and their corresponding amino
acids in the 190 fHbp sequences.
“Fully”
co-occurring
positions
Corresponding amino acids “Partially”
co-occurring
positions
Corresponding amino acids
43 Q (72.1%), D (27.9%) 37 Q (70%), R (2.1%), K (27.9%)
45 V (72.1%), I (27.9%) 42 D (71.6%), N (0.5%), E(27.9%)
49 E (72.1%), G (27.9%) 46 R (72.1%), P (18.4%), S (9.5%)
50 K (72.1%), T (27.9%) 47 K (71.6%), R (0.5%), Q (27.9%)
52 K (72.1%), T (27.9%) 54 A(70%), S(30%)
62 Y (73.7%), F (26.3%) 64 N (73.7%), A (22.1%), V (4.2%)
63 G (73.7%), K (26.3%)
67 – (73.7%), K (26.3%)
68 – (73.7%), D (26.3%)
69 – (73.7%), N (26.3%)
87 I (77.9%), V (22.1%) 88 R(75.8%), H (2.1%), Q (22.1%)
89 Q (77.9%), K (22.1%)
96 L (74.7%), T (25.3%)
100 E (74.7%), A (25.3%)
114 L (55.8%), V (44.2%) 110 S (55.8%), D (35.8%), N (7.9%), G (0.5%)
115 T (55.8%), V (44.2%) 127 H (38.4%), D (17.4%), K (44.2%)
121 Q (55.8%), K (44.2%) 128 S (55.8%), I (40.5%), T (3.7%)
123 Q (55.8%), N (44.2%) 129 G (49.5%), E (3.2%), R (2.6%), A (0.5%), D (44.2%)
124 D (55.8%), N (44.2%) 133 A (55.3%), V (0.5%), N (44.3%)
126 E (55.8%), D (44.2%) 134 K (55.8%), Q (43.7%), R (0.5%)
131 M (55.8%), L (44.2%) 136 Q (41.1%), R (14.7%), S (44.2%)
132 V (55.8%), I (44.2%) 138 R (47.4%), K (8.4%), L (44.2%)
139 I (55.8%), V (44.2%) 141 D (55.8%), G (43.7%), S (0.5%)
140 G (55.8%), S (44.2%) 143 A (52.6%), V (3.2%), G (44.2%)
142 I (55.8%), L (44.2%) 150 D (53.7%), G (2.1%), N (44.2%)
148 S (55.8%), A (44.2%) 154 K (28.9%), E (25.9%), D (0.5%), G (0.5%), – (44.2%)
151 K (55.8%), Q (44.2%) 157 R (26.8%), M (14.8%), S (14.2%), K (44.2%)
159 T (55.8%), E (44.2%)
161 R (55.8%), H (44.2%)
163 T (55.8%), K (44.2%)
170 A (79.5%), T (0.5%), P (20%) 171 G (75.8%), S (3.7%), R (0.5%), N (20%)
181 A (79.5%), V (0.5%), T (20%) 173 K (79%), E (0.5%), R (20.5%)
188 K (79.5%), G (0.5%), R (20%) 175 T (72.1%), I (7.9%), H (20%)
182 A (76.9%), N (2.6%), S (0.5%), K (17.4%), N (2.6%), T (1%)
194 S (55.3%), T (44.7%) 205 Y (29.5%), D (25.3%), N (0.5%), E (44.7%)
206 I (55.3%), L (44.7%) 208 P (54.8%), Q (0.5%), A (44.7%)
217 S (55.3%), L (44.7%) 212 H (27.9%), R (27.4%), S (44.7%)
220 V (55.3%), T (44.7%) 219 S (54.8%), F (0.5%), D (44.7%)
229 S (55.3%), T (44.7%) 221 L (55.3%), H (0.5%), R (44.2%)
Continued on next page
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“Fully”
co-occurring
positions
Corresponding amino acids “Partially”
co-occurring
positions
Corresponding amino acids
231 S (55.3%), H (44.7%) 223 N (55.3%), D (0.5%), G (44.2%)
233 G (55.3%), A (44.7%) 224 Q (54.8%), H (0.5%), S (30%), G (14.7%)
234 I (55.3%), L (44.7%) 225 D (33.7%), A (21.1%), N (0.5%), E (44.7%)
247 E (55.3%), T (44.7%) 237 G (49.5%), E (5.3%), R (0.5%), D (44.7%)
250 T (55.3%), I (44.7%) 238 Q (28.4%), K (26.4%), E (0.5%), R (44.7%)
252 N (55.3%), E (44.7%) 251 A (33.7%), G (21.6%), R (23.1%), V (21.6%)
253 G (55.3%), K (44.7%)
254 I (55.3%), V (44.7%)
256 H (55.3%), E (44.7%)
259 L (55.3%), I (44.7%)
261 A (55.3%), G (44.7%)
5.5 Characterizing constraints of the restricted variable po-
sitions
This section presents the results generated in Step 8 of the Methodology (Figure 4.1) and
discusses constraints characterized for positions with restricted variations.
The first task was to determine the negative selection sites in the multiple sequence alignment of
the 190 fHbp sequences. Section 2.6 discusses the binding of fH and fHbp and the regions in fHbp
which have high affinity for interactions with fH [70]. fHbp has an extended recognition site for
fH across its entire surface. The residues along the regions of both fHbp and fH that are involved
in their binding have been identified. There are 21 positions. Figure 2.1 illustrates those positions
for the UniProtKB sequence Q9JXV4, one of the set of 190 fHbp sequences. The next task was
to use this information in determining the negative selection sites in the alignment of 190 fHbp
sequences. An intuitive assumption is that nature would try to conserve the binding regions of
fHbp, and so these sites would be less likely to change with the high possibility that they would be
under negative selection pressure.
Table 5.2 lists the positions in the UniProtKB sequence Q9JXV4 and the corresponding positions
in the alignment of the 190 fHbp sequences. The table also gives the amino acids and their frequency
of occurences at each position and illustrates to which restricted variable regions–VA through VE
(Figure 2.2)– the binding sites belong. Position 103 of Q9JXV4 corresponds to position 43 of the
alignment because the sequence Q9JXV4 includes the signal portion of the protein. The names
of each of the single-letter data-base codes for the amino acids used in this table can be found in
Table D.1 (Appendix D). It can be seen from the table that the binding sites are distributed across
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the restricted variable regions: VA, VC , and VE . None of the binding sites belong to the regions
VB or VD and also does not overlap with the invariant segments which flanks the variable regions.
Table 5.2: Positions in fHbp that bind with fH and their corresponding variable regions.
Q9JXV4 fHbp alignment Variable Region
Position Amino acids Amino acids Position
103 Q 137Q 43 VA
53D
106 R 137R 46 VA
35P
18S
107 K 136K 47 VA
53Q
1R
108 N 187N 48 VA
3K
180 Q 106Q 123 VC
84N
181 D 106D 124 VC
84N
183 E 106E 126 VC
84D
184 H 84K 127 VC
73H
33D
185 S 106S 128 VC
77I
7T
191 K 106K 134 VC
83Q
1R
193 Q 84S 136 VC
78Q
28R
195 R 90R 138 VC
84L
16K
262 D 85E 205 VE
56Y
48D
1N
264 K 189K 207 VE
1E
Continued on next page
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Table 5.2 – continued from previous page
Q9JXV4 fHbp alignment Variable Region
Position Amino acids Amino acids Position
266 D 190D 209 VE
272 V 190V 215 VE
274 S 105S 217 VE
85L
283 E 190E 226 VE
286 S 105S 229 VE
85T
304 E 105E 247 VE
85T
306 K 133K 249 VE
57E
The task was now to find the positive selection sites in the alignment of the 190 fHbp sequences
plus verify the negative selection sites already listed in Table 5.2. As mentioned in Step 8 of the
Methodology section, determining the positive and negative selection sites required the nucleotide
sequences, which were downloaded from the UniProtKB for all the 190 fHbp protein sequences.
The Kumar method was used in the MEGA4 [22] tool in order to determine the KA/KS ratio.
The KA/KS ratio was first found for the overall sequences and then the codon-based positive
and negative selection sites using the sliding window approach were found. For this approach, the
window width was 18 base pairs (6 amino acids) and the step length was 3 base pairs (1 amino acid).
In the research paper where the codon-based detection of the positive and negative selection sites
using the siding window approach was described [81], it was found that the window width was always
6 times the step length. Hence, in keeping consistency, for this thesis the step length was taken as
3 base pairs or 1 amino acid (the smallest base pair that could have been taken) and the window
width being 6 times more was taken as 18 base pairs. Also, since the 190 fHbp sequences were all
closely related, KS was estimated from the whole sequence alignment as mentioned in Step 8 earlier.
This was done because often KS becomes 0 for closely-related sequences and/or when the window
size was small [81]. For determining the KA/KS ratio, the nucleotide sequences corresponding to
the 190 fHbp protein sequences were downloaded from the UniProtKB database [27].
The results of the Kumar Method in the MEGA4 [22] tool were as follows.
KA = 0.144
KS = 0.366
KA/KS = 0.411
These results were consistent with the finding of Brehony et al. [37] who mentioned that the fHbp
locus had an average KA/KS ratio of 0.35, indicating an overall level of purifying selection (or
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negative selection) against amino acid changes.
The focus now moves onto the codon-based detection of the positive and negative selection
sites of the 190 fHbp sequences using the sliding window approach. Table B.6 in Appendix B
illustrates the findings of the KA/KS ratio. The first column of the table shows the windows,
that is, the range of the positions in the nucleotide sequences considered for the calculation. The
second column shows the corresponding amino acid positions in the 190 fHbp sequence alignment.
The third column gives the value of the ratio of the number of nonsynonymous substitutions per
nonsynonymous site (KA) for the particular nucleotide positions depicted in column one. The last
column gives the corresponding KA/KS ratio. As mentioned above, KS was determined to be 0.366.
Regions where the KA/KS ratio was more than 0.9 were considered to be under positive selection
pressure. This was done because the KA/KS ratio is based on a window of 18 nucleotides, and
negative selection pressure on any one of the nucleotides may affect and reduce the ratio for the
entire window. These regions are highlighted with red colour in Table B.6 of Appendix B.
The KA/KS ratios in Table B.6 were then used to verify that each fH binding position given in
Table 5.2 is under negative selection pressure. Among the 21 positions of Table 5.2, 17 positions
were confirmed to be under negative selection pressure. Table 5.3 illustrates one such position.
The remaining 4 among the 21 positions had conflicting KA/KS ratios, which are illustrated in
Tables 5.4 through 5.7. Tables 5.3 through 5.7 are all portions of Table B.6.
Analyzing Amino Acid Position 43
This was the 1st position in the fHbp sequence that takes part in the binding with fH. Table 5.3
illustrates the values of the ratio of KA/KS for those windows in which position 43 was also a part.
From the values of KA/KS ratio shown in Table 5.3, it was seen that all the values were less than
1, meaning that they were under negative selection pressure.
Table 5.3: Analysis of the KA/KS ratio using the sliding window approach for Position 43.
Window of the nu-
cleotide positions
Corresponding amino
acid positions
KA KA/KS
112-129 38-43 0.026 0.076
115-132 39-44 0.026 0.076
118-135 40-45 0.025 0.073
121-138 41-46 0.006 0.017
124-141 42-47 0.006 0.017
127-144 43-48 0.258 0.752
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Analyzing Amino Acid Position 134
This was the 10th position that takes part in the binding with fH. Table 5.4 illustrates the values
of the ratio of KA/KS for those windows containing position 134. All the values of the KA/KS
ratio were less than 1, except for the last window (positions 134-139). This exception could have
been due to the codon at position 139 being under positive selection pressure. This can be better
understood in the analysis of the amino acid positions 136 and 138 in the next subsections.
Table 5.4: Analysis of the KA/KS ratio using the sliding window approach for Position
134. Positions where the KA/KS ratios are more than 0.9 are highlighted with red colour.
Window of the nu-
cleotide positions
Corresponding amino
acid positions
KA KA/KS
385-402 129-134 0.014 0.041
388-405 130-135 0.002 0.006
391-408 131-136 0.022 0.064
394-411 132-137 0.024 0.070
397-414 133-138 0.044 0.128
400-417 134-139 0.388 1.131
Analyzing Amino Acid Position 136
This was the 11th position that takes part in the binding with fH. Table 5.5 illustrates the values
of the ratio of KA/KS for those windows containing position 136. From the values of the KA/KS
ratio, it was seen that the last three windows (positions 134-139, 135-140, and 136-141) had values
of more than 1. These exceptions could have been due to some codon starting from amino acid
position 139 which might be under positive selection pressure. This is further proved in the next
subsection discussing the analysis of the amino acid position 138.
For the remaining windows which included position 136, the KA/KS ratio was less than 1.
Table 5.5: Analysis of the KA/KS ratio using the sliding window approach for Position
136. Positions where the KA/KS ratios are more than 0.9 are highlighted with red colour.
Window of the nu-
cleotide positions
Corresponding amino
acid positions
KA KA/KS
391-408 131-136 0.022 0.064
394-411 132-137 0.024 0.070
397-414 133-138 0.044 0.128
400-417 134-139 0.388 1.131
403-420 135-140 0.434 1.265
406-423 136-141 0.606 1.767
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Analyzing Amino Acid Position 138
This was the 12th position that takes part in the binding with fH. Table 5.6 illustrates the values
of the ratio of KA/KS for those windows containing position 138. From the values of KA/KS ratio
shown in Table 5.5, it was seen that all the windows except for one (positions 133-138), the KA/KS
ratio was more than 1. This could have been due to some codon starting from position 139 being
under positive selection pressure or it could also be that the initial assumption is wrong. Maybe not
all fH binding sites are under negative selection pressure. Maybe a few of them are under positive
selection pressure.
Table 5.6: Analysis of the KA/KS ratio using the sliding window approach for Position
138. Positions where the KA/KS ratios are more than 0.9 are highlighted with red colour.
Window of the nu-
cleotide positions
Corresponding amino
acid positions
KA KA/KS
397-414 133-138 0.044 0.128
400-417 134-139 0.388 1.131
403-420 135-140 0.434 1.265
406-423 136-141 0.606 1.767
409-426 137-142 0.390 1.137
412-429 138-143 0.472 1.376
Analyzing Amino Acid Position 226
This was the 18th position that takes part in the binding with fH. Table 5.7 illustrates the
values of the KA/KS ratio for those windows containing position 226. All the values of the KA/KS
ratio were less than 1 except for one window (positions 223-228) and this could be due to some
codon within this range. Hence, position 226 could still be under negative selection pressure.
Table 5.7: Analysis of the KA/KS ratio using the sliding window approach for Position
226. Positions where the KA/KS ratios are more than 0.9 are highlighted with red colour.
Window of the nu-
cleotide positions
Corresponding amino
acid positions
KA KA/KS
661-678 221-226 0.038 0.111
664-681 222-227 0.192 0.560
667-684 223-228 0.360 1.050
670-687 224-229 0.272 0.793
Continued on next page
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Table 5.7 – continued from previous page
Window of the nu-
cleotide positions
Corresponding amino
acid positions
KA KA/KS
673-690 225-230 0.089 0.259
676-693 226-231 0.139 0.405
The determination of the positive selection sites using the KA/KS ratio was incorporated as
one of the constraints while developing the pipeline of programs for generating the new variants.
The positive selection sites, since they are prone to mutate more than other positions, had the
option to be generated by separate programs and also with other positions with which they might
be correlated or co-occurring. Section 5.7 shows how the positive selection sites of the new variants
are generated, both separately and with other correlated or co-occurring positions.
Our next step was to find the tertiary structures of all the 190 fHbp sequences using SWISS-
MODEL [13, 33, 47, 67] and to view the structures using the Swiss-PdbViewer [20, 45]. To derive
the tertiary structures, SWISS-MODEL used templates from the PDB (Protein Data Bank) [24].
In this case, two templates were used: 2W80C and 2W80H (both of which were chains of the fHbp
variant 2W80). However, there were instances where another template was used in addition to
either of 2W80C or 2W80H. This template, 1YS5, is always a subset of 2W80C or 2W80H, and
only a small portion of the fHbp sequence was modeled by 1YS5. As a result, 2W80C and 2W80H
were the templates considered for predicting the tertiary structures of fHbp sequences.
Two sequences were selected from the set of 190 fHbp sequences, B6EAW6 and C0JFN4. As
a homologous model structure, SWISS-MODEL used PDB structure 2W80C for B6EAW6 and
2W80H for C0JFN4. B6EAW6 had a sequence identity of 94.191% with 2W80C. For C0JFN4 and
2W80H, the sequence identity was 92.116%. Figures 5.7 and 5.8 illustrate the structures of B6EAW6
and C0JFN4, respectively, built using SWISS-MODEL and Swiss-PdbViewer. These two sequences
using different structural templates were selected in order to identify the structural differences
between 2W80C and 2W80H. For this purpose, the two predicted structures were superimposed and
their RMSD calculated using Swiss-PdbViewer [20, 45]. Figure 5.9 illustrates the two superimposed
structures. Some differences in the two structures were visually evident, and their RMSD was 0.20
A˚, the value of which indicated that there were some structural differences between 2W80C and
2W80H. Two of the differences are highlighted in Figure 5.9 with red circles. One difference was in
one of the beta sheets of the two structures, where the beta sheet in B6EAW6 was shorter than the
corresponding beta sheet of C0JFN4. Another difference (red circle at the bottom of the figure)
was in one of their coils. Other minor differences are not highlighted in Figure 5.9 due to space
limitations.
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Figure 5.7: Predicted tertiary structure of an fHbp sequence B6EAW6 which uses the tem-
plate 2W80C of PDB. The structure was derived using SWISS-MODEL and was visualized
using the Swiss-PdbViewer. The structure shows two beta barrels where the beta sheets
(illustrated by the arrows) have been coloured in yellow, the coils in grey, and the alpha
helix in red.
The tertiary structures act as a constraint for verifying the validation of the new variants to
be generated. From the above findings, it was seen that the existing fHbp sequences used two
templates to derive their structures. Hence, the new variants in order to be considered as valid
should use these two templates to derive their tertiary structures. However, like the existing fHbp
sequences, the variants would have variable percentage identity with the template. This is further
discussed in Section 5.9. The predicted tertiary structures of the fHbp sequences is significant also
because they were used in the next step to determine the energy values and to set the valid energy
boundary for the new variants (Section 5.6). New variants having the energy values less than the
boundary energy value would be considered as a valid new variant (Section 5.9).
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Figure 5.8: Predicted tertiary structure of an fHbp sequence C0JFN4 which uses the tem-
plate 2W80H of PDB. The structure was derived using SWISS-MODEL and was visualized
using the Swiss-PdbViewer. The structure shows two beta barrels where the beta sheets
have been coloured in blue, the coils in lime green, and the alpha helix in red.
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Figure 5.9: Superimposed structures of B6EAW6 and C0JFN4. The structures have been
superimposed using Swiss-PdbViewer and there were some structural differences between the
two. Their RMSD was 0.20 A˚. The red circles mark two of the structural differences in this
figure.
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5.6 Determining the valid boundary set by the highest en-
ergy of existing fHbp structures
The results for this section were derived as part of Step 9 of our Methodology (Figure 4.1).
In this step, we determined the energy values for all the fHbp structures predicted in Step 8.
First, the energy of each structure was minimized using Swiss-PDBViewer [20, 45]. This was done
because energy minimization can repair distorted geometries as discussed in Section 2.9. Then
FoldX [44, 72, 73, 74] was used to determine the energy of each structure. FoldX uses the full
atomic description of a protein structure.
Table B.7 in Appendix B give the results of these energy-related operations for all of the 190
fHbp sequences. The first column names the sequence. The second column identifies the template
used by SWISS-MODEL. The third column lists the sequence identity of the sequence in the first
column with the template listed in the second column. The fourth column provides the energy value
initially determined by SWISS-MODEL when the structure was derived. The fifth column lists the
energy after energy minimization was performed. Both these energies are in KJ/mol. The sixth and
seventh columns are the energy values derived using FoldX before and after energy minimization
was performed, respectively. The energy values in these columns are in Kcal/mol.
Table B.7 reveals that the energy values determined by FoldX were considerably reduced by
energy minimization for all 190 fHbp sequences. For this research the most important column
in the table is the seventh, the FoldX energy after energy minimization. It appears that these
energy values tend to increase inversely to the percentage identity expressed in the column 2. In
general, the higher the percentage identity, the lower the energy values in column 7. However, this
trend is consistent only when comparing sequences whose sequence identities (in column 2) are
considerably different. Figure 5.10 shows a line graph which illustrates this trend. The blue line
represents the percentage identity and the red line the energy values determined by FoldX after
minimization. From the graph it can be seen that as the percentage identity decreases for the
existing 190 fHbp sequences their corresponding energy values tend to increase; hence establishing
an inversely proportional relationship between the two parameters.
For convenience, some sequences are selected—including the one with the highest energy value
in column 7 from Table B.7 in Appendix B—and are given in Table 5.8. The remaining sequences
in Table 5.8 were selected to illustrate the variations in the energy values both before and after
energy minimization compared to the percentage identity. The following are some observations
regarding the information in Table 5.8:
• The percentage identities in rows 1 and 2 are similar. Thus, even though the percentage
identity in row 1 is greater than that in row 2, the FoldX energy after minimization (column
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Existing 190 fHbp sequences
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Figure 5.10: Line graph illustrating the inversely proportional relationship between the
percentage identity and the energy values determined by FoldX after energy minimization is
performed on the existing 190 fHbp sequences.
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7) is lower in the second row.
• In rows 4 and 5, both the sequences (Q6VRY1 and C0JFK6) have the same percentage
identity. Both these sequences had the same energy values after energy minimizations (117.79
Kcal/mol). However, their energy values before minimization were different. In contrast, the
sequences in rows 6 and 7 (Q6QCC2 and Q9JXV4) have the same percentage identity, yet
the FoldX energies after minimization are different.
• Despite the fact that the sequence in row 8 had lower sequence identity compared to the
sequences in rows 6 and 7, this sequence had the lowest energy among the three. However,
the differences in the percentage identity between the three sequences were very small.
• The information in rows 8, 9, 10, and 11 (for sequences C0JF89, B2CQ05, C0JF81, and
C0JF61) illustrates the trend of increasing FoldX energy values after minimization as per-
centage identity decreases. In this case the percentage identity for the four sequences varies
considerably.
• The sequences in the last two rows of Table 5.8 are another instance where the sequences
have similar percentage identity and the sequence with the higher percentage identity had
the higher FoldX energy values.
Table 5.8: Energy values determined from the tertiary structures of the existing 190 fHbp
sequences.
Sequence Template-
SM
%identity Energy-
SM
Energy
minimization-
SPDBV
Energy-FoldX
Before minimization After minimization
Q6VRZ1 2W80C 97.095 -11032.109 -11512.100 127.31 114.22
C0JFF9 2W80C 96.680 -10814.681 -11293.024 125.75 112.41
C0JFH9 2W80C 97.925 -10699.144 -11341.228 126.80 110.79
Q6VRY1 2W80C 96.680 -10938.603 -11417.902 131.37 117.79
C0JFK6 2W80C 96.680 -11087.590 -11562.205 130.53 117.79
Q6QCC2 2W80C 100.000 -11121.699 -11593.374 123.58 110.86
Q9JXV4 2W80C 100.000 -11121.699 -11621.195 125.16 117.99
C0JF89 2W80C 99.585 -11200.402 -11669.392 123.66 110.02
B2CQ05 2W80C 95.021 -10834.814 -11485.610 131.07 114.60
C0JF81 2W80C 83.402 -10499.725 -11052.418 145.54 129.67
C0JF61 2W80C 67.635 -10686.848 -11342.188 178.79 143.38
C0JFM5 2W80H 59.016 -7786.667 -9509.900 259.92 212.76
Q19KF7 2W80H 58.607 -9007.075 -9956.911 222.02 189.29
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The row highlighted with yellow colour in Table 5.8 identify the sequence with the highest FoldX
energy value (after energy minimization) among the 190 fHbp sequences. (The same highlight has
been made for Table B.7 in Appendix B.) Sequence C0JFM5 had the highest energy value (212.76
Kcal/mol). Hence, the valid highest energy boundary for structures of fHbp sequences is 212.76
Kcal/mol. This energy boundary was required to validate the new variants after Step 14.
5.7 Generating the new variants
The results of this section were the set of new variants generated using the pipeline of programs
developed in Step 10 of the Methodology (Figure 4.1). The individual modules in the pipeline were
implemented in Perl.
The programs in the pipeline implemented the amino acid substitution domains for each posi-
tion, the correlated and the co-occurring relationships and the constraints discussed in Sections 5.3
to 5.5. In total there were 164 Perl programs co-ordinated in the pipeline using UNIX shell scripts.
The first program of the pipeline, which required as a command line argument the number of
sequences to be generated, outputted the amino-terminal repetitive region, and the invariant seg-
ments that flank the five modular variable regions (VA to VE). It also produced the template for
all the variant sequences. The remaining programs were designed and implemented so that they
could be executed in any arbitrary order; in particular, their order of execution could be changed.
However, exploring the effects of changing the order of execution was beyond the scope of this
thesis.
There was one program in the pipeline written to denote the negative selection sites as ‘n’ and
the positive selection sites as ‘p’ (Algorithm 4.2). Another separate program was written to mark
the ‘gap’ symbols, where required, along the sequence alignment.
There were 21 separate programs written to realize the positive selection sites of the new variants.
This was done because positive selection sites were the regions which were more likely to change
compared to other regions. The positive selection sites are all highlighted with red colour in
Table B.6 in Appendix B. Next it was seen that there were correlated or co-occurring relationships
among some of the positive selection sites. Among the 21 programs, 6 incorporated such constraints
while realizing the positive selection sites. The remaining 15 programs were used for positive
selection sites which had no such relationships.
The next task was to instantiate the remaining positions, which were either negative selection
sites or were neither positive nor negative selection sites and 140 separate programs were written
to realize these positions. There were six instances of co-occurrence and one instance of correlation
as mentioned in Section 5.4. These individual instances were incorporated in separate programs;
that is, one program for one instance and so on. Hence, 6 separate programs were written to realize
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the 6 instances of co-occurrence (both “partially” and “fully” co-occurring) and one program was
written to realize the single instance of correlation in the sequence alignment. Positions which had
no such relationships were instantiated using individual separate programs; that is, one program
for generating amino acids for a single position with no correlation or co-occurrence. There were
133 separate programs written to realize such positions. However, it was noticed that there were
some positive selection sites (already instantiated by the 21 programs mentioned previously) which
had correlated or co-occurring relationships with some of the positions instantiated in this phase.
For such cases, the positive selection sites which had correlated or co-occurring relationships with
these positions were again included in the programs of this later phase. However, based on the
following criterion (already undertaken in Step 10 of Section 4.2),
if the amino acid is already set for a particular position, then we keep that setting
all the algorithms (except for the algorithm of the first program in the pipeline) based on which the
programs of this pipeline were developed, checks whether a position to be marked was either ‘X’ or
‘n’ or ‘p’ (see Algorithms 4.1 to 4.6) and remains unchanged otherwise. This meant that the positive
selection sites once instantiated by the first 21 programs would not be replaced by the programs of
the later phase, even if some of them had correlated or co-occurring relationships with the positions
instantiated by the later phase. Hence, in order to accommodate both the phenomenon, where in
one case the positive selection sites were generated separately and in the other with the positions
which were not positive selection sites, two sets of variants were generated in this research. For the
first set of new variants, 200 were generated, where the positive selection sites were instantiated
by the programs of the later phase. For this phenomena, the 21 programs which instantiated the
positive selection sites were placed after the 140 programs of the later phase in the pipeline. For the
second set of new variants, 100 were generated, where the positive selection sites were instantiated
by the 21 programs of the first phase; that is, these programs were now placed before the 140
programs in the pipeline. For convenience and better understanding of this thesis, the two sets are
termed Set A (with 200 new variants) and Set B (with 100 new variants).
Figures C.7 to C.12 show portions of the new variants of Set A. The figures illustrate the
characteristics of the new variants. The amino-terminal repetitive regions, the invariant segments
and the five modular variable regions are highlighted with the same colour as was used for the
190 fHbp sequences (illustrated in Figures C.1 to C.6). Note that the new variants lack the signal
protein part and start from the mature protein part; that is, the amino-terminal repetitive segment.
The consensus sequence illustrated in the figures was generated by the EMBOSS prettyplot program
from the set of 200 new variants.
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5.8 Studying the new variants and filtering of duplicates
This section discusses the results generated in Step 11 of the Methodology of this research
(Figure 4.1). After the generation of the two sets of new variants, Set A and Set B, the task was
to check whether the pipeline of programs generated any duplicate sequences. In order to verify
whether both the sets had unique variants, CD-HIT was used at 100% sequence identity on both
the sets. The results obtained showed that there were no duplicates in either set.
The next task was to determine whether any of the new variants were duplicates of the 190
fHbp sequences. To do this, the 190 fHbp sequences were merged first with Set A, and then in a
separate test, with Set B. CD-HIT at 100% sequence identity was applied to the resultant merged
sets. In both cases it was determined that none of the new variants were duplicates of the original
190 sequences. Hence, it was confirmed that both sets had unique new variants.
Next, it was determined whether the amino acid substitution domains for the variants in Sets A
and B were the same as for the original 190 fHbp sequence set. Scripts A.2 and A.3 in Appendix A
were applied, and the results generated are included in Tables B.2 and B.3 in Appendix B. The
results in Table B.2 show that the frequency of the different amino acids in each position along the
alignment of the new variants in both sets was in accordance with the frequencies from the original
190 sequences. The results in Table B.3 confirm that gaps are generated in the correct positions in
both sets of new variants.
Finally, it was desirable to examine the new variants in Sets A and B to determine if they had the
same positive and negative selection sites as the original 190 fHbp sequences. This was performed
using the KA/KS ratio as described in Section 5.5. A hurdle in this procedure was that calculating
KAand KS required the nucleotide sequences for the protein sequences. Since the sequences in Sets A
and B were synthetic, such nucleotide sequences were not available. Synthetic nucleotide sequences
could have been generated using tools such as the EMBOSS backtranseq [3] program. However,
certain issues would have arose. For instance, due to the ambiguity in the genetic code, it could
not be known for certain what nucleotide sequence would correspond to a particular “new variant”.
Even if backtranseq were provided with a table of codon usage frequency for N. meningitidis, it
could still not be known for certain what nucleotide sequence would correspond to a particular
“new variant”. If backtranseq chose a nucleotide which was different, then this in turn would have
affected our KA/KS value and the detection of positive and negative selection sites. Hence, it was
decided not to proceed with this part of verification of the new variants.
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Figure 5.11: Predicted tertiary structure of a new variant of Set A which uses the template
2W80H of PDB. The structure was derived using SWISS-MODEL and was visualized using
the Swiss-PdbViewer. The structure shows two beta barrels where the beta sheets have been
coloured in blue, the coils in lime green, and the alpha helix in red. The same structural
patterns were observed for the existing fHbp sequences (Figures 5.7 and 5.8).
5.9 Determining the validity of the new variants
This section discusses the results generated in the loop which started from Step 12 and involved
Steps 13 to 15 (Figure 4.1). The purpose of the loop was to determine the validity of the new
variants based on their predicted tertiary structures and the energy values of those structures.
The first task in the loop was to determine the structures of the new variants (Step 13, Fig-
ure 4.1). For all of the new variants of both the sets, their tertiary structures were found using
SWISS-MODEL [13, 33, 47, 67] as was done for the original 190 fHbp sequences in Step 8. The
structures were visualized using Swiss-PdbViewer [20, 45]. It was observed that, similar to the orig-
inal sequences, the new variants used three templates from PDB: 2W80C, 2W80H, and 1YS5. For
the same reasons explained in Section 5.5, the structures using the templates 2W80C and 2W80H
were taken into account, and the ones based on 1YS5 were discarded. Figure 5.11 shows a tertiary
structure of one of the new variants of Set A, which uses the template 2W80H of PDB.
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The next task in the loop was to determine the energy values of these tertiary structures for
all the variants in Sets A and B. The same procedure was followed as for the 190 fHbp sequences.
First, energy minimization was performed using Swiss-PdbViewer. Then FoldX [44, 72, 73, 74]
was used to determine the energy. Tables B.8 and B.9 give the results. The information in these
tables is organized in the same manner as in Table B.7, with the first column depicting the name
of the sequence; the second column, the template used in SWISS-MODEL; the third column, the
percentage identity of the sequence in the first column with the template used in the second column;
the fourth column, energy values determined by SWISS-MODEL (in KJ/mol); the fifth column,
energy minimization values generated as a result of energy minimization performed on the sequences
by the Swiss-PdbViewer (KJ/mol); the sixth and seventh columns, energy values (Kcal/mol) derived
using FoldX before and after energy minimizations of the structures, respectively.
A notable reduction in the energy values determined by FoldX is evident in both Tables B.8
and B.9 after the energy minimization on the structures. The same was observed for the original
set of fHbp sequences (Section 5.6). As in Step 14 (Section 4.2), the methodology focused on the
energy values determined after energy minimization (column 7). The highest value in column 7 has
been highlighted with yellow colour in both the Tables B.8 and B.9. It was observed in both tables
that these energy values tend to increase inversely to the percentage identity expressed in column
2; that is, the higher the percentage identity, the lower the energy values in column 7. However,
this trend is consistent only when comparing sequences whose sequence identities (in column 2) are
considerably different. This observation is illustrated in Figures 5.12 and 5.13 for Sets A and B
respectively. The same was seen in Table B.7 and Figure 5.10 for the original set of sequences (see
Section 5.6 for explanation).
In Table B.8, which lists the energy values for Set A (200 new variants), the highest energy
was 195.52 Kcal/mol (variant 52). For Table B.9, which lists the energy values for Set B (100 new
variants) the highest was 202.62 Kcal/mol (variant 39). In Step 9, it was determined that the valid
boundary set by the highest energy value for fHbp sequences was 212.76 Kcal/mol (Section 5.6). All
the energy values for all the new variants in both the sets were less than 212.76 Kcal/mol. Hence,
all the new variants in both sets were judged as valid new variants of fHbp sequences. The Sets A
and B contained new variants that nature might “allow” but which have not as yet appeared.
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Figure 5.12: Line graph illustrating the inversely proportional relationship between the
percentage identity and the energy values determined by FoldX after energy minimization is
performed on the 200 variants of Set A.
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performed on the 100 variants of Set B.
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Chapter 6
Discussion
This research aimed to predict the evolution of fHbp, an antigen present on the surface of
all strains of Neisseria meningitidis. For this purpose, unique sequences of fHbp were studied in
order to determine their various characteristics including the correlated or co-occurring regions
in the sequence alignment, and the energies of their predicted structures. Based on all these
characteristics new variants of fHbp were generated using the pipeline of programs developed as
part of this research. These new sequences were the variants of fHbp that nature might “allow”
but which have not as yet appeared.
This chapter summarizes the results presented in Chapter 5. It discusses the conclusions drawn
from the experiments performed in our research and also highlights some of the future work that
could be done later to further enhance the results.
6.1 Conclusions & Remarks
As mentioned in Chapter 3, the goal of this research was to generate valid new variants of fHbp
sequences and there were certain objectives required to be achieved in order to meet this goal.
• The first objective, which was a significant one, led to the development of an extensible
methodology for this research, which would form the foundation for more work in future.
• The second objective led to the study and determination of the characteristics of the existing
fHbp sequences. The existing fHbp sequences were downloaded from UniProtKB and their
characteristics were studied. It was observed that the sequences had specific variant regions
separated by invariant segments. In addition, the domains of possible amino acid substitutions
for each variable position showed that variation in these regions was restricted.
• The determined constraints showed that there were correlation and co-occurring relationships
amongst various positions in the variable regions of the sequences. In addition, there were
positive selection sites which were prone to change and negative selection sites which tended
to be conserved.
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• SWISS-MODEL was used to predict the tertiary structures of the fHbp sequences and Swiss-
PdbViewer was used to visualize them. It was seen that SWISS-MODEL used three templates
from PDB to predict the structures: 2W80C, 2W80H, and 1YS5, of which only a small portion
of the fHbp sequence was modeled by 1YS5 . The structures had some structural differences
between them, as discussed in Section 5.5.
• As part of achieving the next objective, the energy of the tertiary structures were found using
a widely-used software (FoldX). FoldX was used because it uses a full atomic description of
the structures of proteins.
• The next objective—a significant one—was to develop a pipeline of programs for generating
the new variants of fHbp. For this, the Perl programming language was used to write the
programs and UNIX shell script for coordinating the programs in a pipeline. As part of the
design goal, the pipeline of programs were built such that there was flexibility in the order
of execution of individual programs; that is, the order of the Perl scripts within the pipeline
could be varied except for the first program in the pipeline. Another design goal achieved
was that additional Perl scripts could be added to the pipeline; that is, there was no limit to
the number of programs that could be added, hence, forming a platform for future work.
• The last objective was to determine the validity of the new variants generated by the pipeline
of programs. For this the characteristics of the new variants were studied and compared
with those of the existing fHbp sequences. This was done in order to determine whether
the variants possessed the same characteristics as those of the existing ones. It was also
determined whether the same constraints and correlation or co-occurring relationships existed
in the new variants. The tertiary structures of the new variants were predicted and it was
found that SWISS-MODEL used the same templates as were used for the existing ones. Their
energy values were determined using FoldX and then compared with those of the existing fHbp
sequences.
A more reliable check of the viability of the variants could have been carried out in a wet lab.
However, it was out of the scope of this research; hence it can be carried on as part of future work
for this research.
The results in Chapter 5, specifically Section 5.9, indicated that all the new variants generated
had possible structures with energy values less than the highest energy value (212.76 Kcal/mol),
which was set as the valid boundary of energy for existing fHbp sequences (Section 5.6). This
meant that the sets of new variants were all judged as valid, which was an unexpected result. At
least some variants whose energy values were not within the valid range were expected due to the
stochastic nature of the generation process. The following are some possible reasons for this result.
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i. There were issues regarding the analysis of the fHbp binding sites to see if they were all under
negative selection pressure. Some of the binding sites had conflicting KA/KS ratio value
indicating that all the binding sites might not be under negative selection pressure. This
might be indicative of a problem with the determination of sites under negative selection
pressure, or parts of the methodology.
ii. Different positions of the aligned 190 fHbp sequences were visually examined to determine if
the positions of the restricted variable positions had correlated or co-occurring relationships.
Since co-occurrence and correlation constraints were determined visually, and the situation
being analyzed was complex (263 columns and 190 rows), it is quite conceivable that certain
key constraints of this type were over-looked.
iii. There were types of constraints that were identified but not exploited; the constraints were
deemed to be outside the scope of this research. Examples of such constraints were situations
where one amino acid has higher possibility of substituting another amino acid or occurrences
of intermediate residues in possible mutations (see the two examples illustrated in the Molec-
ular Evolution section of Step 8 Section 4.2). Such constraints may have determined that
some of the new variants would not be allowed by nature or could have made the similarity
boundary—both in structure and energy levels—even tighter.
iv. The 3D molecular structures predicted by SWISS-MODEL may have been erroneous or unre-
alistic due to a lack of model structures available at PDB. This could have led to misleading
or erroneous energy values for the existing sequences or new variants. Even though PDB had
a number of fHbp structures available – e.g. 2W80 (composed of 8 chains), 2W81 (6 chains),
2KDY (1 chain), 2KC0 (1 chain), 1YS5 (1 chain) – Tables B.7 through B.9 indicate that
only two two models (chains C and H of 2W80) were used.
v. The number of variants generated may have been too small. There might have been some
variants with energy values which did not fall within the valid energy range if a larger set of
new variants were generated; for instance, a thousand new variants.
vi. Despite the testing of each program in the pipeline and studying individual results generated in
each phase, there might have been errors in the pipeline of programs developed for generating
the new variants, made either when gathering characteristics from the existing sequences or
when implementing programs to manifest those characteristics.
As a conclusion, it can be said that if the variants satisfies all the constraints mentioned in
Chapter 4.2 and if they are generated by the pipeline of programs, then this thesis provides evidence
they will likely fit into the allowable energy values. What cannot be concluded is the converse: that
if a variant does not satisfy the constraints, that it will not be allowable. Developing a more precise
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Figure 6.1: Scatter plots illustrating energy (Kcal/mol) of the 200 new variants of Set
A generated by FoldX after energy minimization is performed. Energy of C0JFM5 (212.76
Kcal/mol) is the highest energy recorded of the existing fHbp sequences, hence forming the
boundary for valid energy values for the new variants.
characterization is therefore left for future work. Finally, it could be that, in fact, all of the 300
new variants would be allowed by nature (were “valid”) and that the energies are simply reflecting
this fact. The only way to make a definitive determination in this respect is through “wet lab”
verification.
However, it is possible to make a probabilistic conclusion regarding the probability of certain
variants occurring more than other variants from the distribution of the energy values. For this
the energy values of both sets A and B are plotted in the energy distribution graphs in Figures 6.1
and 6.2, respectively. From Section 5.6 it has been shown that the higher the percentage identity,
the lower the energy values; hence, variants with lower energy values having higher percentage
identity will be more likely to occur than those with higher energy values and lower percentage
identity.
In Figure 6.1 the scatter plots illustrating the energy of the 200 new variants of Set A are
highlighted by the blue dots and the energy value of C0JFM5 (212.76 Kcal/mol) which is the
highest energy recorded of the existing fHbp sequences is marked by the red square. This red
square forms the boundary for the maximum energy that the new variants may have. Since all
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Figure 6.2: Scatter plots illustrating energy (Kcal/mol) of the 100 new variants of Set B
generated by FoldX after energy minimization is performed. Energy of COJFM5 (212.76
Kcal/mol) is the highest energy recorded of the existing fHbp sequences, hence forming the
boundary for valid energy values for the new variants.
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Figure 6.3: Scatter plots illustrating energy (Kcal/mol) of the existing 190 fHbp sequences
generated by FoldX after energy minimization is performed.
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the energy values were less than this highest value, it is possible to make a probabilistic conclusion
from the energy distribution graph and mark those variants which were more likely to occur and
those that were less likely to occur. The first region marked by the black oval shape encircles the
energy values of those variants which were far away from the boundary energy and were more likely
to occur. It can be seen that this encircled region is more dense when compared with the other two
encircled regions. The second region marked by the blue oval shape encircles those variants which
have moderate chance of occurrence. The last one encircled by the red oval shape and closer to
the boundary energy marks those variants which are less likely to occur. This region is the least
dense covering approximately around 11 new variants. This constitutes around 5.5% of the 200
new variants in Set A. The last column in Table B.8 illustrates which variant belongs to which of
the three regions.
The same probabilistic study was carried out on the energy values of the 100 new variants of
Set B, illustrated by Figure 6.2. The same blue dots mark the energy values of the new variants
and the red square the energy value of C0JFM5 forming the boundary for the maximum energy the
100 new variants may have. The first region marked by the black oval shape are the energy value of
those variants which are far away from the boundary energy plus it is the most dense region. The
blue oval shape marks those variants which have moderate chance of occurrence. The last shape
illustrated by the red oval shape encircles the energy values of those variants which are closer to the
boundary energy value and are less likely to occur. This region covers 8 new variants approximately,
constituting around 8% of the 100 new variants in Set B. The last column in Table B.9 illustrates
which variant belongs to which of the three regions.
Figure 6.3 illustrates the scatter plot of the energy of the 190 existing fHbp sequences. In this
graph the same kind of energy distribution is observed with the distribution being divided into three
regions. However, the region encircled by the red oval shape has more numbers of fHbp sequences
than were observed for both plots in Figures 6.1 and 6.2.
Based on the scatter plots of Figures 6.1, 6.2, and 6.3 histograms shown in Figures 6.4, 6.5,
and 6.6 were built respectively. The histograms illustrates the energy distributions of the two sets
of variants (Figures 6.4 and 6.5) and the existing 190 fHbp sequences (Figure 6.6). For all the
histograms the energy range has been divided onto a scale of 20 Kcal/mol. It was observed that
for both the sets of variants, the maximum number of variants had energy values ranging between
120-140 Kcal/mol, whereas for the existing fHbp sequences the maximum number of sequences
had energy values ranging between 100-120 Kcal/mol. There were no variants in Set A which had
energy value of more than 200 Kcal/mol, hence that bar is absent in Figure 6.4. For Set B there
were minimum number of variants which had energy values ranging between 200-220 Kcal/mol
(Figure 6.5). However, for the existing fHbp sequences, moderate number of sequences had energy
values within 200-220 Kcal/mol range (Figure 6.6). Based on the energy distributions depicted by
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Figure 6.4: Histogram illustrating energy distribution of the 200 new variants of Set A.
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the histograms of Figures 6.4, 6.5, and 6.6, it can be concluded that the number of variants as well
as the existing fHbp sequences were more for ranges with the lower energy values than for ranges
with the higher ones.
The last discussion on this thesis is based on to what extent this research has tried to capture
realistic variants of Neisseria meningitidis, that is, how confident one can be that the variants
obtained through this research were functionally meaningful. There were some constraints that
were functionally meaningful and some which were superficial in nature. However, the approaches
undertaken in this research is just an early step towards generating realistic variants and requires
much more work in future. For instance, this research due to its limitations was not able to
investigate affinity between the 21 binding sites of fH and fHbp. As suggested by committee
member, Dr. Nate Osgood, one critical “fitness function” that could be worked on in future would
be the affinity of the 21 binding sites of fHbp to fH. A simulation approach can be undertaken
involving incremental generation of variants, that is, one mutation at a time and discarding at
every step those that don’t have high affinity to fH. This simulation process can be repeated
several times until the variants that might seem sufficiently fit emerges. Such simulation process
will result in variants that has passed the affinity test and will be more functionally meaningful in
nature.
The literature was probed to find other similar research works involving the prediction of the
evolution of the factor H binding protein antigen. Unfortunately, similar works could not be found.
However, some works were found which involved study of the fHbp antigen and vaccine develop-
ment. Most of these works were highly concentrated on biochemistry and not on bioinformatics.
Only one work involved some bioinformatics-based research in addition to biochemistry. The title
of this paper is “Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epi-
demiologically Relevant Strains of Serogroup B Neisseria meningitidis” [59]. This research focused
only on the strains of serogroup B. The sequences collected were divided into two subfamilies, A
and B, based on the sequence diversity, unlike our work, where no such classifications were made.
The method used in this research involved Multilocus sequence typing (MLST) analysis. The bioin-
formatics portion of this research involved aligning the sequences using ClustalW, just as was done
here. However, in addition with aligning, distances were also calculated using the neighbor-joining
method in ClustalW, which was not done in our work. Consensus sequence were calculated using
EMBOSS program cons, similar to what was done for our work. Minimum spanning trees were
constructed for both the subfamilies A and B in this research, unlike our work. The fHbp sequences
were studied to identify the conserved and the variable regions, similar to our work. However, no
regions which had co-ocurring or correlational characteristics were identified in this research work.
The concluding remark for this research based on their results was that the diversity of the strains
that were observed implied that studying the distribution of the vaccine antigen itself was more
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important than relying on some epidemiological substitution like MLST.
6.2 Future Work
The following is future work that could be carried out to improve on or extend this work.
i. Testing, analyzing, and verifying of the new variants by biochemists using wet lab techniques.
This is perhaps the most significant future work that can be carried out for further determi-
nation of the validity of the new variants.
ii. More sequences have been deposited at UniProtKB, so the research could be repeated, but
taking advantage of the updated information at UniProtKB.
iii. Step 7 (Section 4.2), which determines the correlation and co-occurrence relationships, can
be performed by a statistical or a computational tool, rather than being performed visually.
Since it was performed visually, some correlations and co-occurrences could have been missed.
iv. Implement the complete characteristics of Molecular Evolution as discussed in Step 8 (Sec-
tion 4.2), so that generation of new variants will make use of those amino acids that have
higher possibility of substituting another amino acid.
v. Include the chemical properties of the amino acids as another type of constraint when gener-
ating the new variants.
vi. While determining the spatial and physicochemical constraints in Step 8 (Section 4.2), the
study of the tertiary structures started with the correlated and co-occurring positions in
region VA. In future, the study can start with positions in other regions.
vii. Include both the tertiary structural constraints as mentioned in Spatial and physicochemical
constraints of Step 8 (Section 4.2):
(a) amino acids that must be within certain distances of each other to form, for example,
an active site;
(b) amino acids with conflicting physicochemical properties cannot be within certain prox-
imities of each other.
viii. The possibility of using phylogenetic analysis to provide constraints to drive the generation
of variants.
ix. Use programs other than SWISS-MODEL to determine the structures of the original sequences
as well as the variants. Of particular interest would be using programs which are not restrained
by the lack of availability of model structures at PDB.
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x. Use a commercial quality energy minimization program, such as Amber [1, 49] to perform the
energy minimization. Amber is available for research use on WestGrid [28].
xi. There were two alternative options for generating positions in the new variants with in-
terference problems (Step 10 of Section 4.2). For such positions, the first alternative was
implemented in this research. The second alternative – to allow subsequent steps to modify
an already placed amino acid according to the constraints at that stage – can be implemented.
xii. Rearranging the programs in the pipeline should result in different variants being produced.
While this might be desirable for the user, it is inefficient since it requires manual modification
of the pipeline. To increase the efficiency, a higher level to the pipeline can be developed,
where the shuffling of the programs in the pipeline is done using an algorithm instead of
shuffling manually by the user as is done now or the user can be invoked to determine the
shuffling order. Such facility to programmatically control the execution of the modules in the
pipeline may lead to the generation of more diverse variants.
xiii. To look at the energy in just the binding pockets of fHbp, that is, at the 21 binding sites.
xiv. To add a control measure to the research, such that variants would be generated which did not
use the constraints or the correlation and co-occurrences properties. The restricted variable
regions of these variants would just have randomly mutated amino acids and then it could be
verified whether these variants had the same tertiary structures and whether they still had
energy values below the valid boundary energy, or whether they had higher energy.
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Appendix A
Scripts
The following scripts were used to identify the conserved, restricted variable, and unrestricted
variable regions of the multiple sequence alignment and to determine the amino acid substitution
domains for the variable regions (Steps 6 and 11 of the Methodology, Section 4.2).
A.1 Script 01
This script generates a table which depicts how often each symbol appears in each column of
the alignment excluding the ‘gap’ symbols. Columns of the table are delimited by tab characters.
Each row of the table begins with a position of the multiple sequence alignment. There follow some
number of columns, possibly only 1, where each column consists of an occurrence count and the
amino acid code with that occurrence count separated by a space.
1. #!/bin/csh
2. set DATASET=MSA seq
3. set N=263
4. set INFILE=${DATASET}.msf
5. set OTFILE=${DATASET}.cnts.nogaps.script.txt
6. echo -n > ! $OTFILE
7. foreach I (‘jot $N 1 $N 1’)
8. printf “%d\t” $I >> $OTFILE
9. seqret -sequence “${INFILE}:*[${I}:${I}]” -outseq stdout -auto | \
10. grep -v ‘∧>’ | grep -v ‘-’ | \
11. sort | uniq -c | \
12. tr -s ‘ ’ | tr ‘\n’ ‘\t’ >> $OTFILE
13. echo >> $OTFILE
14. end
Explanation for Script 01.
• Line 2: set the name of the dataset.
• Line 3: set the variable ‘N’ to the value 263, the maximum length of the fHbp sequences
after removal of the signal protein part.
• Lines 4 and 5: set the names of the input and output files based on the dataset name.
• Line 6: create the output file, or if it already exists, empty it of previous content.
• Lines 7 through 14: iteratively examine each position of the alignment, with positions ranging
from 1 to 263. The jot command produces the sequence of numbers from 1 to 263 in
increments of 1. The loop index variable is I.
• Line 8: output the position number in the sequence.
• Lines 9 through 12: this set of lines constitutes a single UNIX command pipeline. The first
step is to obtain the amino acid in position I for all the sequences where a multi-FASTA file
with 190 single-character sequences is generated. The next step is to delete all the header
records (lines starting with ‘>’) from the multi-FASTA file, generating 190 one-character lines
of raw sequence information and then remove all occurrences of the ‘gap’ character. Count
the number of each character. Finally produce an output line that contains tab-delimited
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columns. Each column consists of an occurrence count and the character with that count
separated by a space.
• Line 9: have the EMBOSS seqret command produce on the standard output, a multi-FASTA
file with 190 single-character sequences in it.
• Line 10: the two grep commands here act as filters. UNIX command grep -v inverts the
sense of matching. Command grep -v ‘∧>’ removes any line which starts with the ‘>’
symbol and grep -v ‘-’ excludes the ‘gap’ symbol.
• Line 11: sort the set of amino acids using the UNIX sort command, and then count the
number of occurrences of each amino acid using the command uniq -c. The latter command
will produce a table with one line for each amino acid. On the line will be a count and an
amino acid separated by space characters.
• Line 12: UNIX command tr -s ‘ ’ replaces the repeated occurrences of the character ‘ ’
with its single occurrence. The second command on line 12 replaces each newline character
by a tab character. The purpose is so that all the output related to a particular multiple
sequence alignment position is contained in a single line to be output.
• Line 13: terminate the line of output from line 12 with a newline character.
• Line 14: terminate the for loop.
A.2 Script 02
This script generates a table which depicts how often each symbol appears in each column of
the alignment including the ‘gap’ symbols. Columns of the table are delimited by tab characters.
Each row of the table begins with a position of the multiple sequence alignment. There follow some
number of columns, possibly only 1, where each column consists of an occurrence count and the
amino acid code or ‘gap’ symbol, with that occurrence count. The latter two fields in each column
are separated by a space.
1. #!/bin/csh
2. set DATASET=MSA seq
3. set N=263
4. set INFILE=${DATASET}.msf
5. set OTFILE=${DATASET}.cnts.gaps.script.txt
6. echo -n > ! $OTFILE
7. foreach I (‘jot $N 1 $N 1’)
8. printf “%d\t” $I >> $OTFILE
9. seqret -sequence “${INFILE}:*[${I}:${I}]” -outseq stdout -auto | \
10. grep -v ‘∧>’ | \
11. sort | uniq -c | \
12. tr -s ‘ ’ | tr ‘\n’ ‘\t’ >> $OTFILE
13. echo >> $OTFILE
14. end
Explanation for Script 02.
• Line 2: set the name of the dataset.
• Line 3: set the variable ‘N’ to the value 263, the maximum length of the fHbp sequences
after removal of the signal protein part.
• Lines 4 and 5: set the names of the input and output files based on the dataset name.
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• Line 6: create the output file, or if it already exists, empty it of previous content.
• Lines 7 through 14: iteratively examine each position of the alignment, with positions ranging
from 1 to 263. The jot command produces the sequence of numbers from 1 to 263 in
increments of 1. The loop index variable is I.
• Line 8: output the position number in the sequence.
• Lines 9 through 12: this set of lines constitutes a single UNIX command pipeline. The first
step is to obtain the amino acid or the ‘gap’ symbol in position I for all the sequences where
a multi-FASTA file with 190 single-character sequences is generated. The next step is to
delete all the header records (lines starting with ‘>’) from the multi-FASTA file, generating
190 one-character lines of raw sequence information. Count the number of each character.
Finally produce an output line that contains tab-delimited columns. Each column consists of
an occurrence count and the character with that count separated by a space.
• Line 9: have the EMBOSS seqret command produce on the standard output, a multi-FASTA
file with 190 single-character sequences in it.
• Line 10: the grep command here act as a filter. UNIX command grep -v inverts the sense
of matching. Command grep -v ‘∧>’ removes any line which starts with the ‘>’ symbol.
• Line 11: sort the set of amino acids and ‘gap’ symbols using the UNIX sort command, and
then count the number of occurrences of each amino acid or ‘gap’ using the command uniq
-c. The latter command will produce a table with one line for each amino acid or ‘gap’
symbol. On the line will be a count and an amino acid or ‘gap’ symbol separated by space
characters.
• Line 12: UNIX command tr -s ‘ ’ replaces the repeated occurrences of the character ‘ ’
with its single occurrence. The second command in line 12 replaces each newline character
by a tab character. The purpose is so that all the output related to a particular multiple
sequence alignment position is contained in a single line to be output.
• Line 13: terminate the line of output from line 12 with a newline character.
• Line 14: terminate the for loop.
A.3 Script 03
This script determines which columns of an alignment have at least one ‘gap’ symbol and
produces a list of those columns, one column number per line.
1. #!/bin/csh
2. set DATASET=MSA seq
3. set N=263
4. set INFILE=${DATASET}.msf
5. set OTFILE=${DATASET}.cols with gaps.script.txt
6. echo -n > ! $OTFILE
7. foreach I (‘jot $N 1 $N 1’)
8. seqret -sequence “${INFILE}:*[${I}:${I}]” -outseq stdout -auto | \
9. grep -v ‘∧>’ | grep -e ‘-’ > /dev/null
10. if ( $status == 0 ) then
11. echo $I >> $OTFILE
12. endif
13. end
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Explanation for Script 03.
• Line 2: set the name of the dataset.
• Line 3: set the variable ‘N’ to the value 263, the maximum length of the fHbp sequences
after removal of the signal protein part.
• Lines 4 and 5: set the names of the input and output files based on the dataset name.
• Line 6: create the output file, or if it already exists, empty it of previous content.
• Lines 7 through 13: iteratively examine each position of the alignment, with positions ranging
from 1 to 263. The jot command produces the sequence of numbers from 1 to 263 in
increments of 1. The loop index variable is I.
• Lines 8 and 9: this set of lines constitutes a single UNIX command pipeline. The exit status
of the pipeline will be “success” if the current column position of the alignment (stored in
variable I) contains any ‘gap’ symbols.
• Line 8: have the EMBOSS seqret command produce on the standard output, a multi-FASTA
file with 190 single-character sequences in it.
• Line 9: the first grep command here act as a filter. UNIX command grep -v inverts the sense
of matching. Command grep -v ‘∧>’ removes any line which starts with the ‘>’ symbol and
grep -e ‘-’ specifies the matching of the pattern beginning with ‘-’ symbol. The /dev/null
used here is a special file that discards all data written to it and in this case ‘-’ is written to
it, whenever it is found.
• Lines 10 through 12: constitutes the if condition. The if condition checks the exit status
returned by the last command, which in this case is the pipeline in lines 8 and 9. The csh
variable status returns a status of 1 for an unsuccessful exit of the pipeline and returns a 0
for a successful exit of the pipeline.
• Line 11: command is executed only when the if condition of Line 10 is true. Output consists
of the position number in the sequence alignment with at least one ‘gap’ symbol.
• Line 13: terminate the for loop.
A.4 Script 04
This script determines the frequency distribution for the counts of the different amino acids
across the columns of the alignment, with ‘gap’ symbols excluded and involves the use of an in-
termediate file. The intermediate result generates a file where each row represents each column
position in the multiple sequence alignment followed by the count of the number of unique amino
acids occurring in that position delimited by a tab character. For instance, suppose the first row
has the output 1 followed by 1 delimited by a tab character, the second row has 2 followed by 1, the
third row has 3 followed by 2 and so on. This means that the first column position in the sequence
alignment has 1 type of amino acid, the second position has 1 type too, the third position have 2
unique amino acids, etc. The final phase of this script reads the intermediate result as input and
outputs a file which consists of two columns separated by a space character. The first column is the
frequency of the counts; that is, how often each count appears and the second column is the count
itself. For instance, suppose the first row in the final output has 122 followed by 1 separated by a
space character. This means that in our alignment ignoring the occurrences of the ‘gap’ symbols,
there were 122 positions with only one type of amino acid.
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1. #!/bin/csh
2. set DATASET=MSA seq
3. set N=263
4. set INFILE=${DATASET}.msf
5. set OTFILE=${DATASET}.cnts residues each column.nogaps.script.txt
6. echo -n > ! $OTFILE
7. foreach I (‘jot $N 1 $N 1’)
8. printf “%d\t” $I >> $OTFILE
9. seqret -sequence “${INFILE}:*[${I}:${I}]” -outseq stdout -auto | \
10. grep -v ‘∧>’ | grep -v ‘-’ | \
11. sort -u | wc -l | \
12. tr -d “ ” >> $OTFILE
13. end
14. set INFILE=${DATASET}.cnts residues each column.nogaps.script.txt
15. set OTFILE=${DATASET}.freq.nogaps.script.txt
16. cut -f 2 $INFILE | sort | uniq -c > ! $OTFILE
Explanation for Script 04.
This script has two parts. The first part outputs the count of the number of unique amino acids
for each column position in the alignment excluding the ‘gap’ symbols. This output becomes the
input for the next part of this script which determines a frequency distribution for the intermediate
result generated in the first part. Note that the ‘gap’ symbols are excluded in this script. Lines 1
to 13 form the first phase of this script and lines 14 to 16 the second phase.
• Line 2: set the name of the dataset.
• Line 3: set the variable ‘N’ to the value 263, the maximum length of the fHbp sequences
after removal of the signal protein part.
• Lines 4 and 5: set the names of the input and output files based on the dataset name.
• Line 6: create the output file, or if it already exists, empty it of previous content.
• Lines 7 through 13: iteratively examine each position of the alignment, with positions ranging
from 1 to 263. For each position, output to the intermediate output file a line which contains
two tab-separated values: the position number and a count of the number of unique amino
acids occurring at that position. The jot command produces the sequence of numbers from
1 to 263 in increments of 1. The loop index variable is I.
• Line 8: output the position number in the sequence.
• Lines 9 through 12: this set of lines constitutes a single UNIX command pipeline. The pipeline
produces a count of how many different amino acids occur at this position (in the alignment).
• Line 9: have the EMBOSS seqret command produce on the standard output a multi-FASTA
file with 190 single-character sequences in it.
• Line 10: the two grep commands here act as filters. UNIX command grep -v inverts the
sense of matching. Command grep -v ‘∧>’ removes any line which starts with the ‘>’
symbol and grep -v ‘-’ excludes the ‘gap’ symbol.
• Line 11: UNIX command sort -u sorts the list of amino acids and suppresses all but one
occurrence of matching keys. The command wc -l counts the lines generated; i.e. it counts
the number of unique amino acids. Note that this output from wc will be terminated by a
newline character.
• Line 12: UNIX command tr -d ‘ ’ removes any space characters surrounding the count, and
outputs the bare count to the intermediate output file.
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• Line 13: terminate the for loop.
• Line 14: set the output file generated in the first phase as the input file for the second phase.
• Line 15: set the name of the output file based on the dataset name.
• Line 16: UNIX command cut -f 2 $INFILE extracts just the second column from the input
file, which contains the count of the different amino acids occurring for each particular posi-
tion. The UNIX command sort sorts these counts and uniq -c determines the frequency of
the counts; that is, the uniq command will determine how often each count occurs. It will
then produce a two column table, with the columns separated by a space, with a frequency
in the first column and a count in the second column and forwards it to the output file of the
second phase.
A.5 Script 05
This script determines the frequency distribution of the counts of the different amino acids,
including the occurrences of the ‘gap’ symbols across the columns of the alignment, and involves
the use of an intermediate file. The intermediate result generates a file where each row represents
each column position in the multiple sequence alignment followed by the count of the number of
unique amino acids or ‘gaps’ occurring in that position delimited by a tab character. For instance,
suppose the first row has the output 1 followed by 1 delimited by a tab character, the second row
has 2 followed by 1, the third row has 3 followed by 2 and so on. This means that the first column
position in the sequence alignment has 1 type of amino acid or just ‘gaps’, the second position has
1 type too, the third position have 2 unique amino acids or one type of amino acid and ‘gaps’, etc.
The final phase of this script reads the intermediate result as input and outputs a file which consists
of two columns separated by a space character. The first column is the frequency of the counts; that
is, how often each count appears and the second column is the count itself. For instance, suppose
the first row in the final output has 115 followed by 1 separated by a space character. This means
that in our alignment including the occurrences of the ‘gap’ symbols, there were 115 positions with
only one type of amino acid or ‘gaps’.
1. #!/bin/csh
2. set DATASET=MSA seq
3. set N=263
4. set INFILE=${DATASET}.msf
5. set OTFILE=${DATASET}.cnts residues each column.gaps.script.txt
6. echo -n > ! $OTFILE
7. foreach I (‘jot $N 1 $N 1’)
8. printf “%d\t” $I >> $OTFILE
9. seqret -sequence “${INFILE}:*[${I}:${I}]” -outseq stdout -auto | \
10. grep -v ‘∧>’ | \
11. sort -u | wc -l | \
12. tr -d “ ” >> $OTFILE
13. end
14. set INFILE=${DATASET}.cnts residues each column.gaps.script.txt
15. set OTFILE=${DATASET}.freq.gaps.script.txt
16. cut -f 2 $INFILE | sort | uniq -c > ! $OTFILE
Explanation for Script 05.
This script has two parts. The first part outputs the count of the number of unique amino acids
including the ‘gap’ symbols for each column position in the alignment. This output becomes the
input for the next part of this script which determines a frequency distribution for the intermediate
result generated in the first part. Lines 1 to 13 form the first phase of this script and lines 14 to 16
the second phase.
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• Line 2: set the name of the dataset.
• Line 3: set the variable ‘N’ to the value 263, the maximum length of the fHbp sequences
after removal of the signal protein part.
• Lines 4 and 5: set the names of the input and output files based on the dataset name.
• Line 6: create the output file, or if it already exists, empty it of previous content.
• Lines 7 through 13: iteratively examine each position of the alignment, with positions ranging
from 1 to 263. For each position, output to the intermediate output file a line which contains
two tab-separated values: the position number and a count of the number of unique amino
acids and ‘gaps’ occurring at that position. The jot command produces the sequence of
numbers from 1 to 263 in increments of 1. The loop index variable is I.
• Lines 9 through 12: this set of lines constitutes a single UNIX command pipeline. The pipeline
produces a count of how many different amino acids and ‘gaps’ occur at this position (in the
alignment).
• Line 9: have the EMBOSS seqret command produce on the standard output a multi-FASTA
file with 190 single-character sequences in it.
• Line 10: the grep command here act as a filter. UNIX command grep -v inverts the sense
of matching. Command grep -v ‘∧>’ removes any line which starts with the ‘>’ symbol.
• Line 11: UNIX command sort -u sorts the list of amino acids and ‘gaps’ and suppresses all
but one occurrence of matching keys. The command wc -l counts the lines generated; i.e. it
counts the number of unique amino acids or the occurrences of ‘gap’ symbols. Note that this
output from wc will be terminated by a newline character.
• Line 12: UNIX command tr -d ‘ ’ removes any space characters surrounding the count, and
outputs the bare count to the intermediate output file.
• Line 13: terminate the for loop.
• Line 14: set the output file generated in the first phase as the input file for the second phase.
• Line 15: set the name of the output file based on the dataset name.
• Line 16: UNIX command cut -f 2 $INFILE extracts just the second column from the input
file, which contains the count of the different amino acids including the ‘gaps’ occurring
for each particular position. The UNIX command sort sorts these counts and uniq -c
determines the frequency of the counts; that is, the uniq command will determine how often
each count occurs. It will then produce a two column table, with the columns separated by
a space, with a frequency in the first column and a count in the second column and forwards
it to the output file of the second phase.
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Appendix B
Tables of Results
Table B.1: Frequency of different amino acids in each position of the 190 fHbp sequences
with ‘gap’ symbol excluded. The results of this table were generated using Script A.1 of
Appendix A.
Position 190 fHbp sequences
1 190C
2 190S
3 190S
4 190G
5 134G 2S
6 58G
7 58G
8 57S
9 56G
10 100G 11S
11 190G
12 190G
13 3I 187V
14 183A 7T
15 189A 1V
16 190D
17 190I
18 190G
19 138A 48T 4V
20 187G 1R 2V
21 190L
22 190A
23 189D 1Y
24 190A
25 190L
26 190T
27 173A 16T 1V
28 2L 188P
29 2F 186L 2P
30 190D
31 190H
32 190K
33 189D 1N
34 190K
35 144G 46S
36 190L
37 53K 133Q 4R
38 190S
39 190L
40 1A 1I 18M 170T
41 190L
42 136D 53E 1N
43 53D 137Q
44 190S
45 53I 137V
46 35P 137R 18S
47 136K 53Q 1R
48 3K 187N
49 137E 53G
50 137K 53T
Continued on next page
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Table B.1 – continued from previous page
Position 190 fHbp sequences
51 190L
52 137K 53T
53 190L
54 133A 57S
55 190A
56 190Q
57 190G
58 189A 1V
59 190E
60 4E 177K 9R
61 2I 188T
62 50F 140Y
63 140G 50K
64 42A 140N 8V
65 190G
66 187D 2G 1N
67 50K
68 50D
69 50N
70 1N 2R 187S
71 190L
72 3D 186N 1S
73 190T
74 189G 1S
75 190K
76 190L
77 190K
78 190N
79 190D
80 190K
81 64I 126V
82 190S
83 190R
84 190F
85 190D
86 190F
87 148I 42V
88 4H 42Q 144R
89 42K 148Q
90 190I
91 189E 1R
92 1S 189V
93 188D 2N
94 186G 4R
95 14K 176Q
96 142L 48T
97 190I
98 190T
99 190L
100 48A 142E
101 2N 1R 187S
102 190G
103 190E
104 190F
105 190Q
106 83I 107V
107 190Y
108 190K
109 190Q
110 68D 1G 15N 106S
111 186H 4Y
112 190S
Continued on next page
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Table B.1 – continued from previous page
Position 190 fHbp sequences
113 190A
114 106L 84V
115 106T 84V
116 190A
117 18F 172L
118 190Q
119 82I 108T
120 190E
121 84K 106Q
122 20E 100I 70V
123 84N 106Q
124 106D 84N
125 2L 99P 89S
126 84D 106E
127 33D 73H 84K
128 77I 106S 7T
129 1A 84D 6E 94G 5R
130 104K 86S
131 84L 106M
132 84I 106V
133 105A 84N 1V
134 106K 83Q 1R
135 190R
136 78Q 28R 84S
137 190F
138 16K 84L 90R
139 106I 84V
140 106G 84S
141 106D 83G 1S
142 106I 84L
143 100A 84G 6V
144 190G
145 190E
146 190H
147 1I 189T
148 84A 106S
149 190F
150 102D 4G 84N
151 106K 84Q
152 190L
153 1H 188P 1R
154 1D 49E 1G 55K
155 45D 112G 30S 3V
156 13D 143G 3S 31V
157 84K 28M 51R 27S
158 188A 1S 1V
159 84E 106T
160 190Y
161 84H 106R
162 190G
163 84K 106T
164 190A
165 187F 3L
166 89G 101S
167 190S
168 190D
169 190D
170 151A 38P 1T
171 144G 38N 1R 7S
172 190G
173 1E 150K 39R
174 190L
Continued on next page
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Table B.1 – continued from previous page
Position 190 fHbp sequences
175 38H 15I 137T
176 190Y
177 33S 157T
178 190I
179 190D
180 190F
181 151A 38T 1V
182 146A 33K 5N 1S 2T 3V
183 190K
184 190Q
185 190G
186 1C 131H 12N 46Y
187 190G
188 1G 151K 38R
189 190I
190 190E
191 190H
192 190L
193 190K
194 105S 85T
195 1L 189P
196 190E
197 107L 83Q
198 190N
199 190V
200 74D 115E 1N
201 190L
202 188A 2V
203 99A 53S 29T 9V
204 182A 8S
205 48D 85E 1N 56Y
206 105I 85L
207 1E 189K
208 85A 104P 1Q
209 190D
210 169E 9G 12K
211 190K
212 53H 52R 85S
213 188H 2Y
214 190A
215 190V
216 190I
217 85L 105S
218 190G
219 85D 1F 104S
220 85T 105V
221 1H 105L 84R
222 190Y
223 1D 84G 105N
224 28G 1H 104Q 57S
225 40A 64D 85E 1N
226 190E
227 190K
228 189G 1S
229 105S 85T
230 190Y
231 85H 105S
232 190L
233 85A 105G
234 105I 85L
235 190F
236 189G 1S
Continued on next page
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Table B.1 – continued from previous page
Position 190 fHbp sequences
237 85D 10E 94G 1R
238 1E 50K 54Q 85R
239 190A
240 190Q
241 190E
242 86I 104V
243 190A
244 190G
245 190S
246 190A
247 105E 85T
248 190V
249 57E 133K
250 85I 105T
251 64A 41G 44R 41V
252 85E 105N
253 105G 85K
254 105I 85V
255 127H 7Q 56R
256 85E 105H
257 190I
258 1D 183G 6S
259 85I 105L
260 190A
261 105A 85G
262 190K
263 190Q
Table B.2: Frequency of different amino acids and the ‘gap’ symbol in each position of the
190 fHbp sequences and the two sets of new variants, Set A and Set B. The results of this
table were generated using Script A.2 of Appendix A.
Position 190 fHbp sequences Set A (200 new variants) Set B (100 new variants)
1 190C 200C 100C
2 190S 200S 100S
3 190S 200S 100S
4 190G 200G 100G
5 54 – 134G 2S 50 – 148G 2S 30 – 70G
6 132 – 58G 135 – 65G 64 – 36G
7 132 – 58G 144 – 56G 73 – 27G
8 133 – 57S 141 – 59S 72 – 28S
9 134 – 56G 152 – 48G 69 – 31G
10 79 – 100G 11S 72 – 109G 19S 32 – 62G 6S
11 190G 200G 100G
12 190G 200G 100G
13 3I 187V 6I 194V 4I 96V
14 183A 7T 194A 6T 97A 3T
15 189A 1V 197A 3V 98A 2V
16 190D 200D 100D
17 190I 200I 100I
18 190G 200G 100G
19 138A 48T 4V 152A 42T 6V 78A 21T 1V
20 187G 1R 2V 194G 1R 5V 99G 1R
21 190L 200L 100L
22 190A 200A 100A
23 189D 1Y 198D 2Y 100D
24 190A 200A 100A
25 190L 200L 100L
26 190T 200T 100T
Continued on next page
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Table B.2 – continued from previous page
Position 190 fHbp sequences Set A (200 new variants) Set B (100 new variants)
27 173A 16T 1V 179A 16T 5V 92A 8T
28 2L 188P 1L 199P 3L 97P
29 2F 186L 2P 4F 193L 3P 97L 3P
30 190D 200D 100D
31 190H 200H 100H
32 190K 200K 100K
33 189D 1N 199D 1N 100D
34 190K 200K 100K
35 144G 46S 144G 56S 78G 22S
36 190L 200L 100L
37 53K 133Q 4R 57K 142Q 1R 29K 70Q 1R
38 190S 200S 100S
39 190L 200L 100L
40 1A 1I 18M 170T 1A 3I 19M 177T 1I 8M 91T
41 190L 200L 100L
42 136D 53E 1N 142D 57E 1N 70D 29E 1N
43 53D 137Q 57D 143Q 29D 71Q
44 190S 200S 100S
45 53I 137V 57I 143V 29I 71V
46 35P 137R 18S 36P 143R 21S 16P 71R 13S
47 136K 53Q 1R 142K 57Q 1R 70K 29Q 1R
48 3K 187N 10K 190N 3K 97N
49 137E 53G 143E 57G 71E 29G
50 137K 53T 143K 57T 71K 29T
51 190L 200L 100L
52 137K 53T 143K 57T 71K 29T
53 190L 200L 100L
54 133A 57S 142A 58S 70A 30S
55 190A 200A 100A
56 190Q 200Q 100Q
57 190G 200G 100G
58 189A 1V 199A 1V 99A 1V
59 190E 200E 100E
60 4E 177K 9R 2E 191K 7R 1E 96K 3R
61 2I 188T 1I 199T 3I 97T
62 50F 140Y 52F 148Y 33F 67Y
63 140G 50K 148G 52K 67G 33K
64 42A 140N 8V 43A 148N 9V 32A 67N 1V
65 190G 200G 100G
66 187D 2G 1N 194D 2G 4N 96D 1G 3N
67 140 – 50K 148 – 52K 67 – 33K
68 140 – 50D 148 – 52D 67 – 33D
69 140 – 50N 148 – 52N 67 – 33N
70 1N 2R 187S 2N 3R 195S 1N 1R 98S
71 190L 200L 100L
72 3D 186N 1S 2D 193N 5S 1D 97N 2S
73 190T 200T 100T
74 189G 1S 197G 3S 99G 1S
75 190K 200K 100K
76 190L 200L 100L
77 190K 200K 100K
78 190N 200N 100N
79 190D 200D 100D
80 190K 200K 100K
81 64I 126V 78I 122V 30I 70V
82 190S 200S 100S
83 190R 200R 100R
84 190F 200F 100F
85 190D 200D 100D
86 190F 200F 100F
87 148I 42V 153I 47V 77I 23V
88 4H 42Q 144R 3H 47Q 150R 1H 23Q 76R
Continued on next page
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Table B.2 – continued from previous page
Position 190 fHbp sequences Set A (200 new variants) Set B (100 new variants)
89 42K 148Q 47K 153Q 23K 77Q
90 190I 200I 100I
91 189E 1R 199E 1R 99E 1R
92 1S 189V 2S 198V 100V
93 188D 2N 199D 1N 100D
94 186G 4R 193G 7R 96G 4R
95 14K 176Q 15K 185Q 4K 96Q
96 142L 48T 151L 49T 72L 28T
97 190I 200I 100I
98 190T 200T 100T
99 190L 200L 100L
100 48A 142E 49A 151E 28A 72E
101 2N 1R 187S 2N 2R 196S 1R 99S
102 190G 200G 100G
103 190E 200E 100E
104 190F 200F 100F
105 190Q 200Q 100Q
106 83I 107V 83I 117V 36I 64V
107 190Y 200Y 100Y
108 190K 200K 100K
109 190Q 200Q 100Q
110 68D 1G 15N 106S 65D 1G 15N 119S 33D 7N 60S
111 186H 4Y 198H 2Y 99H 1Y
112 190S 200S 100S
113 190A 200A 100A
114 106L 84V 119L 81V 60L 40V
115 106T 84V 119T 81V 60T 40V
116 190A 200A 100A
117 18F 172L 16F 184L 9F 91L
118 190Q 200Q 100Q
119 82I 108T 91I 109T 48I 52T
120 190E 200E 100E
121 84K 106Q 81K 119Q 40K 60Q
122 20E 100I 70V 17E 105I 78V 7E 59I 34V
123 84N 106Q 81N 119Q 40N 60Q
124 106D 84N 119D 81N 60D 40N
125 2L 99P 89S 2L 98P 100S 1L 45P 54S
126 84D 106E 81D 119E 40D 60E
127 33D 73H 84K 39D 80H 81K 12D 48H 40K
128 77I 106S 7T 74I 119S 7T 37I 60S 3T
129 1A 84D 6E 94G 5R 81D 3E 104G 12R 40D 2E 57G 1R
130 104K 86S 108K 92S 58K 42S
131 84L 106M 81L 119M 40L 60M
132 84I 106V 81I 119V 40I 60V
133 105A 84N 1V 119A 81N 60A 40N
134 106K 83Q 1R 119K 80Q 1R 60K 40Q
135 190R 200R 100R
136 78Q 28R 84S 88Q 31R 81S 49Q 11R 40S
137 190F 200F 100F
138 16K 84L 90R 19K 81L 100R 6K 40L 54R
139 106I 84V 119I 81V 60I 40V
140 106G 84S 119G 81S 60G 40S
141 106D 83G 1S 119D 80G 1S 60D 40G
142 106I 84L 119I 81L 60I 40L
143 100A 84G 6V 112A 81G 7V 58A 40G 2V
144 190G 200G 100G
145 190E 200E 100E
146 190H 200H 100H
147 1I 189T 1I 199T 100T
148 84A 106S 81A 119S 40A 60S
149 190F 200F 100F
150 102D 4G 84N 115D 4G 81N 60D 40N
Continued on next page
104
Table B.2 – continued from previous page
Position 190 fHbp sequences Set A (200 new variants) Set B (100 new variants)
151 106K 84Q 119K 81Q 60K 40Q
152 190L 200L 100L
153 1H 188P 1R 3H 196P 1R 100P
154 84 – 1D 49E 1G 55K 81 – 4D 58E 57K 40 – 23E 37K
155 45D 112G 30S 3V 41D 115G 39S 5V 29D 60G 10S 1V
156 13D 143G 3S 31V 13D 154G 2S 31V 7D 70G 1S 22V
157 84K 28M 51R 27S 81K 36M 53R 30S 43K 15M 31R 11S
158 188A 1S 1V 195A 2S 3V 98A 1S 1V
159 84E 106T 81E 119T 43E 57T
160 190Y 200Y 100Y
161 84H 106R 81H 119R 43H 57R
162 190G 200G 100G
163 84K 106T 81K 119T 40K 60T
164 190A 200A 100A
165 187F 3L 196F 4L 96F 4L
166 89G 101S 100G 100S 43G 57S
167 190S 200S 100S
168 190D 200D 100D
169 190D 200D 100D
170 151A 38P 1T 163A 35P 2T 85A 15P
171 144G 38N 1R 7S 160G 35N 2R 3S 79G 15N 6S
172 190G 200G 100G
173 1E 150K 39R 163K 37R 4E 81K 15R
174 190L 200L 100L
175 38H 15I 137T 35H 12I 153T 15H 12I 73T
176 190Y 200Y 100Y
177 33S 157T 36S 164T 21S 79T
178 190I 200I 100I
179 190D 200D 100D
180 190F 200F 100F
181 151A 38T 1V 163A 35T 2V 79A 21T
182 146A 33K 5N 1S 2T 3V 162A 28K 7N 2S 1V 76A 17K 4N 3T
183 190K 200K 100K
184 190Q 200Q 100Q
185 190G 200G 100G
186 1C 131H 12N 46Y 4C 129H 13N 54Y 1C 65H 9N 25Y
187 190G 200G 100G
188 1G 151K 38R 2G 163K 35R 1G 79K 20R
189 190I 200I 100I
190 190E 200E 100E
191 190H 200H 100H
192 190L 200L 100L
193 190K 200K 100K
194 105S 85T 118S 82T 55S 45T
195 1L 189P 1L 199P 1L 99P
196 190E 200E 100E
197 107L 83Q 116L 84Q 51L 49Q
198 190N 200N 100N
199 190V 200V 100V
200 74D 115E 1N 74D 123E 3N 31D 69E
201 190L 200L 100L
202 188A 2V 198A 2V 98A 2V
203 99A 53S 29T 9V 117AV57SV20T 6V 54A 24S 18T 4V
204 182A 8S 193A 7S 97A 3S
205 48D 85E 1N 56Y 62D 82E 2N 54Y 26D 45E 1N 28Y
206 105I 85L 118I 82L 55I 45L
207 1E 189K 200K 2E 98K
208 85A 104P 1Q 82A 116P 2Q 45A 54P 1Q
209 190D 200D 100D
210 169E 9G 12K 181E 6G 13K 85E 7G 8K
211 190K 200K 100K
212 53H 52R 85S 51H 67R 82S 27H 28R 45S
Continued on next page
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Position 190 fHbp sequences Set A (200 new variants) Set B (100 new variants)
213 188H 2Y 196H 4Y 99H 1Y
214 190A 200A 100A
215 190V 200V 100V
216 190I 200I 100I
217 85L 105S 82L 118S 45L 55S
218 190G 200G 100G
219 85D 1F 104S 82D 2F 116S 45D 1F 54S
220 85T 105V 82T 118V 45T 55V
221 1H 105L 84R 3H 118L 79R 2H 55L 43R
222 190Y 200Y 100Y
223 1D 84G 105N 3D 79G 118N 3D 45G 52N
224 28G 1H 104Q 57S 34G 2H 116Q 48S 18G 1H 51Q 30S
225 40A 64D 85E 1N 52A 64D 82E 2N 23A 28D 48E 1N
226 190E 200E 100E
227 190K 200K 100K
228 189G 1S 198G 2S 98G 2S
229 105S 85T 118S 82T 55S 45T
230 190Y 200Y 100Y
231 85H 105S 82H 118S 45H 55S
232 190L 200L 100L
233 85A 105G 82A 118G 45A 55G
234 105I 85L 118I 82L 55I 45L
235 190F 200F 100F
236 189G 1S 200G 100G
237 85D 10E 94G 1R 82D 13E 103G 2R 45D 5E 49G 1R
238 1E 50K 54Q 85R 2E 65K 51Q 82R 1E 27K 27Q 45R
239 190A 200A 100A
240 190Q 200Q 100Q
241 190E 200E 100E
242 86I 104V 95I 105V 48I 52V
243 190A 200A 100A
244 190G 200G 100G
245 190S 200S 100S
246 190A 200A 100A
247 105E 85T 118E 82T 55E 45T
248 190V 200V 100V
249 57E 133K 60E 140K 35E 65K
250 85I 105T 82I 118T 45I 55T
251 64A 41G 44R 41V 66A 48G 34R 52V 35A 23G 22R 20V
252 85E 105N 82E 118N 45E 55N
253 105G 85K 118G 82K 53G 47K
254 105I 85V 118I 82V 53I 47V
255 127H 7Q 56R 125H 10Q 65R 64H 4Q 32R
256 85E 105H 82E 118H 47E 53H
257 190I 200I 100I
258 1D 183G 6S 1D 196G 3S 96G 4S
259 85I 105L 82I 118L 45I 55L
260 190A 200A 100A
261 105A 85G 118A 82G 55A 45G
262 190K 200K 100K
263 190Q 200Q 100Q
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Table B.3: Positions that had (at least one) ‘gap’ symbol in the 190 fHbp sequences and
the two sets of new variants, Set A and Set B. The results in this table were generated using
Script A.3 of Appendix A. The table shows that there were 10 positions that had at least
one ‘gap’ symbol.
190 fHbp sequences Set A (200 new variants) Set B (100 new variants)
5 5 5
6 6 6
7 7 7
8 8 8
9 9 9
10 10 10
67 67 67
68 68 68
69 69 69
154 154 154
Table B.4: Frequency distribution for the counts of the different amino acids across the
positions of the alignment of the 190 fHbp sequences, with ‘gap’ symbols excluded. For
example, only 1 position had 5 different symbols occuring there. The results in this table
were generated using Script A.4 in Appendix A.
Frequency Number of symbols (‘gap’ excluded)
122 1
82 2
42 3
15 4
1 5
1 6
Table B.5: Frequency distribution for the counts of the different amino acids across the
positions of the alignment of the 190 fHbp sequences, with ‘gap’ symbols included. The
results in this table were generated using Script A.5 in Appendix A.
Frequency Number of symbols (‘gap’ included)
115 1
87 2
44 3
14 4
2 5
1 6
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Table B.6: Codon-based calculation of the KA/KS ratio using the sliding window approach.
Positions where the KA/KS ratios are more than or equal to 0.9 are highlighted with red
colour.
Window of the nu-
cleotide positions
Corresponding amino
acid positions
KA KA/KS
1-18 1-6 0.002 0.006
4-21 2-7 0.003 0.009
7-24 3-8 0.004 0.012
10-27 4-9 0.002 0.006
13-30 5-10 0.011 0.032
16-33 6-11 0.013 0.038
19-36 7-12 0.009 0.026
22-39 8-13 0.011 0.032
25-42 9-14 0.018 0.052
28-45 10-15 0.016 0.047
31-48 11-16 0.010 0.029
34-51 12-17 0.010 0.029
37-54 13-18 0.010 0.029
40-57 14-19 0.044 0.128
43-60 15-20 0.039 0.114
46-63 16-21 0.038 0.111
49-66 17-22 0.038 0.111
52-69 18-23 0.042 0.122
55-72 19-24 0.042 0.122
58-75 20-25 0.004 0.012
61-78 21-26 0.001 0.003
64-81 22-27 0.017 0.050
67-84 23-28 0.020 0.058
70-87 24-29 0.024 0.070
73-90 25-30 0.024 0.070
76-93 26-31 0.015 0.044
79-96 27-32 0.022 0.064
82-99 28-33 0.007 0.020
85-102 29-34 0.005 0.015
88-105 30-35 0.035 0.102
91-108 31-36 0.038 0.111
94-111 32-37 0.069 0.201
97-114 33-38 0.046 0.134
100-117 34-39 0.055 0.160
103-120 35-40 0.079 0.230
106-123 36-41 0.036 0.105
109-126 37-42 0.032 0.093
112-129 38-43 0.026 0.076
115-132 39-44 0.026 0.076
118-135 40-45 0.025 0.073
121-138 41-46 0.006 0.017
124-141 42-47 0.006 0.017
127-144 43-48 0.258 0.752
130-147 44-49 0.110 0.321
133-150 45-50 0.012 0.035
136-153 46-51 0.160 0.466
139-156 47-52 0.124 0.362
142-159 48-53 0.100 0.292
145-162 49-54 0.202 0.589
148-165 50-55 0.142 0.414
151-168 51-56 0.087 0.254
154-171 52-57 0.089 0.259
157-174 53-58 0.036 0.105
160-177 54-59 0.033 0.096
163-180 55-60 0.013 0.038
166-183 56-61 0.015 0.044
169-186 57-62 0.044 0.128
172-189 58-63 0.138 0.402
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Window of the nu-
cleotide positions
Corresponding amino
acid positions
KA KA/KS
175-192 59-64 0.273 0.796
178-195 60-65 0.277 0.808
181-198 61-66 0.240 0.700
184-201 62-67 0.345 1.006
187-204 63-68 0.427 1.245
190-207 64-69 0.169 0.493
193-210 65-70 0.016 0.047
196-213 66-71 0.016 0.047
199-216 67-72 0.022 0.064
202-219 68-73 0.017 0.050
205-222 69-74 0.014 0.041
208-225 70-75 0.008 0.023
211-228 71-76 0.006 0.017
214-231 72-77 0.005 0.015
217-234 73-78 0.001 0.003
220-237 74-79 0.001 0.003
223-240 75-80 0.000 0.000
226-243 76-81 0.043 0.125
229-246 77-82 0.039 0.114
232-249 78-83 0.040 0.117
235-252 79-84 0.040 0.117
238-255 80-85 0.040 0.117
241-258 81-86 0.040 0.117
244-261 82-87 0.039 0.114
247-264 83-88 0.004 0.012
250-267 84-89 0.004 0.012
253-270 85-90 0.008 0.023
256-273 86-91 0.011 0.032
259-276 87-92 0.131 0.382
262-279 88-93 0.081 0.236
265-282 89-94 0.015 0.044
268-285 90-95 0.023 0.067
271-288 91-96 0.086 0.251
274-291 92-97 0.022 0.064
277-294 93-98 0.019 0.055
280-297 94-99 0.016 0.047
283-300 95-100 0.011 0.032
286-303 96-101 0.004 0.012
289-306 97-102 0.003 0.009
292-309 98-103 0.004 0.012
295-312 99-104 0.003 0.009
298-315 100-105 0.003 0.009
301-318 101-106 0.044 0.128
304-321 102-107 0.041 0.120
307-324 103-108 0.009 0.026
310-327 104-109 0.009 0.026
313-330 105-110 0.043 0.125
316-333 106-111 0.047 0.137
319-336 107-112 0.100 0.292
322-339 108-113 0.015 0.044
325-342 109-114 0.016 0.047
328-345 110-115 0.016 0.047
331-348 111-116 0.005 0.015
334-351 112-117 0.018 0.052
337-354 113-118 0.202 0.589
340-357 114-119 0.038 0.111
343-360 115-120 0.021 0.061
346-363 116-121 0.085 0.248
349-366 117-122 0.051 0.149
352-369 118-123 0.031 0.090
355-372 119-124 0.031 0.090
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358-375 120-125 0.020 0.058
361-378 121-126 0.020 0.058
364-381 122-127 0.037 0.108
367-384 123-128 0.023 0.067
370-387 124-129 0.052 0.152
373-390 125-130 0.052 0.152
376-393 126-131 0.035 0.102
379-396 127-132 0.036 0.105
382-399 128-133 0.017 0.050
385-402 129-134 0.014 0.041
388-405 130-135 0.002 0.006
391-408 131-136 0.022 0.064
394-411 132-137 0.024 0.070
397-414 133-138 0.044 0.128
400-417 134-139 0.388 1.131
403-420 135-140 0.434 1.265
406-423 136-141 0.606 1.767
409-426 137-142 0.390 1.137
412-429 138-143 0.472 1.376
415-432 139-144 0.083 0.242
418-435 140-145 0.010 0.029
421-438 141-146 0.010 0.029
424-441 142-147 0.007 0.020
427-444 143-148 0.007 0.020
430-447 144-149 0.001 0.003
433-450 145-150 0.006 0.017
436-453 146-151 0.006 0.017
439-456 147-152 0.005 0.015
442-459 148-153 0.006 0.017
445-462 149-154 0.041 0.120
448-465 150-155 0.207 0.603
451-468 151-156 0.194 0.566
454-471 152-157 0.272 0.793
457-474 153-158 0.235 0.685
460-477 154-159 0.231 0.673
463-480 155-160 0.340 0.991
466-483 156-161 0.328 0.956
469-486 157-162 0.050 0.146
472-489 158-163 0.002 0.006
475-492 159-164 0.054 0.157
478-495 160-165 0.027 0.079
481-498 161-166 0.052 0.152
484-501 162-167 0.017 0.050
487-504 163-168 0.022 0.064
490-507 164-169 0.028 0.082
493-510 165-170 0.042 0.122
496-513 166-171 0.083 0.242
499-516 167-172 0.010 0.029
502-519 168-173 0.010 0.029
505-522 169-174 0.016 0.047
508-525 170-175 0.321 0.936
511-528 171-176 0.232 0.676
514-531 172-177 0.076 0.222
517-534 173-178 0.103 0.300
520-537 174-179 0.068 0.198
523-540 175-180 0.091 0.265
526-543 176-181 0.049 0.143
529-546 177-182 0.129 0.376
532-549 178-183 0.031 0.090
535-552 179-184 0.086 0.251
538-555 180-185 0.019 0.055
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541-558 181-186 0.049 0.143
544-561 182-187 0.043 0.125
547-564 183-188 0.078 0.227
550-567 184-189 0.072 0.210
553-570 185-190 0.072 0.210
556-573 186-191 0.071 0.207
559-576 187-192 0.031 0.090
562-579 188-193 0.031 0.090
565-582 189-194 0.018 0.052
568-585 190-195 0.031 0.090
571-588 191-196 0.004 0.012
574-591 192-197 0.004 0.012
577-594 193-198 0.021 0.061
580-597 194-199 0.003 0.009
583-600 195-200 0.044 0.128
586-603 196-201 0.042 0.122
589-606 197-202 0.060 0.175
592-609 198-203 0.132 0.385
595-612 199-204 0.052 0.152
598-615 200-205 0.128 0.373
601-618 201-206 0.087 0.254
604-621 202-207 0.093 0.271
607-624 203-208 0.077 0.224
610-627 204-209 0.162 0.472
613-630 205-210 0.044 0.128
616-633 206-211 0.021 0.061
619-636 207-212 0.055 0.160
622-639 208-213 0.056 0.163
625-642 209-214 0.113 0.329
628-645 210-215 0.133 0.388
631-648 211-216 0.028 0.082
634-651 212-217 0.028 0.082
637-654 213-218 0.002 0.006
640-657 214-219 0.001 0.003
643-660 215-220 0.001 0.003
646-663 216-221 0.002 0.006
649-666 217-222 0.003 0.009
652-669 218-223 0.076 0.222
655-672 219-224 0.020 0.058
658-675 220-225 0.043 0.125
661-678 221-226 0.038 0.111
664-681 222-227 0.192 0.560
667-684 223-228 0.360 1.050
670-687 224-229 0.272 0.793
673-690 225-230 0.089 0.259
676-693 226-231 0.139 0.405
679-696 227-232 0.144 0.420
682-699 228-233 0.210 0.612
685-702 229-234 0.275 0.802
688-705 230-235 0.001 0.003
691-708 231-236 0.005 0.015
694-711 232-237 0.011 0.032
697-714 233-238 0.028 0.082
700-717 234-239 0.034 0.099
703-720 235-240 0.036 0.105
706-723 236-241 0.086 0.251
709-726 237-242 0.116 0.338
712-729 238-243 0.064 0.187
715-732 239-244 0.004 0.012
718-735 240-245 0.012 0.035
721-738 241-246 0.163 0.475
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724-741 242-247 0.001 0.003
727-744 243-248 0.000 0.000
730-747 244-249 0.028 0.082
733-750 245-250 0.028 0.082
736-753 246-251 0.076 0.222
739-756 247-252 0.076 0.222
742-759 248-253 0.078 0.227
745-762 249-254 0.073 0.213
748-765 250-255 0.078 0.227
751-768 251-256 0.079 0.230
754-771 252-257 0.027 0.079
757-774 253-258 0.308 0.898
760-777 254-259 0.181 0.528
763-780 255-260 0.144 0.420
766-783 256-261 0.199 0.580
769-786 257-262 0.005 0.015
772-789 258-263 0.007 0.020
775-792 259-264 0.000 0.000
778-795 260-265 0.000 0.000
781-798 261-266 0.000 0.000
784-801 262-267 0.000 0.000
787-804 263-268 0.000 0.000
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Table B.7: Energy values determined from the tertiary structures of the existing 190 fHbp
sequences. Below are the explanations for the table:
Column 1: name of the sequence of which the tertiary structure was predicted and energy
values determined.
Column 2: template used by SWISS-MODEL to predict the structure of the corresponding
sequence in column 1. Here SM is the abbreviation for SWISS-MODEL.
Column 3: percentage identity of the sequence in column 1 with the template used in column
2.
Column 4: energy of the structure determined by SWISS-MODEL (in KJ/mol).
Column 5: energy value after energy minimization was performed on the structures by Swiss-
PdbViewer (in KJ/mol). Here SPDBV is the abbreviation for Swiss-PdbViewer.
Column 6: energy determined by FoldX before energy minimization was performed on the
structure (Kcal/mol).
Column 7: energy determined by FoldX after energy minimization was performed on the
structure (Kcal/mol).
Sequence structures with the highest energy values (after minimization) are highlighted with
yellow colour.
Sequence Template-
SM
%identity Energy-
SM
Energy
minimization-
SPDBV
Energy-FoldX
Before minimization After minimization
B6EAW6 2W80C 94.191 -10531.661 -11133.833 131.55 121.181
C0JFM7 2W80C 95.436 -10616.156 -11152.968 129.99 113.61
B5U0Q5 2W80C 93.361 -10756.280 -11286.105 126.96 113.19
B2CQ01 2W80C 93.361 -10482.681 -11057.957 128.71 113.50
C0JFL9 2W80C 92.946 -10549.528 -11019.172 134.81 119.62
C0JF88 2W80C 92.946 -10577.336 -11155.581 132.48 117.25
B2CQ02 2W80C 93.776 -10762.610 -11350.365 129.43 113.21
Q6VRY3 2W80C 93.361 -10226.646 -10867.855 139.00 118.39
C0JFJ0 2W80C 92.946 -10224.869 -10800.083 128.44 113.77
B2CQ14 2W80C 92.531 -10217.853 -10793.306 129.08 113.08
C0JFI0 2W80C 92.116 -10777.321 -11315.262 134.24 118.43
C0JFJ1 2W80C 92.531 -10713.425 -11364.190 134.73 117.40
C0JF55 2W80C 92.531 -10739.799 -11378.031 134.85 118.06
C0JFF4 2W80C 92.946 -10800.684 -11454.406 136.43 119.37
C0JFJ5 2W80C 92.531 -10631.487 -11159.812 140.56 125.89
C0JFK9 2W80C 93.361 -10820.896 -11463.966 132.85 116.72
C0JF77 2W80C 93.361 -10656.380 -11304.994 136.01 118.00
C0JFJ8 2W80C 93.776 -10712.312 -11290.231 126.40 112.21
C0JFC9 2W80C 93.776 -11133.926 -11780.069 136.62 117.87
C0JF66 2W80C 94.606 -10941.952 -11591.748 134.21 118.14
C0JF56 2W80C 92.531 -10578.812 -11146.649 136.18 119.43
C0JFD7 2W80C 92.531 -10578.812 -11146.649 136.18 119.43
C0JF86 2W80C 91.701 -10215.619 -10892.890 138.41 120.61
C0JFN8 2W80C 91.701 -10652.901 -11232.785 135.33 118.74
C0JF51 2W80C 90.456 -10206.750 -10762.514 138.03 119.69
C0JFC8 2W80C 90.871 -10454.724 -10973.460 137.99 122.80
Q6QCB7 2W80C 91.286 -10318.200 -10995.616 141.92 123.67
B6EAW9 2W80C 92.531 -10095.026 -10768.841 136.98 117.69
C0JF69 2W80C 92.531 -10120.293 -10790.710 137.87 117.60
C0JFC7 2W80C 92.116 -10137.560 -10817.146 139.83 119.90
C0JFL7 2W80C 92.116 -10137.560 -10817.146 139.83 119.90
C0JFF1 2W80C 92.946 -10425.335 -11107.412 140.58 122.35
C0JFD0 2W80C 92.531 -10024.691 -10698.051 138.03 118.68
C0JFD1 2W80C 94.191 -10359.649 -10843.340 140.58 117.38
C0JFM1 2W80C 94.606 -10928.335 -11460.077 138.03 116.14
C0JF78 2W80C 94.606 -11774.460 -12261.739 132.19 116.51
C0JFA0 2W80C 94.606 -11876.771 -12363.976 131.14 120.33
C0JFN4 2W80H 92.116 -11272.427 -11725.354 130.61 124.14
B6EAW8 2W80C 92.531 -10891.298 -11408.136 134.45 120.12
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Sequence Template-
SM
%identity Energy-
SM
Energy
minimization-
SPDBV
Energy-FoldX
Before minimization After minimization
Q6VRY2 2W80C 95.851 -10767.896 -11415.429 132.32 115.56
B5AAS3 2W80C 96.266 -10624.971 -11275.423 130.67 113.41
C0JFD9 2W80C 96.266 -10575.316 -11236.889 131.29 111.25
C0JF76 2W80C 96.680 -10623.077 -11275.744 129.70 111.45
B2CQ04 2W80C 94.606 -10613.559 -11253.764 139.36 122.85
C0JFD6 2W80C 96.680 -11072.190 -11559.334 129.59 115.15
Q6VRZ1 2W80C 97.095 -11032.109 -11512.100 127.31 114.22
C0JFF9 2W80C 96.680 -10814.681 -11293.024 125.75 112.41
C0JFH9 2W80C 97.925 -10699.144 -11341.228 126.80 110.79
C0JFN3 2W80C 96.680 -10879.147 -11522.341 127.00 111.77
C0JFG5 2W80H 95.436 -10752.379 -11294.184 128.34 118.61
C0JFJ6 2W80H 94.191 -10738.342 -11266.279 129.68 118.08
C0JF60 2W80C 97.095 -10645.220 -11294.862 131.24 115.47
Q6VRY1 2W80C 96.680 -10938.603 -11417.902 131.37 117.79
C0JFK6 2W80C 96.680 -11087.590 -11562.205 130.53 117.79
C0JF52 2W80C 96.680 -11002.455 -11483.229 128.11 114.69
C0JFH8 2W80C 95.021 -11437.172 -11947.255 128.33 115.08
C0JFC1 2W80C 96.680 -10639.744 -11116.229 124.88 111.72
C0JF53 2W80C 97.925 -10918.848 -11396.784 125.62 111.41
C0JFI8 2W80C 97.510 -11013.282 -11495.131 129.56 116.38
Q6VS09 2W80H 95.833 -11349.701 -11769.615 126.79 121.20
A1IQ30 2W80H 95.833 -11349.701 -11769.615 126.79 121.20
Q6QCB6 2W80C 95.851 -11338.722 -11817.962 133.33 120.42
C0JFJ3 2W80C 95.021 -11190.874 -11673.789 134.07 120.59
C0JF57 2W80C 95.436 -11690.869 -12171.490 133.52 120.51
C0JFN1 2W80H 95.021 -11238.752 -11655.619 126.43 121.98
C0JFH0 2W80C 95.851 -11583.762 -12065.236 133.27 119.89
C0JF82 2W80C 96.266 -11164.731 -11644.607 133.36 120.18
C0JFE6 2W80C 95.851 -11369.610 -11868.643 133.57 119.02
C0JFA4 2W80C 96.266 -11441.965 -11919.707 125.53 112.22
C0JF68 2W80H 100.000 -11180.135 -11612.103 123.74 115.46
C0JFL8 2W80C 99.170 -11426.974 -11883.679 123.66 112.17
Q6VRX9 2W80C 99.585 -11025.031 -11591.768 130.30 117.44
C0JF49 2W80C 99.585 -11216.915 -11691.964 127.49 114.78
Q6QCC2 2W80C 100.000 -11121.699 -11593.374 123.58 110.86
Q9JXV4 2W80C 100.000 -11121.699 -11621.195 125.16 117.99
C0JF85 2W80C 99.585 -11431.713 -11906.461 124.68 111.88
C0JF89 2W80C 99.585 -11200.402 -11669.392 123.66 110.02
C0JFG6 2W80C 99.170 -11393.284 -11912.731 124.38 111.94
C0JFM8 2W80C 99.170 -11033.789 -11514.570 126.84 112.90
C0JFA3 2W80H 97.925 -10832.818 -11274.697 127.31 119.86
C0JFI1 2W80C 98.340 -11142.247 -11617.897 126.80 113.79
C0JF54 2W80C 92.946 -11062.328 -11583.791 130.18 115.80
B2CQ11 2W80C 95.851 -10874.896 -11392.997 126.79 113.50
Q6QCB9 2W80C 94.191 -11140.438 -11789.780 135.45 118.13
Q6QCC0 2W80C 95.021 -10499.775 -11158.187 136.90 118.04
B2CQ06 2W80C 95.021 -10603.600 -11054.826 122.82 111.12
B2CQ05 2W80C 95.021 -10834.814 -11485.610 131.07 114.60
C0JF81 2W80C 83.402 -10499.725 -11052.418 145.54 129.67
C0JF61 2W80C 67.635 -10686.848 -11342.188 178.79 143.38
B6EAW7 2W80C 67.635 -10754.555 -11363.701 177.51 147.42
C0JFE5 2W80C 65.975 -10625.757 -11248.660 180.22 150.46
C0JF65 2W80C 66.805 -10958.096 -11610.725 185.92 151.06
A1KS29 2W80C 67.220 -10844.030 -11457.808 181.22 150.53
Q15I62 2W80C 67.220 -10844.030 -11457.808 181.22 150.53
C0JFB4 2W80C 67.635 -10806.710 -11450.919 182.26 147.84
C0JFN0 2W80C 67.220 -10798.854 -11415.437 179.14 148.10
B9VX97 2W80C 67.635 -10895.406 -11538.047 184.19 149.56
B9VX91 2W80C 65.975 -11020.517 -11752.468 183.57 151.90
C0JFF2 2W80C 65.560 -11151.741 -11778.542 187.04 154.39
Continued on next page
114
Table B.7 – continued from previous page
Sequence Template-
SM
%identity Energy-
SM
Energy
minimization-
SPDBV
Energy-FoldX
Before minimization After minimization
C0JF74 2W80C 66.390 -11002.064 -11649.442 182.66 150.11
B9VX98 2W80C 66.390 -11019.174 -11668.050 180.99 146.08
C0JF75 2W80C 66.390 -10899.526 -11630.599 182.11 148.14
C0JF79 2W80C 66.390 -10565.960 -11187.553 180.32 148.69
C0JFD5 2W80C 67.220 -10479.586 -11098.334 181.01 152.28
C0JF59 2W80C 67.635 -10806.710 -11450.919 182.26 147.84
C0JFH4 2W80C 67.220 -10878.382 -11521.309 181.80 146.51
C0JFB3 2W80C 67.635 -10895.406 -11538.047 184.19 149.56
C0JFN6 2W80C 68.050 -10791.079 -11437.161 181.04 146.12
C0JF97 2W80C 67.635 -9337.645 -10777.181 220.77 176.65
C0JFB2 2W80C 68.050 -10551.379 -11196.111 183.88 149.51
B7U1A0 2W80C 70.833 -9711.880 -10450.872 180.82 149.25
Q19KF8 2W80C 70.954 -9750.944 -10492.463 182.45 151.22
C0JFF5 2W80C 70.539 -9675.944 -10394.493 178.78 149.78
B9VX96 2W80C 70.954 -9750.944 -10492.463 182.45 151.22
C0JFE7 2W80C 70.539 -9846.163 -10600.577 182.98 152.03
Q6VS14 2W80C 70.539 -9789.599 -10523.953 184.70 153.80
Q6VS12 2W80C 71.369 -9751.148 -10400.058 181.37 149.04
C0JF90 2W80C 70.124 -10033.418 -10662.467 181.79 160.35
Q6VS11 2W80C 70.954 -9831.283 -10581.907 182.38 151.14
C0JF87 2W80C 70.954 -9638.568 -10384.189 179.50 147.79
B9VX93 2W80C 70.539 -10040.818 -10782.177 182.29 150.82
C0JFA9 2W80C 70.124 -10017.021 -10651.178 184.69 154.28
C0JFA5 2W80C 70.124 -10036.527 -10756.798 182.01 152.49
B2CQ00 2W80C 70.539 -10040.818 -10782.177 182.29 150.82
C0JFC4 2W80C 70.539 -9959.590 -10697.271 178.37 149.26
B9VX82 2W80C 70.954 -10026.688 -10767.900 181.12 150.28
C0JFG8 2W80C 70.539 -9927.947 -10672.065 178.98 147.37
B5U0Q7 2W80C 70.124 -9859.055 -10484.930 175.18 145.59
C0JF96 2W80C 70.954 -9937.392 -10679.862 179.01 147.60
B5U0Q4 2W80C 91.701 -9910.618 -10423.753 141.02 124.76
C0JFH5 2W80C 90.871 -9877.449 -10480.127 140.45 122.71
C0JFI9 2W80C 91.286 -9906.229 -10424.311 141.30 123.97
C0JF99 2W80H 90.871 -10310.191 -10815.887 147.29 135.52
C0JF84 2W80C 91.701 -10761.366 -11329.370 136.95 121.02
A9M1G0 2W80C 96.266 -11654.548 -12173.951 131.72 118.38
C0JF58 2W80C 95.021 -10822.093 -11323.104 134.70 119.53
C0JFH2 2W80C 93.776 -11425.279 -11946.477 132.43 118.54
C0JF64 2W80C 87.552 -9866.758 -10457.859 149.48 131.81
Q6VRY4 2W80C 87.967 -10012.252 -10621.463 150.49 132.43
C0JFD3 2W80C 87.552 -9864.772 -10390.163 147.16 128.68
A1E5L5 2W80C 86.885 -9758.841 -10523.716 190.52 165.57
C0JFD4 2W80C 86.885 -9758.841 -10523.716 190.52 165.57
B9VX99 2W80C 87.295 -9851.169 -10613.350 190.47 165.69
C0JFF3 2W80H 88.115 -9932.995 -10512.156 173.97 158.45
B2CQ09 2W80C 88.525 -9833.204 -10563.511 190.54 163.91
B9VX94 2W80C 84.836 -9371.489 -10295.334 195.16 168.19
C0JF62 2W80C 86.885 -8871.511 -9973.303 189.04 162.56
B2CPZ9 2W80C 62.705 -8128.872 -9093.258 228.75 190.60
Q15I64 2W80C 62.295 -8132.525 -9097.169 229.84 191.74
B5LY76 2W80C 62.295 -8143.680 -9109.000 229.78 191.62
C0JF91 2W80C 61.885 -8142.168 -9337.731 221.55 176.71
C0JF83 2W80C 62.705 -8209.204 -9168.207 227.14 190.61
C0JFC6 2W80C 63.115 -8136.478 -9102.779 224.73 187.10
B9VX85 2W80C 62.705 -8128.872 -9093.258 228.75 190.60
B9VX90 2W80C 61.885 -8591.852 -9518.320 232.55 194.89
C0JFG2 2W80C 61.885 -8512.559 -9436.139 230.32 193.07
C0JF80 2W80C 62.295 -8646.759 -9560.436 226.42 191.31
C0JFM9 2W80C 62.295 -8646.759 -9560.436 226.42 191.31
C0JFI2 2W80C 62.295 -8650.425 -9563.077 226.17 190.84
Continued on next page
115
Table B.7 – continued from previous page
Sequence Template-
SM
%identity Energy-
SM
Energy
minimization-
SPDBV
Energy-FoldX
Before minimization After minimization
C0JFA6 2W80C 62.705 -8494.505 -9460.716 226.22 189.27
B9VX89 2W80C 62.705 -8404.295 -9362.868 224.32 187.53
C0JFA8 2W80C 62.705 -8315.057 -9269.160 222.32 186.44
C0JF63 2W80C 62.705 -8473.467 -9437.166 228.97 191.02
C0JFI7 2W80C 63.115 -8480.316 -9445.769 225.09 188.61
C0JFG3 2W80C 61.885 -8720.467 -9673.294 232.87 198.41
B9VX84 2W80C 63.115 -8136.478 -9102.779 224.73 187.10
B9VX92 2W80C 62.705 -8507.856 -9464.061 224.06 187.49
C0JFB9 2W80C 62.705 -8256.821 -9214.522 225.07 188.23
C0JFK2 2W80C 63.115 -8352.843 -9315.410 225.11 188.81
C0JFL0 2W80C 61.885 -8888.626 -9823.227 231.49 194.52
C0JFE9 2W80C 62.295 -8664.627 -9582.113 227.58 192.02
B5U0Q6 2W80C 62.295 -8664.627 -9582.113 227.58 192.02
C0JFC3 2W80C 61.885 -8369.775 -9300.877 234.15 198.78
B5L521 2W80C 60.246 -9166.502 -10132.031 225.19 186.03
B2CQ08 2W80H 60.656 -7830.792 -9419.820 248.48 201.10
C0JFJ9 2W80H 59.426 -8010.897 -9623.688 264.59 212.15
C0JFL1 2W80H 59.836 -7645.381 -9351.549 255.54 209.85
C0JF92 2W80H 59.016 -7697.173 -9390.774 256.25 211.29
C0JFB0 2W80H 59.426 -7499.236 -9196.076 254.35 208.66
C0JFM6 2W80H 59.426 -7499.236 -9196.076 254.35 208.66
Q6VS28 2W80H 59.426 -7142.289 -8840.635 254.44 209.27
C0JFF0 2W80H 59.426 -7846.313 -9539.544 255.39 209.41
C0JFJ4 2W80H 59.426 -7434.237 -9145.395 257.86 211.38
C0JFM5 2W80H 59.016 -7786.667 -9509.900 259.92 212.76
B6VAX7 2W80H 59.426 -7846.313 -9539.544 255.39 209.41
Q19KF7 2W80H 58.607 -9007.075 -9956.911 222.02 189.29
C0JFL2 2W80H 59.836 -7518.411 -9213.378 256.73 210.61
C0JFP2 2W80H 59.016 -8843.925 -10302.643 244.47 201.27
C0JFM3 2W80H 59.836 -7600.051 -9256.514 253.81 210.34
C0JFM0 2W80C 64.344 -8766.095 -9704.785 229.93 193.77
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Table B.8: Energy values determined from the tertiary structures of the 200 new variants
of Set A. Refer back to the caption for Table B.7 for an explanation of the columns.
Sequence Template-
SM
%identity Energy-
SM
Energy
minimization-
SPDBV
Energy-FoldX Region
Before minimization After minimization
variant1 2W80H 80.083 -9457.933 -9945.355 155.51 145.51 Black
variant2 2W80C 72.951 -9148.821 -10139.492 203.99 172.83 Blue
variant3 2W80C 79.918 -9286.078 -10195.232 190.76 165.75 Blue
variant4 2W80C 70.539 -9765.071 -10472.156 179.61 150.63 Black
variant5 2W80C 92.946 -10782.896 -11328.200 137.16 121.07 Black
variant6 2W80C 83.402 -10795.215 -11311.810 157.47 139.60 Black
variant7 2W80C 88.797 -11271.610 -11867.308 141.69 122.14 Black
variant8 2W80C 75.104 -9990.903 -10505.535 170.14 149.45 Black
variant9 2W80C 80.328 -10143.482 -10820.600 198.71 170.82 Black
variant10 2W80C 91.701 -10578.847 -11209.582 139.21 122.80 Black
variant11 2W80C 91.393 -10125.021 -11027.775 185.58 163.96 Blue
variant12 2W80C 82.573 -10390.766 -10934.659 161.81 142.04 Black
variant13 2W80C 79.253 -10622.531 -11184.693 156.47 130.53 Black
variant14 2W80C 83.817 -11359.850 -11924.604 148.33 131.85 Black
variant15 2W80C 94.606 -10839.326 -11323.919 131.48 117.37 Black
variant16 2W80C 68.465 -9911.778 -10540.377 177.60 147.08 Black
variant17 2W80H 82.158 -10224.146 -10727.066 149.54 136.67 Black
variant18 2W80C 79.253 -10634.650 -11129.028 161.66 143.20 Black
variant19 2W80H 83.402 -10299.726 -10764.678 147.09 133.14 Black
variant20 2W80C 95.436 -10578.972 -11082.401 138.44 122.37 Black
variant21 2W80H 70.082 -9530.610 -10469.700 217.85 189.89 Red
variant22 2W80C 67.213 -10116.630 -11098.079 224.47 192.23 Red
variant23 2W80C 87.967 -10535.107 -11078.983 149.69 133.12 Black
variant24 2W80C 72.541 -9358.739 -10301.488 206.75 175.15 Blue
variant25 2W80C 79.253 -10472.126 -11063.370 160.83 134.74 Black
variant26 2W80C 80.498 -10210.012 -10760.080 162.10 143.39 Black
variant27 2W80C 84.232 -10376.513 -10981.525 147.41 125.08 Black
variant28 2W80C 80.738 -10047.333 -10705.186 192.61 166.95 Blue
variant29 2W80C 80.738 -9668.347 -10439.609 197.77 169.25 Blue
variant30 2W80H 85.246 -8725.480 -9519.747 176.03 160.69 Blue
variant31 2W80C 81.743 -10050.083 -10589.047 151.43 125.66 Black
variant32 2W80C 80.913 -10139.267 -10674.039 161.82 143.68 Black
variant33 2W80C 84.426 -9201.427 -10122.076 197.89 174.19 Blue
variant34 2W80C 76.349 -9939.480 -10474.274 162.51 137.77 Black
variant35 2W80C 90.456 -11309.157 -11810.707 139.23 120.26 Black
variant36 2W80C 83.402 -11063.755 -11560.197 156.69 136.95 Black
variant37 2W80C 82.988 -10452.530 -10963.493 146.08 127.21 Black
variant38 2W80H 79.253 -9560.660 -10008.704 153.33 144.50 Black
variant39 2W80C 72.614 -9877.507 -10506.573 177.75 148.16 Black
variant40 2W80C 79.098 -9784.690 -10537.945 194.06 165.89 Blue
variant41 2W80C 69.262 -9843.384 -10657.755 210.00 176.06 Blue
variant42 2W80C 87.705 -9622.698 -10284.426 182.57 160.07 Blue
variant43 2W80C 80.913 -10015.891 -10607.223 158.50 132.32 Black
variant44 2W80C 80.083 -10254.484 -10755.518 150.67 133.16 Black
variant45 2W80C 89.212 -10802.322 -11387.605 145.49 126.78 Black
variant46 2W80C 79.508 -9466.285 -10132.309 200.30 168.56 Blue
variant47 2W80C 66.803 -10060.303 -11039.364 219.05 186.27 Red
variant48 2W80C 88.525 -9588.789 -10382.045 190.19 163.10 Blue
variant49 2W80C 83.817 -10855.912 -11359.273 157.66 138.46 Black
variant50 2W80C 94.191 -10846.040 -11373.340 131.68 116.91 Black
variant51 2W80C 69.710 -10394.806 -11021.561 174.92 142.75 Black
variant52 2W80H 66.393 -8531.624 -9475.286 225.46 195.52 Red
variant53 2W80C 82.988 -9818.149 -10337.633 155.28 131.29 Black
variant54 2W80C 77.593 -9921.555 -10721.499 165.95 137.91 Black
variant55 2W80C 68.050 -9368.602 -10077.069 179.44 146.92 Black
variant56 2W80C 65.145 -9079.731 -9768.427 176.93 146.66 Black
variant57 2W80C 93.361 -10486.833 -11144.964 132.72 116.08 Black
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variant58 2W80C 83.607 -9536.220 -10385.263 200.56 174.80 Blue
variant59 2W80C 80.498 -10341.617 -10892.579 161.24 139.73 Black
variant60 2W80C 84.583 -10734.181 -11277.963 146.97 131.15 Black
variant61 2W80C 70.539 -9459.084 -10189.881 173.58 142.47 Black
variant62 2W80C 80.833 -10124.169 -10658.074 162.92 145.48 Black
variant63 2W80C 82.787 -11777.827 -12379.118 193.57 166.08 Blue
variant64 2W80C 78.689 -9902.706 -10573.473 201.68 173.53 Blue
variant65 2W80C 67.220 -9790.835 -10542.499 187.84 152.11 Black
variant66 2W80C 92.531 -11396.927 -11876.922 131.18 117.47 Black
variant67 2W80C 78.279 -10223.786 -11021.528 186.33 157.44 Black
variant68 2W80C 87.967 -11550.169 -12123.965 150.75 131.09 Black
variant69 2W80C 92.531 -11501.028 -12163.365 137.91 121.19 Black
variant70 2W80C 77.178 -10886.383 -11380.337 162.31 142.22 Black
variant71 2W80C 85.062 -11578.486 -12087.947 149.08 131.89 Black
variant72 2W80C 68.465 -9352.567 -9963.908 177.94 148.53 Black
variant73 2W80C 78.008 -11142.536 -11822.432 156.09 126.90 Black
variant74 2W80C 79.918 -10024.214 -10699.768 198.79 171.03 Blue
variant75 2W80C 70.082 -9237.715 -10084.507 212.45 177.56 Blue
variant76 2W80H 94.672 -10586.634 -11152.307 165.55 152.41 Black
variant77 2W80C 82.573 -9865.973 -10414.266 146.48 120.20 Black
variant78 2W80C 88.382 -10953.373 -11479.360 140.59 124.66 Black
variant79 2W80C 71.784 -9525.796 -10137.747 176.75 146.59 Black
variant80 2W80C 90.984 -9631.081 -10722.171 176.25 154.80 Black
variant81 2W80C 78.279 -9675.076 -10703.731 212.15 180.19 Red
variant82 2W80C 88.934 -10179.438 -11068.558 175.46 152.25 Black
variant83 2W80C 81.148 -9992.201 -10753.974 188.53 161.12 Blue
variant84 2W80C 75.519 -9367.917 -10080.765 167.62 140.74 Black
variant85 2W80C 71.369 -10160.604 -10803.292 177.61 147.65 Black
variant86 2W80C 90.456 -11369.580 -11875.500 133.40 116.97 Black
variant87 2W80C 78.008 -9564.075 -10072.911 159.35 135.26 Black
variant88 2W80C 82.917 -10580.610 -11115.575 150.71 133.09 Black
variant89 2W80C 89.627 -10316.643 -10816.772 143.78 127.43 Black
variant90 2W80H 86.667 -10703.701 -11153.046 137.43 128.73 Black
variant91 2W80C 92.531 -10220.166 -10868.675 132.10 115.95 Black
variant92 2W80C 96.266 -11163.879 -11662.473 132.76 119.62 Black
variant93 2W80C 89.627 -10012.005 -10542.592 148.11 130.92 Black
variant94 2W80C 93.443 -9869.062 -10692.230 167.08 150.83 Black
variant95 2W80H 89.627 -10116.369 -10574.310 144.83 137.26 Black
variant96 2W80C 84.232 -10337.072 -10850.841 155.12 135.41 Black
variant97 2W80C 79.668 -9833.333 -10518.075 156.57 131.02 Black
variant98 2W80C 90.456 -11585.327 -12006.833 125.89 113.62 Black
variant99 2W80C 79.253 -9672.446 -10242.239 164.11 137.64 Black
variant100 2W80H 77.178 -8657.629 -9984.699 189.45 156.50 Black
variant101 2W80C 80.328 -9442.451 -10110.702 200.01 169.77 Blue
variant102 2W80C 80.913 -10157.588 -10677.139 157.35 138.39 Black
variant103 2W80H 93.776 -10456.299 -10891.264 135.91 125.06 Black
variant104 2W80C 92.116 -11024.611 -11682.397 141.33 121.32 Black
variant105 2W80H 80.083 -9704.047 -10101.760 151.32 141.63 Black
variant106 2W80C 90.984 -9698.368 -10795.982 175.80 154.69 Black
variant107 2W80C 79.668 -11299.051 -11830.786 161.78 138.18 Black
variant108 2W80H 93.361 -10967.451 -11491.380 127.10 118.31 Black
variant109 2W80C 81.328 -10398.499 -10969.610 157.52 130.94 Black
variant110 2W80C 80.498 -11144.553 -11731.245 158.72 129.01 Black
variant111 2W80C 69.262 -9774.072 -10596.871 211.65 177.82 Blue
variant112 2W80C 95.021 -10736.114 -11258.754 131.70 119.17 Black
variant113 2W80C 83.817 -10454.758 -10970.132 146.22 129.27 Black
variant114 2W80H 89.627 -11579.053 -12090.739 140.31 122.82 Black
variant115 2W80C 74.180 -9298.311 -10070.895 179.59 160.74 Blue
variant116 2W80C 95.851 -10926.499 -11495.369 128.76 113.69 Black
variant117 2W80C 82.573 -10812.596 -11344.157 156.04 139.55 Black
Continued on next page
118
Table B.8 – continued from previous page
Sequence Template-
SM
%identity Energy-
SM
Energy
minimization-
SPDBV
Energy-FoldX Region
Before minimization After minimization
variant118 2W80C 70.539 -9776.823 -10409.971 179.05 155.01 Black
variant119 2W80C 76.763 -11224.499 -11686.066 174.58 150.65 Black
variant120 2W80C 69.262 -9941.857 -10742.342 216.66 186.15 Red
variant121 2W80C 82.573 -10168.320 -10800.557 150.30 125.79 Black
variant122 2W80C 78.279 -9590.757 -10461.796 193.70 164.92 Blue
variant123 2W80C 68.050 -10322.688 -11060.227 172.86 138.83 Black
variant124 2W80C 76.230 -9811.961 -10595.711 213.87 180.79 Red
variant125 2W80C 74.590 -9669.887 -10432.032 216.27 183.80 Red
variant126 2W80C 85.062 -10889.364 -11426.450 151.75 131.67 Black
variant127 2W80C 74.689 -9254.352 -9835.760 164.50 134.66 Black
variant128 2W80C 82.988 -10797.580 -11352.781 148.29 130.02 Black
variant129 2W80C 69.295 -10327.256 -10937.885 182.12 152.40 Black
variant130 2W80C 77.593 -9709.159 -10269.781 156.32 133.98 Black
variant131 2W80C 80.498 -9729.384 -10308.627 159.03 130.61 Black
variant132 2W80C 90.574 -10331.854 -10812.516 171.57 148.83 Black
variant133 2W80C 82.988 -11386.021 -11911.022 150.90 134.32 Black
variant134 2W80C 90.984 -10484.272 -11114.430 171.80 149.00 Black
variant135 2W80C 67.623 -10407.936 -11302.178 214.00 177.23 Blue
variant136 2W80H 91.286 -10400.424 -10844.545 134.30 122.75 Black
variant137 2W80C 94.606 -10793.630 -11318.522 130.66 116.56 Black
variant138 2W80C 87.137 -10997.760 -11571.583 146.31 127.96 Black
variant139 2W80H 80.913 -9722.173 -10153.371 150.48 141.83 Black
variant140 2W80C 76.349 -9355.457 -10017.917 167.31 141.16 Black
variant141 2W80C 92.946 -10733.037 -11262.052 139.15 120.80 Black
variant142 2W80C 65.560 -9114.008 -9740.824 184.44 148.97 Black
variant143 2W80C 80.328 -10222.184 -10766.485 166.94 144.54 Black
variant144 2W80C 70.539 -9709.394 -10430.348 179.44 146.09 Black
variant145 2W80C 89.627 -10655.434 -11204.207 133.10 118.08 Black
variant146 2W80C 85.000 -10642.542 -11157.885 142.35 126.91 Black
variant147 2W80C 89.627 -10126.970 -10748.699 140.20 121.96 Black
variant148 2W80C 73.029 -9599.265 -10235.366 175.34 146.74 Black
variant149 2W80C 71.784 -9816.910 -10540.073 178.70 151.40 Black
variant150 2W80C 89.754 -10471.438 -11064.831 180.00 158.67 Blue
variant151 2W80C 83.817 -10138.154 -10684.090 156.67 137.67 Black
variant152 2W80C 79.668 -9475.329 -9998.044 157.71 132.69 Black
variant153 2W80C 89.300 -10147.582 -10764.452 169.39 149.48 Black
variant154 2W80C 91.286 -11869.120 -12381.519 131.14 115.24 Black
variant155 2W80C 82.573 -10541.580 -11112.409 151.91 127.82 Black
variant156 2W80C 82.573 -10222.317 -10757.182 160.70 138.89 Black
variant157 2W80C 84.647 -10969.767 -11509.052 154.05 135.33 Black
variant158 2W80H 94.191 -10506.514 -11050.241 141.37 131.32 Black
variant159 2W80C 85.062 -11123.965 -11665.229 155.80 137.02 Black
variant160 2W80C 79.253 -10143.925 -10634.547 162.34 142.88 Black
variant161 2W80H 74.180 -9439.729 -10575.953 208.03 184.72 Red
variant162 2W80C 80.498 -10865.378 -11482.168 176.42 152.19 Black
variant163 2W80C 82.158 -9633.353 -10214.046 150.01 127.29 Black
variant164 2W80C 67.220 -8878.178 -9465.873 180.42 148.60 Black
variant165 2W80C 64.754 -8292.276 -9210.207 225.47 190.05 Red
variant166 2W80C 83.817 -11163.284 -11714.295 153.26 134.14 Black
variant167 2W80C 93.033 -10041.437 -10561.724 169.46 150.66 Black
variant168 2W80C 77.178 -9356.653 -9878.675 157.47 133.48 Black
variant169 2W80C 81.743 -9649.434 -10233.217 147.26 121.93 Black
variant170 2W80C 80.913 -9895.980 -10610.665 152.42 125.89 Black
variant171 2W80C 86.475 -9557.582 -10079.159 188.80 165.31 Blue
variant172 2W80C 87.967 -11843.673 -12335.377 138.63 120.91 Black
variant173 2W80C 81.743 -10701.622 -11248.795 163.80 144.28 Black
variant174 2W80C 89.212 -11220.054 -11777.958 132.10 115.41 Black
variant175 2W80C 95.021 -10590.702 -11129.076 131.18 117.79 Black
variant176 2W80C 78.008 -10564.250 -11117.474 174.26 154.68 Black
variant177 2W80C 79.098 -10790.891 -11471.730 201.26 171.23 Blue
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variant178 2W80C 75.104 -9448.995 -10046.504 160.05 134.30 Black
variant179 2W80C 92.116 -11301.126 -11856.587 133.39 114.84 Black
variant180 2W80C 92.946 -10847.402 -11332.817 126.75 112.91 Black
variant181 2W80C 81.743 -9924.828 -10454.911 163.24 140.54 Black
variant182 2W80C 66.393 -8616.766 -9450.605 223.03 187.05 Red
variant183 2W80C 93.361 -10754.855 -11412.120 135.69 119.06 Black
variant184 2W80C 91.701 -11922.575 -12350.325 130.29 119.38 Black
variant185 2W80C 74.180 -10634.179 -11416.469 212.24 179.72 Blue
variant186 2W80C 83.817 -10939.318 -11509.831 152.19 135.78 Black
variant187 2W80C 83.817 -11450.323 -12006.175 154.46 135.85 Black
variant188 2W80C 83.402 -10412.571 -10961.562 156.21 136.93 Black
variant189 2W80H 90.871 -10290.048 -10779.827 134.63 129.69 Black
variant190 2W80C 79.253 -9773.637 -10335.595 167.48 144.62 Black
variant191 2W80C 74.590 -10403.420 -11305.454 205.25 175.84 Blue
variant192 2W80C 92.531 -12087.654 -12651.916 135.13 118.85 Black
variant193 2W80C 89.212 -10422.977 -11068.375 151.52 133.28 Black
variant194 2W80C 90.871 -10175.699 -10636.776 141.22 125.96 Black
variant195 2W80C 84.647 -11002.570 -11515.552 154.23 134.72 Black
variant196 2W80H 75.934 -8430.079 -9862.659 189.40 156.14 Black
variant197 2W80C 87.552 -10159.515 -10662.250 147.47 134.90 Black
variant198 2W80C 83.817 -10776.937 -11291.300 143.68 129.44 Black
variant199 2W80C 84.647 -10089.458 -10686.725 154.53 133.90 Black
variant200 2W80H 77.178 -8602.641 -10021.542 194.34 159.87 Black
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variant1 2W80H 82.573 -10324.950 -10701.946 157.19 135.70 Black
variant2 2W80C 90.871 -10766.152 -11247.407 128.99 113.66 Black
variant3 2W80C 88.382 -10287.660 -10801.854 142.36 121.88 Black
variant4 2W80C 66.803 -9144.697 -10122.778 224.27 189.18 Red
variant5 2W80C 84.232 -10784.713 -11253.972 142.69 124.68 Black
variant6 2W80H 76.230 -8688.720 -9885.193 215.93 190.24 Red
variant7 2W80H 82.988 -8780.003 -10072.824 169.98 140.38 Black
variant8 2W80C 86.066 -9153.137 -10041.002 181.54 157.07 Blue
variant9 2W80C 75.104 -10081.688 -10800.198 170.61 139.97 Black
variant10 2W80C 87.705 -9890.827 -10854.473 182.40 156.30 Blue
variant11 2W80C 88.797 -10180.986 -10731.847 135.92 118.63 Black
variant12 2W80C 67.213 -10520.815 -11155.994 206.64 175.58 Blue
variant13 2W80C 92.531 -10672.493 -11182.649 134.02 118.82 Black
variant14 2W80C 78.838 -10809.700 -11329.611 169.44 145.84 Black
variant15 2W80C 82.573 -10059.699 -10723.966 156.85 136.23 Black
variant16 2W80C 80.498 -9631.497 -10221.550 158.62 132.99 Black
variant17 2W80C 82.158 -10295.935 -10774.081 157.24 142.09 Black
variant18 2W80C 67.635 -10697.323 -11231.710 175.49 148.88 Black
variant19 2W80C 88.525 -9369.943 -10531.088 183.40 159.19 Blue
variant20 2W80C 92.531 -9900.839 -10399.626 140.18 123.99 Black
variant21 2W80C 86.722 -11590.951 -11993.192 153.16 138.12 Black
variant22 2W80C 79.508 -10909.305 -11649.275 199.03 169.91 Blue
variant23 2W80C 89.212 -10446.812 -10930.201 137.48 120.15 Black
variant24 2W80C 89.212 -10105.470 -10737.102 141.07 124.83 Black
variant25 2W80C 86.885 -9950.098 -10764.620 184.60 161.09 Blue
variant26 2W80C 79.253 -10039.235 -10829.078 159.85 135.22 Black
variant27 2W80C 85.246 -9948.574 -10599.855 189.49 158.29 Blue
variant28 2W80H 82.158 -9009.153 -10304.185 175.31 146.16 Black
variant29 2W80C 68.050 -9646.900 -10267.302 179.39 148.59 Black
variant30 2W80H 76.763 -8498.539 -9834.258 191.72 158.63 Blue
variant31 2W80C 92.116 -10928.396 -11443.401 135.02 118.73 Black
variant32 2W80C 78.279 -10117.967 -10805.604 201.17 172.72 Blue
variant33 2W80C 89.627 -10847.556 -11316.542 145.92 132.35 Black
variant34 2W80C 80.738 -9342.032 -9958.600 185.27 159.67 Blue
variant35 2W80C 75.934 -10040.645 -10537.941 154.26 136.65 Black
variant36 2W80C 82.988 -11354.896 -11911.835 157.97 138.07 Black
variant37 2W80C 85.656 -9591.529 -10427.470 192.02 170.23 Blue
variant38 2W80C 83.607 -8069.898 -9268.037 203.79 172.65 Blue
variant39 2W80C 66.393 -9654.659 -10584.923 239.74 202.62 Red
variant40 2W80C 89.212 -10447.781 -11007.547 144.87 129.87 Black
variant41 2W80C 84.232 -10122.150 -10650.969 151.84 131.13 Black
variant42 2W80H 84.426 -8803.450 -9691.706 186.08 161.84 Blue
variant43 2W80C 82.158 -10244.059 -10819.255 169.40 141.09 Black
variant44 2W80C 83.197 -9767.897 -10523.331 186.12 161.56 Blue
variant45 2W80C 80.498 -10131.054 -10839.701 166.20 141.33 Black
variant46 2W80C 75.934 -9298.632 -9864.213 173.11 147.09 Black
variant47 2W80C 69.262 -10092.500 -11069.918 222.55 183.71 Red
variant48 2W80C 81.743 -11228.696 -11778.420 156.66 139.90 Black
variant49 2W80C 76.349 -10082.690 -10494.047 183.75 159.46 Blue
variant50 2W80C 91.701 -9990.165 -10519.723 129.85 113.26 Black
variant51 2W80H 72.951 -9717.099 -10820.308 209.05 182.31 Red
variant52 2W80C 75.820 -10430.614 -11338.894 204.02 175.59 Blue
variant53 2W80C 82.787 -9170.633 -9868.550 185.41 159.93 Blue
variant54 2W80C 76.639 -10689.628 -11461.009 213.04 178.64 Red
variant55 2W80C 84.232 -10783.727 -11311.987 148.17 130.46 Black
variant56 2W80C 83.402 -10733.672 -11295.898 154.91 136.65 Black
variant57 2W80C 90.041 -10821.503 -11366.747 139.69 124.61 Black
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variant58 2W80C 73.029 -9657.539 -10271.945 170.01 141.37 Black
variant59 2W80H 82.917 -9133.718 -10463.365 177.25 147.42 Black
variant60 2W80C 83.817 -11139.703 -11660.049 152.33 128.51 Black
variant61 2W80C 90.456 -10231.006 -10761.467 136.39 119.12 Black
variant62 2W80C 83.402 -10803.501 -11391.791 163.30 136.74 Black
variant63 2W80C 77.178 -10762.551 -11306.629 170.13 143.28 Black
variant64 2W80C 77.459 -9393.287 -10044.455 188.01 162.43 Blue
variant65 2W80C 87.552 -9992.338 -10516.071 147.59 130.39 Black
variant66 2W80C 83.402 -11780.542 -12312.651 151.86 131.77 Black
variant67 2W80C 90.871 -10781.665 -11304.812 144.45 128.53 Black
variant68 2W80H 81.743 -10691.781 -11143.228 163.37 143.72 Black
variant69 2W80C 81.148 -9589.752 -10396.552 208.57 179.90 Red
variant70 2W80C 75.934 -10519.759 -11109.483 169.59 142.30 Black
variant71 2W80C 75.410 -9310.462 -9987.796 207.87 175.00 Blue
variant72 2W80C 81.967 -9851.590 -10509.594 182.80 156.51 Blue
variant73 2W80C 91.701 -10260.119 -10801.245 126.29 115.16 Black
variant74 2W80C 81.328 -10382.327 -11087.752 159.87 137.77 Black
variant75 2W80C 68.050 -11192.534 -11911.011 180.68 148.05 Black
variant76 2W80C 68.443 -9807.025 -10699.413 213.31 179.54 Red
variant77 2W80H 69.295 -8715.495 -10101.164 214.29 174.84 Blue
variant78 2W80C 83.402 -10538.289 -11021.200 148.55 129.32 Black
variant79 2W80C 80.498 -10905.543 -11585.215 149.91 124.64 Black
variant80 2W80C 73.029 -9829.572 -10484.208 180.56 148.41 Black
variant81 2W80C 83.817 -9419.487 -9890.812 139.99 122.22 Black
variant82 2W80C 76.639 -9942.893 -10869.638 195.67 166.91 Blue
variant83 2W80C 75.820 -9720.432 -10369.436 207.24 175.51 Blue
variant84 2W80C 78.689 -10103.282 -10700.568 187.84 159.63 Blue
variant85 2W80C 82.573 -9866.408 -10385.570 153.95 138.59 Black
variant86 2W80C 79.668 -10514.534 -10967.464 147.80 129.82 Black
variant87 2W80C 90.041 -11060.084 -11576.387 142.84 128.39 Black
variant88 2W80C 79.098 -10149.094 -10898.811 201.05 173.57 Blue
variant89 2W80C 76.349 -10178.084 -10627.459 161.58 136.69 Black
variant90 2W80C 87.137 -9966.197 -10633.252 153.31 130.29 Black
variant91 2W80C 80.913 -10492.107 -11128.555 159.99 136.92 Black
variant92 2W80C 88.115 -10067.083 -10887.166 178.08 153.12 Black
variant93 2W80C 81.867 -10072.097 -10660.872 193.07 164.68 Blue
variant94 2W80H 79.253 -10090.178 -10544.397 157.72 145.33 Black
variant95 2W80C 80.498 -11032.714 -11654.353 166.09 137.35 Black
variant96 2W80C 82.787 -8672.978 -9618.117 197.15 172.25 Blue
variant97 2W80C 80.498 -11630.682 -12169.227 160.10 138.22 Black
variant98 2W80C 84.232 -11455.903 -11847.486 154.34 136.25 Black
variant99 2W80H 81.328 -9737.430 -10164.905 151.73 145.01 Black
variant100 2W80C 85.477 -10918.499 -11490.443 143.46 121.36 Black
122
Appendix C
Figures: Multiple Sequence Alignments
Figures C.1 to C.6 illustrate portions of the multiple sequence alignment of the 190 fHbp
sequences including the signal protein portion. Figures C.7 to C.12 illustrate the various regions
of the new variants of Set A. These figures lack the signal protein parts.
The signal protein parts (in Figures C.1 to C.6) and the various regions of the mature protein
have been highlighted with different colours. The colour highlighting is co-ordinated across both
sets of figures (for the 190 fHbp sequences and the new variants of Set A).
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Figure C.1: A portion of the multiple sequence alignment of the 190 fHbp sequences il-
lustrating the signal peptides (highlighted in brown colour), the amino-terminal repetitive
region (highlighted in green colour) marking the beginning of the mature protein part (the
N-term region of Figure 2.2), and the beginning of the first variable region VA (highlighted
in red) (Section 2.6 and Figure 2.2). The numbers on the right are the count of amino acids
for individual sequence starting from the first amino acid of each sequence respectively; that
is, the count starts from the first amino acid of the signal protein portion if it is present in a
sequence or the first amino acid of the amino-terminal repetitive region, which will be a ‘C’.
The number excludes the count of ‘gaps’.
The consensus sequence illustrated in this figure is obtained by using the consensus com-
mand of the EMBOSS prettyplot program. The command uses the sequence weights and a
scoring matrix to calculate a score for each amino acid at each position in the alignment [4, 5].
The highest scoring residue goes into the consensus sequence if the score is higher than a
user-specified plurality value, which in this case was set to 0. Hence, for positions where
there was only one amino acid with the rest being ‘gaps’, that single amino acid appeared in
the consensus sequence. Note that the consensus sequence illustrated here is derived from
the alignment of the 190 fHbp sequences and the occurrences of ‘gap’ symbols are excluded
while deriving the consensus sequence.
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Figure C.2: A portion of the multiple sequence alignment of the 190 fHbp sequences
illustrating the continuation of the variable region VA. The numbers on the right again
represent the count of the amino acids starting from the first amino acid in each individual
sequence respectively. For instance, for the first sequence A1IQ30, the number on the right
shows 92. This 92 is the sum of the amino acids that have occurred starting from the first
amino acid of the signal part (amino acid ‘M’) in this sequence (c.f. Figure C.1) until this
segment of the alignment.
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Figure C.3: A portion of the multiple sequence alignment of the 190 fHbp sequences
illustrating the variable regions VA, VB , and VC flanked by the invariant segments. The
blue regions represent the invariant blocks and the other regions the modular variable ones.
The red region, from the left, corresponds to the continuation of region VA, region VB is
coloured in cyan, and VC in orange. The blue regions (‘SRFDF’ and ‘GEFQ’) are the black
vertical rectangles that separate the regions VA - VB and VB - VC , respectively, in Figure 2.2.
126
Figure C.4: A portion of the multiple sequence alignment of the 190 fHbp sequences
illustrating the variable regions VC and VD flanked by the invariant segment ‘DD’. The
orange region is the continuation of the variable region VC from Figure C.3 and variable
region VD is rendered in the lime colour. The blue region represents the invariant block
‘DD’ which flanks the variable regions VC and VD.
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Figure C.5: A portion of the multiple sequence alignment of the 190 fHbp sequences
illustrating the variable regions VD and VE flanked by the invariant segment ‘IEHLK’. The
lime coloured region is the continuation of the variable region VD from Figure C.4 and the
variable segment VE is rendered in yellow. The blue region represents the invariant block
‘IEHLK’ which flanks the variable regions VD and VE .
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Figure C.6: A portion of the multiple sequence alignment of the 190 fHbp sequences
illustrating the last variable region VE and the last invariant segment ‘KQ’ rendered in blue
colour. The yellow region is the continuation of the variable segment VE from Figure C.5.
The explanation of the derivation of the consensus sequence in Figure C.1 would explain the
last three amino acids ‘E’, ‘P’, and ‘L’ even though the positions show all ‘gap’ symbols for
all the displayed sequences. These three amino acids occurred at least for once in one of the
190 sequences and those sequences have not been illustrated in this figure, since this figure
is a portion of the alignment of the 190 fHbp sequences.
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Figure C.7: A portion of the alignment of the new variants of Set A illustrating the
amino-terminal repetitive element and the variable region VA. The green region represents
the amino-terminal repetitive element, which marks the beginning of the mature protein
part with cysteine (the N-term region of Figure 2.2), and the red region represents the first
variable region VA (see Section 2.6 and Figure 2.2). The numbers on the right are the same
as explained in Figures C.1 and C.2.
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Figure C.8: A portion of the alignment of the new variants of Set A illustrating the variable
regions VA and VB flanked by the invariant segment ‘SRFDF’. The red region on the left is
a continuation of VA from Figure C.7. Region VB is coloured in cyan and the blue region
‘SRFDF’ corresponds to the black vertical rectangle that separates the regions VA and VB
in Figure 2.2.
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Figure C.9: A portion of the alignment of the new variants of Set A illustrating the variable
regions VB and VC flanked by the invariant segment ‘GEFQ’. The cyan coloured region is
the continuation of region VB from Figure C.8 and region VC is coloured in orange. The
blue region represents the invariant block ‘GEFQ’, which flanks the variable regions VB and
VC .
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Figure C.10: A portion of the alignment of the new variants of Set A illustrating the
variable regions VC , VD, and VE flanked by the invariant segments. The orange coloured
region is the continuation of region VC from Figure C.9. The lime coloured region illustrates
region VD and the yellow region on the far right represents region VE . The blue regions
‘DD’ and ‘IEHLK’ are the invariant blocks of residues that separate the modular variable
regions VC-VD and VD-VE , respectively.
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Figure C.11: A portion of the alignment of the new variants of Set A illustrating the
continuation (from Figure C.10) of last variable region VE . This whole region is highlighted
in yellow.
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Figure C.12: A portion of the alignment of the new variants of Set A illustrating the last
variable region VE and the last invariant segment ‘KQ’. The yellow region is a continuation
of the region VE from Figures C.10 and C.11. The blue region is the last invariant region,
‘KQ’.
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Appendix D
Amino Acid Chart
Table D.1: 20 Amino acids, their single-letter codes (SLC), and their corresponding DNA
codons.
Amino Acid SLC DNA codons
Isloleucine I ATT, ATC, ATA
Leucine L CTT, CTC, CTA, CTG, TTA, TTG
Valine V GTT, GTC, GTA, GTG
Phenylalanine F TTT, TTC
Methionine M ATG
Cysteine C TGT, TGC
Alanine A GCT, GCC, GCA, GCG
Glycine G GGT, GGC, GGA, GGG
Proline P CCT, CCC, CCA, CCG
Threonine T ACT, ACC, ACA, ACG
Serine S TCT, TCC, TCA, TCG, AGT, AGC
Tyrosine Y TAT, TAC
Tryptophan W TGG
Glutamine Q CAA, CAG
Asparagine N AAT, AAC
Histidine H CAT, CAC
Glutamic acid E GAA, GAG
Aspartic acid D GAT, GAC
Lysine K AAA, AAG
Arginine R CGT, CGC, CGA, CGG, AGA, AGG
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